Nutex Health Inc 10-K for FY2020
Nutex Health Inc. (NUTX)
About this 10-K
Nutex Health Inc filed this 10-K on April 5, 2021, covering the fiscal year ended December 31, 2020 (FY2020).
Headline figures
Fiscal year ended December 31, 2020, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $1.59M
- up 16.1% from $1.37M a year earlier
- Net loss
- $5.65M
- compared with a net loss of $7.12M a year earlier
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Fiscal Year Ended December 31, 2020
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 000-53862
CLINIGENCE HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 11-3363609 | |
| (State
or other jurisdiction of incorporation or organization) |
(I.R.S.
Employer Identification No.) |
501 1st Avenue N, Suite 901
St.
Petersburg, Florida 33701
(Address of Principal Executive Offices) (Zip Code)
(678)
607-6393
(Issuer’s Telephone Number, Including Area Code)
Securities registered under Section 12(b) of the Exchange Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.001 par value | CLNH | OTCMKTS |
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.
Yes ☐ No ☒
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Date File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of the chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ |
Accelerated filer ☐ |
| Non-accelerated filer ☒ | Smaller reporting company ☒ |
| Emerging growth company ☐ |
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 126-2 of the act):
Yes ☐ No ☒
The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 30, 2020 (the last day of the registrant’s most recently completed second fiscal quarter) based on the closing sale price as reported on the OTCQB Market as approximately $4.88 million. For purposes of calculating the aggregate market value of shares held by non-affiliates, we have assumed that all outstanding shares are held by non-affiliates, except for shares held by each of our executive officers, directors and 5% or greater stockholders. In the case of 5% or greater stockholders, we have not deemed such stockholders to be affiliates unless there are facts and circumstances which would indicate that such stockholders exercise any control over our company, or unless they hold 10% or more of our outstanding common stock. These assumptions should not be deemed to constitute an admission that all executive officers, directors and 5% or greater stockholders are, in fact, affiliates of our company, or that there are not, other persons who may be deemed to be affiliates of our company. Further information concerning shareholdings of our officers, directors and principal stockholders is included or incorporated by reference in Part III, Item 12 of this Annual Report on Form 10-K.
As of March 31, 2021, there were 39,251,013 shares of the Registrant’s $0.001 par value common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE: None
| 1 |
Clinigence
Holdings, Inc.
FORM 10-K — FOR THE YEAR ENDED DECEMBER 31, 2019
TABLE OF CONTENTS
| Page No. | ||
| PART I | ||
| Item 1 | Business | 3 |
| Item 1A | Risk Factors | 10 |
| Item 1B | Unresolved Staff Comments | 29 |
| Item 2 | Properties | 29 |
| Item 3 | Legal Proceedings | 29 |
| Item 4 | (Removed and Reserved) | 29 |
| PART II | ||
| Item 5 | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 29 |
| Item 6 | Selected Financial Data | 34 |
| Item 7 | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 34 |
| Item 7A | Quantitative and Qualitative Disclosure About Market Risk | 43 |
| Item 8 | Financial Statements and Supplementary Data | 43 |
| Item 9 | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | 43 |
| Item 9A | Controls and Procedures | 43 |
| Item 9B | Other Information | 44 |
| PART III | ||
| Item 10 | Directors, Executive Officers and Corporate Governance | 45 |
| Item 11 | Executive Compensation | 52 |
| Item 12 | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 54 |
| Item 13 | Certain Relationships, Related Transactions and Director Independence | 56 |
| Item 14 | Principal Accountant Fees and Services | 57 |
| PART IV | ||
| Item 15 | Exhibits and Financial Statement Schedules | 58 |
| 2 |
PART I
This annual report on Form 10-K is for the year ended December 31, 2020. The Securities and Exchange Commission (“SEC”) allows us to “incorporate by reference” information that we file with the SEC, which means that we can disclose important information to you by referring you directly to those documents. Information incorporated by reference is considered to be part of this annual report. In addition, information that we file with the SEC in the future will automatically update and supersede information contained in this annual report. In this annual report, “Company,” “we,” “us” and “our” refer to Clinigence Holdings, Inc. and its subsidiaries.
This Annual Report on Form 10-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company has based these forward-looking statements on the Company’s current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us and the Company’s subsidiaries that may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In many cases, you can identify forward-looking statements by terminology such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target” and other similar words. However, the absence of these words does not mean that the statements are not forward-looking. Factors that might cause or contribute to a material difference include, but are not limited to, those discussed elsewhere in this Annual Report, including the section entitled “Risk Factors” and the risks discussed in the Company’s other Securities and Exchange Commission filings. The following discussion should be read in conjunction with the Company’s audited Consolidated Financial Statements and related Notes thereto included elsewhere in this report.
ITEM 1. BUSINESS
HISTORY
On March 1, 2019, Clinigence Holdings, Inc., a Delaware corporation (“Clinigence”) entered into a Contribution Agreement by and among Clinigence, Qualmetrix, Inc., a Delaware corporation and the Members of Clinigence, LLC, a Georgia limited liability company (“Agreement”) whereby Clinigence acquired all of the assets and operations and assumed all of the liabilities of Qualmetrix, Inc. Pursuant to the Agreement, all of the outstanding Series A and Series B Preferred Stock and Common Stock of Qualmetrix, Inc. totaling 34,726,659 shares were exchanged for 5,021,951 common shares of Clinigence. All outstanding shares of Qualmetrix, Inc. immediately preceding the exchange were treated as one class. On the date of the transaction, the shares of common stock issued to Qualmetrix, Inc. had an estimated fair value of $0.83 per share.
In addition to the acquisition of Qualmetrix, Inc., as part of the Contribution Agreement, 15,978,062 issued and outstanding member units of Clinigence LLC were exchanged for 7,533,000 shares of common stock of Clinigence. All outstanding preferred member units, common member units, and incentive units of Clinigence, LLC immediately preceding the exchange were treated as one class.
On August 8, 2019, we entered into an Agreement and Plan of Merger (the “Reverse Merger Agreement”) by and among Clinigence, iGambit, Inc., a Delaware corporation (“iGambit”), HealthDatix, Inc., a Delaware corporation and wholly owned subsidiary of iGambit (“Merger Sub”), and John Salerno, an individual and holder of shares of iGambit capital stock constituting a majority of the votes eligible to be cast by all of the stockholders of iGambit. The transactions contemplated by the Reverse Merger Agreement were consummated on October 29, 2019 (the “Closing”).
| 3 |
The signing of the Reverse Merger Agreement was disclosed on iGambit’s current report on Form 8-K filed on August 9, 2019.
The Reverse Merger Agreement provided for the merger of Merger Sub with and into Clinigence, hereafter referred to as the “Acquisition.” As a result of the Acquisition, Merger Sub ceased to exist, and Clinigence became the surviving corporation and a direct wholly owned subsidiary of iGambit, and the former stockholders of Clinigence (the “Clinigence Stockholders”) have a direct equity ownership and controlling interest in iGambit. Merger Sub was renamed Clinigence Health Inc. iGambit was renamed Clinigence Holdings, Inc. Merger Sub was originally incorporated in Delaware on October 17, 2013 and had no operating activity prior to the reported transaction. Merger Sub is wholly separate and distinct from our subsidiary HealthDatix, Inc. a Florida corporation (“HDX FL”).
At the Closing, all of the outstanding shares of Clinigence common stock (the “Clinigence Shares”) were converted solely into the right to receive a number of shares of iGambit common stock (the “Company Shares”) such that the holders of outstanding equity of Clinigence immediately prior to the Closing own 85%, on a fully-diluted basis, of the outstanding equity of iGambit immediately following the Closing, and holders of outstanding equity of iGambit immediately prior to the Closing own 15%, on a fully-diluted basis, of the outstanding equity of iGambit. For each share of Clinigence Shares, each former Clinigence Stockholder received 0.22489093 shares of Company Shares after giving effect to the reverse stock split described immediately below.
In connection with the Acquisition, the Company amended its certificate of incorporation to (i) effect a reverse stock split of the Company Shares at a ratio of 1 for 500, and (ii) change its name to Clinigence Holdings, Inc. to better align with the business of Clinigence.
The Acquisition was disclosed on the Company’s current report on Form 8-K filed on November 1, 2019.
Discontinued Operations
eEffective March 1, 2020 we completed the sale of our subsidiary HealthDatix Inc., a Florida corporation (HDX FL) to Jerry Robinson, Mary-Jo Robinson and Kathleen Shepherd (“HDX Management”) in accordance with a Stock Purchase Agreement (the “Purchase Agreement”) by and between the Company and HDX Management. Pursuant to the Purchase Agreement, the total consideration paid for the outstanding capital stock of HDX FL was the execution of Settlement and Release Agreements by HDX Management, releasing the Company from all obligations pursuant to certain HDX Management Employment Agreements dated April 1, 2017. As per the Purchase Agreement, the Company’s operations of HDX FL ended February 29, 2020 and HDX Management’s operation of the business became effective as of March 1, 2020. HDX FL had nominal revenue and its expenses were insignificant for the period ended December 31, 2019. We recorded a loss of the sale of operations of $158,744.
| 4 |
Asset Purchase Agreement
On May 27, 2020, we. entered into an Intellectual Property Asset Purchase Agreement (the “IP APA Agreement”) by and among Clinigence Health, the Company, AHA Analytics, Inc., a Delaware corporation (“Purchaser”) and Accountable Healthcare America Inc., a Delaware corporation (“AHA”). The transactions contemplated by the IP APA Agreement were consummated on May 29, 2020.
The IP APA Agreement provided for the sale of certain intellectual property and rights, including but not limited to copyrights, patents, pending patents, and continuation in part, to Purchaser from Clinigence Health, in exchange for AHA Series E Preferred Stock (the “Asset Sale”).
The Series E Preferred Stock as more fully described and stated in the Series E Preferred Stock Certificate of Designation (the “Certificate of Designation”), has an initial stated value of $15,000,000 in the aggregate (the “Stated Value”), unless adjusted as set forth in the IP APA Agreement. The Stated Value, however, may be reduced by the certain assumed liabilities, as set forth in the IP APA Agreement which also includes a hold back amount, as set forth in Article 9 of the IP APA Agreement. The Series E Stock will automatically convert upon either of the following events:
| (1) | Immediately (A) before AHA’s consummation of a merger with or an acquisition by a Publicly Traded Company listed on NASDAQ, all of the Series E Preferred Shares will be automatically converted into shares of Common Stock of Purchaser or (B) upon AHA’s consummation of any such merger or acquisition into Common Shares of the Publicly Traded Company (“Pubco Shares”) equal to the Stated Value (as may be adjusted in accordance with the terms of the Certificate of Designation), which Pubco Shares will be valued at the Fair Market Value of those shares; or |
| (2) | After two hundred and forty (240) days from the date of Closing of the Asset Sale, if the event described in paragraph (1) above has not occurred, the Series E Preferred Stock shall automatically convert into 3,750,000 of Common Shares of Stock of AHA, based upon a $4 per share valuation on the date of Conversion. |
The Asset Purchase was disclosed on the Company’s current report on Form 8-K filed on June 3, 2020.
As discussed, below the AHA Series E Preferred Stock was surrendered a part of the Merger with Accountable Healthcare America, Inc.
License Agreement
In connection with the Asset Purchase, the Company’s subsidiary Clinigence Health, Inc. (“Clinigence Health”) entered into an Intellectual Property License Agreement (the “License Agreement”) with AHA Analytics Inc., a Delaware corporation (“Licensor”).
Pursuant to the License Agreement Licensor granted Clinigence Health a worldwide, irrevocable, royalty-free, non-transferable (other than as set forth herein), non-exclusive license to use, solely for Clinigence Health’s ongoing Analytics Business Customers, the Licensor Intellectual Property (as defined in the License Agreement) to make, have made, use, offer to sell, sell and import, copy, reproduce, modify, publish, display, publicly perform and make derivative works on the Licensed Products and to incorporate the Licensor Intellectual Property and Licensed Products (as defined in the License Agreement), in whole or in part, into the Analytics Business platform maintained by Licensee, within the Territory (as defined in the License Agreement), and subject to the License Agreement, to develop improvements based on the Licensor Intellectual Property.
| 5 |
Licensor also granted Clinigence Health the right to grant limited sub-licenses to customers as a non-exclusive license to use the Licensed Material, for the Term of the License Agreement. It is understood that the use of the licensed material will be offered to Clinigence Health ‘s customers as part of its ongoing Analytics Business.
The following events occurred subsequent to December 31, 2020.
Managed Services Agreement
In connection with the Asset Purchase, Clinigence Health entered into a Managed Services Agreement (the “Managed Services Agreement”) by and between AHA Analytics, Inc. (“AHA Analytics”), a Delaware corporation and Clinigence Health, Inc., a Delaware corporation.
Pursuant to the Managed Services Agreement Clinigence Health will provide, supply and render management and operational support services as are necessary to continue to maintain and keep the AHA Analytics technology up to date, in keeping with the ordinary course of business as it has customarily been used in the Clinigence Health Analytics Business.
Merger with AHP Management Inc.
On February 25, 2021, we entered into an agreement and plan of merger (the “AHP Merger Agreement”) with AHP Management, Inc., a California corporation (“AHP”), AHP Acquisition Corp., a Delaware corporation, a wholly owned subsidiary of Clinigence Holdings, Inc. (“Merger Sub”), and Robert Chan (the “Shareholders’ Representative”). The transactions contemplated by the AHP Merger Agreement were consummated on February 26, 2021 (the “AHP Closing”).
The AHP Merger Agreement provided for the merger of Merger Sub with and into AHP, hereafter referred to as the “AHP Acquisition.” As a result of the Acquisition, Merger Sub ceased to exist, and AHP became the surviving corporation and a direct wholly owned subsidiary of Clinigence, and the former stockholders of AHP (the “AHP Stockholders”) have a direct equity ownership in Clinigence. Merger Sub was renamed AHP Management Inc. Merger Sub was originally incorporated in Delaware on January 26, 2021 and had no operating activity prior to the reported transaction.
AHP is a privately held company with controlling interest in its’ affiliate Associated Hispanic Physicians of Southern California IPA, a California Medical corporation, (“AHPIPA”). A key term of the AHP Merger Agreement is that at Closing, AHP Management Inc entered into a Management Services Agreement with AHPIPA (the “Management Services Agreement”) making AHPIPA a Variable Interest Entity (VIE) of Clinigence.
The AHP Merger Agreement and Management Services Agreement was disclosed on the Company’s current report on Form 8-K filed on March 2, 2021.
Merger with Accountable Healthcare America, Inc.
On February 25, 2021, we entered into an agreement and plan of merger with Accountable Healthcare America, Inc., a Delaware corporation (“AHA”), and AHA Acquisition Corp., a Delaware corporation, a wholly owned subsidiary of Parent (“Merger Sub entered into an agreement and plan of merger (the “AHA Merger Agreement”). The transactions contemplated by the AHA Merger Agreement were consummated on February 26, 2021 (the “AHA Closing”).
| 6 |
The AHA Merger Agreement provided for the merger of Merger Sub with and into AHA, hereafter referred to as the “AHA Acquisition.” As a result of the Acquisition, Merger Sub ceased to exist, and AHA became the surviving corporation and a direct wholly owned subsidiary of Clinigence, and the former stockholders of AHA (the “AHA Stockholders”) have a direct equity ownership in Clinigence. Merger Sub was renamed Accountable Healthcare America, Inc. Merger Sub was originally incorporated in Delaware on January 2, 2020 and had no operating activity prior to the reported transaction.
The AHA Merger Agreement was disclosed on the Company’s current report on Form 8-K filed on March 2, 2021.
At the AHP Closing and the AHA Closing, hereafter collectively referred to as the “Closing”, all of the outstanding shares of AHP common stock (the “AHP Shares”) were converted solely into the right to receive a number of shares of Clinigence common stock (the “Company Shares”) such that the holders of outstanding equity of AHP immediately prior to the Closing own 45%, on a fully-diluted basis, of the outstanding equity of Clinigence immediately following the Closing, and all of the outstanding shares of AHA common stock (the “AHA Shares”) were converted solely into the right to receive a number of the Company Shares such that the holders of outstanding equity of AHA immediately prior to the Closing own 35%, on a fully-diluted basis, of the outstanding equity of Clinigence immediately following the Closing, and holders of outstanding equity of Clinigence immediately prior to the Closing own 20%, on a fully-diluted basis, of the outstanding equity of Clinigence. Additionally, the AHA Series E Preferred Stock was surrendered a part of the Acquisition of 100% of AHA.
The accounting for our merger with AHP and AHA has not been completed because we have not finalized the December 31, 2020 AHP and AHA audits and valuation of the acquired AHP and AHA intangible assets.
OUR COMPANY
Introduction
The Company is a technology-enabled, risk-bearing population health management company that manages provider networks. Our primary focus has been on the medical technology markets and the growth of our subsidiary Clinigence Health Inc. (“Clinigence Health”). With the recent acquisitions of Accountable Healthcare Americas, Inc. (“AHA”) and AHP Management, Inc. (“AHP”) the Company’s focus is expanding to the seeking additional acquisitions of risk-bearing organizations, including Management Service Organizations (MSO), Independent Practice Associations (IPA) and Accountable Care Organizations (ACO) that are principally serving Medicare Advantage Plans or CMS Primary Care initiatives.
Clinigence Health’s Platform Services
Clinigence Health is a healthcare information technology company providing a cloud-based platform that enables healthcare organizations to provide value-based care and population health management (PHM). Our proprietary cloud-based PHM platform extracts claims and clinical data from multiple claims and EHR systems, which it then uses to report clinical quality measures (GPRO, MIPS, etc.), gaps in care, risk-stratification of patients, generates a utilization dashboard on every provider, has predictive analytics and a provider scorecard. The Clinigence Health platform provides turnkey SaaS solutions that enable connected intelligence across the care continuum by transforming massive amounts of data into actionable insights. Clinigence Health’s solutions help healthcare organizations improve the quality and cost effectiveness of care, enhance population health management and optimize provider networks.
| 7 |
Clinigence Health’s platform provides a clinical business intelligence Software-as-a-Service (“SaaS”). Clinigence Health’s solution integrates clinical and financial data across all electronic health record (“EHR”) systems and care settings and delivers comprehensive patient views and real-time, dynamic and predictive population reports critical to success in value-based payment. The Clinigence Health platform aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of each patient and provider and virtually unlimited insights into patient populations.
The Company’s solutions help healthcare organizations improve the quality and cost-effectiveness of care, enhance population health management and optimize provider networks. The Company enables risk-bearing healthcare organizations to achieve their objectives on the path to value-based care.
Competitive Comparison
Clinigence Health has a pending patent application for its technology (U.S. Patent Application No. 15/882,688). Clinigence Health believes its technology is unique in two critical ways: (1) it efficiently integrates data from any EHR and claims sources; and (2) it enables clinicians to target any patient population and measure any clinical key performance indicator in real time with no dependence on EHR vendors, information technology or informatics staff.
Customers
Clinigence Health’s services have been utilized by more than 1,000 health care practices, including some 14 accountable care organizations (“ACOs”), 7 Managed Services Organizations (“MSOs”), 5 health plans, 35 hospitals, and over 8,000 individual providers, and hosting more than 9 million patient records. In 2020, the largest three customers of the Company represented 36.83% of revenues during that period and in 2021 we expect to derive a significant portion of our revenues from these same three customers.
Expansion Summary
Expansion through Acquisition
AHA Acquisition
Based in Ft. Lauderdale, Florida and founded in 2017 by industry veterans with a combined 125 years of experience in the Medicare managed care space, AHA is a medical management platform company that currently has an investment in an accountable care organization with approximately 16,000 Medicare members through a network of over 65 providers. Through its investment, AHA provides a suite of services for its providers, including care coordination, high-risk care managers, documentation improvement and medical coding programs, medical management best practices programs, health management programs such as annual wellness visits and chronic care management, and performance improvement plans.
| 8 |
AHP Acquisition
Based in Los Angeles, California and founded in 2000, AHP Management, Inc.’s affiliated medical group, AHP IPA, currently provides care for 22,065 patients, including approximately 1800 Medicare Advantage patients, through a network of 141 primary care physicians and 660 specialists. AHP Management’s affiliated medical group, AHP IPA, has become a variable interest entity (“VIE”) of Clinigence in order to be compliant with California’s corporate practice of medicine regulations.
Expansion of Platform
Clinigence Health’s objective is to be a market leader in providing a world class software application as well as expand our offering to current and new customers, including healthcare practitioners, ACOs, MSOs.
Summary
The combination of the three companies fuses a healthcare information technology company with medical management companies to form a unique, scalable operating platform that we believe is well positioned for the ongoing transition of U.S. healthcare from fee-for-service payments to value-based reimbursements, including full-risk, global capitation models. The platform also addresses another major theme in U.S. healthcare: faced with mounting costs, shifting regulations and burdensome billing, reporting and technology requirements, many physicians and medical groups have been selling their practices to larger hospital systems. The strategy of the combined company is to be one of the few, technology-enabled national medical groups by acquiring and/or operating medical groups, independent practice associations (“IPAs”), accountable care organizations (“ACOs”), management services organizations (“MSOs”) and individual practices, allowing providers to focus on providing the best quality of care to their patients.
Regulatory Environment
The healthcare industry is heavily regulated and closely scrutinized by federal, state and local governments. Comprehensive statutes and regulations govern the manner in which we provide and bill for services and collect reimbursement from governmental programs and private payors, our contractual relationships with our providers, vendors and clients, our marketing activities and other aspects of our operations. Of particular importance are:
| • | the federal physician self-referral law, commonly referred to as the Stark Law; |
| • | the federal Anti-Kickback Act; |
| • | the criminal healthcare fraud provisions of HIPAA; |
| • | the federal False Claims Act; |
| • | reassignment of payment rules that prohibit certain types of billing and collection; |
| • | similar state law provisions pertaining to anti-kickback, self-referral and false claims issues; |
| • | state laws that prohibit general business corporations, such as us, from practicing medicine; |
| • | laws that regulate debt collection practices as applied to our debt collection practices; |
| 9 |
Our revenue will be dependent on the healthcare industry and could be affected by changes in healthcare spending and policy. The healthcare industry is subject to changing political, regulatory and other influences. The Patient Protection and Affordable Care Act or PPACA made major changes in how healthcare is delivered and reimbursed and increased access to health insurance benefits to the uninsured and underinsured population of the United States.
HIPAA establishes a set of basic national privacy and security standards for the protection of protected health information, or PHI, by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services, which includes us.
Because of the extreme sensitivity of the PII we store and transmit, the security features of our technology platform are very important. If our security measures, some of which are managed by third parties, are breached or fail, unauthorized persons may be able to obtain access to sensitive client and patient data, including HIPAA-regulated PHI.
Employees
We presently have 14 total employees all of whom are full-time for operations.
OUR CORPORATE INFORMATION
Our principal corporate office is located at 501 1st Avenue, Suite 901 St. Petersburg, FL 33701. Our telephone number is (678) 607-6393. AHA’s office are located at 2455 East Sunrise Blvd. Suite 1204 Fort Lauderdale FL, 33304. AHP’s offices are located at 7422 Garvey Ave. Ste 101 Rosemead, CA 91755. We currently operate a corporate websites that can be found at www.clinigencehealth.com., www.ahpscipa.com and www.ahahealthcare.net (The information on the foregoing websites do not form a part of this report).
ITEM 1A. RISK FACTORS
Our operations and financial results are subject to various risks and uncertainties, including but not limited to those described below, which could harm our business, reputation, financial condition, and operating results.
There is substantial doubt as to our ability to continue as a going concern.
The notes accompanying our December 31, 2020 and 2019 audited financial statements, and as noted on the Report of Independent Registered Public Accounting Firm , contain an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern. The financial statements have been prepared “assuming that the Company will continue as a going concern.” Our ability to continue as a going concern is dependent on raising additional capital to fund our operations and ultimately on generating future profitable operations. There can be no assurance that we will be able to raise sufficient additional capital or eventually have positive cash flow from operations to address all of our cash flow needs. If we are not able to find alternative sources of cash or generate positive cash flow from operations, our business and shareholders may be materially and adversely affected.
| 10 |
We may not be able to obtain adequate financing to continue our operations.
As of December 31, 2020 we had a working capital deficiency and we have operated at a net loss since inception. In order to execute our business plan, including the expansion of operations, our primary capital requirements in 2021 are likely to rise. It is not possible to quantify those costs at this point in time, in that they depend on Clinigence Health’s business opportunities and the state of the overall economy. We anticipate raising capital in the private markets to cover any such costs, though there can be no guaranty we will be able to do so on terms we deem to be acceptable. We do not have any plans at this point in time to obtain a line of credit or other loan facility from a commercial bank. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock that may have a greater dilutive impact to our current shareholders. Additional financing may not be available upon acceptable terms, or at all.
Clinigence Health has a limited prior operating history and it is impossible to reliably predict future growth and operating results.
The Company was incorporated in April 2000 and consummated a reverse merger with Clinigence Holdings Inc. on October 29, 2019 and two additional Mergers in February 2021. Clinigence Health is the Company’s wholly owned subsidiary and was the result of the combination of Clinigence LLC (founded in 2010) and QualMetrix, Inc. (founded in 2013), on March 1, 2019. Accordingly, the Company has a limited prior operating history upon which you can evaluate its business prospects, and it is difficult to forecast the Company’s future operating results. The evolving nature of the PHM industry increases these uncertainties. You must consider the Company’s business prospects in light of the risks, uncertainties, and problems frequently encountered by companies with limited operating histories. Clinigence, LLC provided clinical business intelligence software-as-a-service (SaaS) to healthcare organizations. QualMetrix, Inc. was a population health claims analytics company that provided turnkey SaaS solutions to healthcare organizations.
The success of the Company’s growth strategy depends on the successful identification, completion and integration of acquisitions.
The Company’s future success will depend on the ability to identify, complete, and integrate the acquired businesses with the Company’s existing operations. The growth strategy will result in additional demands on the Company’s infrastructure, and will place further strain on limited management, administrative, operational, financial and technical resources. Acquisitions involve numerous risks, including, but not limited to:
| • | the possibility that the Company is not able to identify suitable acquisition |
| • | candidates or consummate acquisitions on acceptable terms, if at all; |
| • | possible decreases in capital resources or dilution to existing stockholders; |
| • | difficulties and expenses incurred in connection with an acquisition; |
| • | the diversion of management’s attention from other business concerns; |
| • | the difficulties of managing an acquired business; |
| • | the potential loss of key employees and customers of an acquired business; |
| • | in the event that the operations of an acquired business do not meet expectations, |
| • | the Company may be required to restructure the acquired entity or write-off the |
| • | value of some or all of the assets of the acquisition. |
| 11 |
The Company has an unproven business model with no assurance of significant revenues or operating profit.
The current business model is unproven and the profit potential, if any, is unknown at this time. The Company is subject to all of the risks inherent in the creation of a new business. The Company’s ability to achieve profitability is dependent, among other things, on its initial marketing to generate sufficient operating cash flow to fund future expansion. There can be no assurance that the Company’s results of operations or business strategy will achieve significant revenue or profitability.
The PHM market is fairly new and unproven, and it may decline or experience limited growth, which would adversely affect our ability to fully realize the potential of our platform.
The PHM market is relatively new and evaluating the size and scope of the market is subject to a number of risks and uncertainties. We believe that our future success will depend in large part on the growth of this market. The utilization of our platform is still relatively new, and customers may not recognize the need for, or benefits of, our platform, which may prompt them to cease use of our platform or decide to adopt alternative products and services to satisfy their healthcare requirements. In order to expand our business and extend our market position, we intend to focus our marketing and sales efforts on educating customers about the benefits and technological capabilities of our platform and the application of our platform to specific needs of customers in different market verticals. Our ability to access and expand the market that our platform is designed to address depends upon a number of factors, including the cost, performance and perceived value of our platform. Assessing the market for our solutions in each of the vertical markets we are competing in, or planning to compete in, is particularly difficult due to a number of factors, including limited available information and rapid evolution of the market. The market for our platform, or for PHM applications, may fail to grow significantly or be unable to meet the level of growth we expect. As a result, we may experience lower-than-expected demand for our products and services due to lack of customer acceptance, technological challenges, competing products and services, decreases in spending by current and prospective customers, weakening economic conditions and other causes. If our market does not experience significant growth, or if demand for our platform does not increase, then our business, results of operations and financial condition will be adversely affected.
We conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, financial condition, and results of operations.
The healthcare industry is heavily regulated and closely scrutinized by federal, state and local governments. Comprehensive statutes and regulations govern the manner in which we provide and bill for services and collect reimbursement from governmental programs and private payors, our contractual relationships with our providers, vendors and clients, our marketing activities and other aspects of our operations. Of particular importance are:
| • | the federal physician self-referral law, commonly referred to as the Stark Law; |
| • | the federal Anti-Kickback Act; |
| • | the criminal healthcare fraud provisions of HIPAA; |
| • | the federal False Claims Act; |
| • | reassignment of payment rules that prohibit certain types of billing and collection; |
| • | similar state law provisions pertaining to anti-kickback, self-referral and false claims issues; |
| • | state laws that prohibit general business corporations, such as us, from practicing medicine; |
| • | laws that regulate debt collection practices as applied to our debt collection practices; |
| 12 |
Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Achieving and sustaining compliance with these laws may prove costly. Failure to comply with these laws and other laws can result in civil and criminal penalties such as fines, damages, overpayment recoupment loss of enrollment status and exclusion from the Medicare and Medicaid programs. The risk of our being found in violation of these laws and regulations is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are sometimes open to a variety of interpretations. Our failure to accurately anticipate the application of these laws and regulations to our business or any other failure to comply with regulatory requirements could create liability for us and negatively affect our business. Any action against us for violation of these laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management’s attention from the operation of our business and result in adverse publicity.
To enforce compliance with the federal laws, the U.S. Department of Justice and the OIG, have recently increased their scrutiny of healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Dealing with investigations can be time- and resource-consuming and can divert management’s attention from the business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business. In addition, because of the potential for large monetary exposure under the federal False Claims Act, which provides for treble damages and mandatory minimum penalties of $5,500 to $11,000 per false claim or statement, healthcare providers often resolve allegations without admissions of liability for significant and material amounts to avoid the uncertainty of treble damages that may be awarded in litigation proceedings. Such settlements often contain additional compliance and reporting requirements as part of a consent decree, settlement agreement or corporate integrity agreement. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers’ compliance with the healthcare reimbursement rules and fraud and abuse laws.
The laws, regulations and standards governing the provision of healthcare services may change significantly in the future. We cannot assure you that any new or changed healthcare laws, regulations or standards will not materially adversely affect our business. We cannot assure you that a review of our business by judicial, law enforcement, regulatory or accreditation authorities will not result in a determination that could adversely affect our operations.
The impact of recent healthcare reform legislation and other changes in the healthcare industry and in healthcare spending in the US is currently unknown, but may adversely affect our business, financial condition and results of operations.
Our revenue will be dependent on the healthcare industry and could be affected by changes in healthcare spending and policy. The healthcare industry is subject to changing political, regulatory and other influences. The Patient Protection and Affordable Care Act or PPACA made major changes in how healthcare is delivered and reimbursed and increased access to health insurance benefits to the uninsured and underinsured population of the United States.
The PPACA, among other things, increased the number of individuals with Medicaid and private insurance coverage, implemented reimbursement policies that tie payment to quality, facilitated the creation of accountable care organizations that may use capitation and other alternative payment methodologies, strengthened enforcement of fraud and abuse laws and encouraged the use of information technology. Several of these changes require implementing regulations which have not yet been drafted or have been released only as proposed rules.
| 13 |
Such changes in the regulatory environment may also result in changes to our payor mix that may affect our operations and revenue.
In addition, certain provisions of the PPACA authorize voluntary demonstration projects, which include the development of bundling payments for acute, inpatient hospital services, physician services and post-acute services for episodes of hospital care. Further, the PPACA may adversely affect payors by increasing medical costs generally, which could have an effect on the industry and potentially impact our business and revenue as payors seek to offset these increases by reducing costs in other areas. The full impact of these changes on us cannot be determined at this time.
We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments and other third-party payors will pay for healthcare products and services, which could adversely affect our business, financial condition and results of operations.
Any future litigation against us could be costly and time-consuming to defend.
We may become subject, from time to time, to legal proceedings and claims that arise in the ordinary course of business such as claims brought by our clients in connection with commercial disputes or employment claims made by our current or former associates. Litigation may result in substantial costs and may divert management’s attention and resources, which may substantially harm our business, financial condition and results of operations. Insurance may not cover such claims, may not provide sufficient payments to cover all of the costs to resolve one or more such claims and may not continue to be available on terms acceptable to us. A claim brought against us that is uninsured or underinsured could result in unanticipated costs, thereby reducing our revenue and potential profits.
Our use and disclosure of personally identifiable information, including health information, is subject to federal and state privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm and, in turn, a material adverse effect on our client base, membership base and revenue.
Numerous state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability and integrity of personally identifiable information, or PII, including protected health information. These laws and regulations include HIPAA. HIPAA establishes a set of basic national privacy and security standards for the protection of protected health information, or PHI, by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services, which includes us.
HIPAA requires healthcare providers like us to develop and maintain policies and procedures with respect to PHI that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect such information. HIPAA also implemented the use of standard transaction code sets and standard identifiers that covered entities must use when submitting or receiving certain electronic healthcare transactions, including activities associated with the billing and collection of healthcare claims.
| 14 |
HIPAA imposes mandatory penalties for certain violations. Penalties for violations of HIPAA and its implementing regulations start at $100 per violation and are not to exceed $50,000 per violation, subject to a cap of $1.5 million for violations of the same standard in a single calendar year. However, a single breach incident can result in violations of multiple standards. HIPAA also authorizes state attorneys general to file suit on behalf of their residents. Courts are able to award damages, costs and attorneys’ fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.
In addition, HIPAA mandates that the Secretary of Health and Human Services, or HHS conduct periodic compliance audits of HIPAA covered entities or business associates for compliance with the HIPAA Privacy and Security Standards. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a percentage of the Civil Monetary Penalty fine paid by the violator.
HIPAA further requires that patients be notified of any unauthorized acquisition, access, use or disclosure of their unsecured PHI that compromises the privacy or security of such information, with certain exceptions related to unintentional or inadvertent use or disclosure by employees or authorized individuals. HIPAA specifies that such notifications must be made “without unreasonable delay and in no case later than 60 calendar days after discovery of the breach.” If a breach affects 500 patients or more, it must be reported to HHS without unreasonable delay, and HHS will post the name of the breaching entity on its public web site. Breaches affecting 500 patients or more in the same state or jurisdiction must also be reported to the local media. If a breach involves fewer than 500 people, the covered entity must record it in a log and notify HHS at least annually.
Numerous other federal and state laws protect the confidentiality, privacy, availability, integrity and security of PII, including PHI. These laws in many cases are more restrictive than, and may not be preempted by, the HIPAA rules and may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and our Clients and potentially exposing us to additional expense, adverse publicity and liability.
New health information standards, whether implemented pursuant to HIPAA, congressional action or otherwise, could have a significant effect on the manner in which we must handle healthcare related data, and the cost of complying with standards could be significant. If we do not comply with existing or new laws and regulations related to PHI, we could be subject to criminal or civil sanctions.
Because of the extreme sensitivity of the PII we store and transmit, the security features of our technology platform are very important. If our security measures, some of which are managed by third parties, are breached or fail, unauthorized persons may be able to obtain access to sensitive client and patient data, including HIPAA-regulated PHI. As a result, our reputation could be severely damaged, adversely affecting client and patient confidence. Members may curtail their use of or stop using our services or our client base could decrease, which would cause our business to suffer. In addition, we could face litigation, damages for contract breach, penalties and regulatory actions for violation of HIPAA and other applicable laws or regulations and significant costs for remediation, notification to individuals and for measures to prevent future occurrences. Any potential security breach could also result in increased costs associated with liability for stolen assets or information, repairing system damage that may have been caused by such breaches, incentives offered to clients or other business partners in an effort to maintain our business relationships after a breach and implementing measures to prevent future occurrences, including organizational changes, deploying additional personnel and protection technologies, training employees and engaging third-party experts and consultants. While we maintain insurance covering certain security and privacy damages and claim expenses in the amount of at least $3.0 million, we may not carry insurance or maintain coverage sufficient to compensate for all liability and in any event, insurance coverage would not address the reputational damage that could result from a security incident.
| 15 |
We outsource important aspects of the storage and transmission of Client and Member information, and thus rely on third parties to manage functions that have material cyber-security risks. We attempt to address these risks by requiring outsourcing subcontractors who handle client and patient information to sign business associate agreements contractually requiring those subcontractors to adequately safeguard personal health data to the same extent that applies to us and in some cases by requiring such outsourcing subcontractors to undergo third-party security examinations. In addition, we periodically hire third-party security experts to assess and test our security posture. However, we cannot assure you that these contractual measures and other safeguards will adequately protect us from the risks associated with the storage and transmission of client and patient’s proprietary and protected health information.
In addition, various states have enacted laws governing the privacy of personal information collected and used by businesses online. For example, California has recently adopted the California Consumer Privacy Act of 2018, which went into effect on January 1, 2020. This law, in part, requires that companies make certain disclosures to consumers via their privacy policies, or otherwise at the time the personal data is collected. The Company will have to determine what personal data it is collecting from individuals and for what purposes, and to update its privacy policy every 12 months to make the required disclosures, among other things. Since this law is newly enacted and has not yet gone into effect, it is unclear whether it will have any material impact on the Company’s business and operations.
The success of our business depends on our ability to expand into new vertical markets and attract new customers in a cost-effective manner.
In order to grow our business, we plan to drive greater awareness and adoption of our platform from enterprises across new vertical markets. We intend to increase our investment in sales and marketing, as well as in technological development, to meet evolving customer needs in these and other markets. There is no guarantee, however, that we will be successful in gaining new customers from any or all of these markets. We have limited experience in marketing and selling our products and services generally, and in particular in these new markets, which may present unique and unexpected challenges and difficulties.
If the costs of the new marketing channels we use increase dramatically, then we may choose to use alternative and less expensive channels, which may not be as effective as the channels we currently use. As we add to or change the mix of our marketing strategies, we may need to expand into more expensive channels than those we are currently in, which could adversely affect our business, results of operations and financial condition. In addition, we have limited experience marketing our products and platform and we may not be successful in selecting the marketing channels that will provide us with exposure to customers in a cost-effective manner. As part of our strategy to penetrate the new vertical markets, we will incur marketing expenses before we are able to recognize any revenue in such markets, and these expenses may not result in increased revenue or brand awareness. We have made in the past, and may make in the future, significant expenditures and investments in new marketing campaigns, and these investments may not lead to the cost-effective acquisition of additional customers. If we are unable to maintain effective marketing programs, then our ability to attract new customers or enter into new vertical markets could be adversely affected.
| 16 |
We expect to derive a significant portion of our revenues from our largest customers. The loss, termination or renegotiation of any contract could negatively impact our results.
Historically, the Company relied on a limited number of customers for a substantial portion of their total revenue and accounts receivable. In 2020, the largest three customers of the Company represented 36.83% of revenues during that period.
The sudden loss of any of our customers, or the renegotiation of any of our customer contracts, could adversely affect our operating results. In 2020, our customer base remained relatively level whereas in 2019 our operating results were adversely affected as a result of the loss of several customer contracts, principally due to consolidation in the health care industry. Some customer contracts were lost due to the acquisition of our customer by another organization. Additionally, other smaller customer contracts were lost because these smaller customers were unable to compete against the larger consolidated companies and they subsequently had to discontinue their businesses.
Because we rely on a limited number of customers for a significant portion of our revenues, we depend on the creditworthiness of these customers. Our customers are subject to a number of risks including reductions in payment rates from governmental payers, higher than expected health care costs and lack of predictability of financial results when entering new lines of business, particularly with high-risk populations, such as plans established under the ACA and Aged, Blind and Disabled Medicaid. If the financial condition of our customers declines, our credit risk could increase. Should one or more of our significant customers declare bankruptcy, be declared insolvent or otherwise be restricted by state or federal laws or regulation from continuing in some or all of their operations, this could adversely affect our ongoing revenues, the collectability of our accounts receivable and affect our bad debt reserves and net income.
Although we have long-term contracts with many customers, these contracts may be terminated before their term expires for various reasons, such as changes in the regulatory landscape and poor performance by us, subject to certain conditions. For example, after a specified period, certain of these contracts are terminable for convenience by our customers after a notice period has passed and the customer has paid a termination fee. Certain of our contracts are terminable immediately upon the occurrence of certain events. For example, some of our contracts may be terminated by the customer if we fail to achieve target performance metrics over a specified period. Certain of the contracts to which the Company or its subsidiaries is a party may be terminated by the customer immediately following repeated failures by us to provide specified levels of service over periods ranging from six months to more than a year. Certain of our contracts may be terminated immediately by the customer if we lose applicable licenses, go bankrupt, lose our liability insurance or receive an exclusion, suspension or debarment from state or federal government authorities. In addition, one of our contracts may be terminated immediately if we become insolvent or file for bankruptcy. If any of our contracts with our customers is terminated, we may not be able to recover all fees due under the terminated contract, which may adversely affect our operating results. We expect that future contracts will contain similar provisions.
| 17 |
Consolidation in the health care industry could have a material adverse effect on our business, financial condition and results of operations.
Many health care industry participants and payers are consolidating to create larger and more integrated health care delivery systems with greater market power. We expect regulatory and economic conditions to result in additional consolidation in the health care industry in the future. As consolidation accelerates, the economies of scale of our customers’ organizations may grow. If a customer experiences sizable growth following consolidation, it may determine that it no longer needs to rely on us and may reduce its demand for our products and services. In addition, as health care providers consolidate to create larger and more integrated health care delivery systems with greater market power, these providers may try to use their market power to negotiate fee reductions for our products and services. Finally, consolidation may also result in the acquisition or future development by our customers of products and services that compete with our products and services. Any of these potential results of consolidation could have a material adverse effect on our business, financial condition and results of operations.
Our use of “open source” software could adversely affect our ability to offer our services and subject us to possible litigation.
We use open source software in connection with our products and services. Companies that incorporate open source software into their products have, from time to time, faced claims challenging the use of open source software and/or compliance with open source license terms. As a result, we could be subject to suits by parties claiming ownership of what we believe to be open source software or claiming noncompliance with open source licensing terms. Some open source software licenses require users who distribute software containing open source software to publicly disclose all or part of the source code to such software and/or make available any derivative works of the open source code, which could include valuable proprietary code of the user, on unfavorable terms or at no cost. While we monitor the use of open source software and try to ensure that none is used in a manner that would require us to disclose our proprietary source code or that would otherwise breach the terms of an open source agreement, such use could inadvertently occur, in part because open source license terms are often ambiguous. Any requirement to disclose our proprietary source code or pay damages for breach of contract could have a material adverse effect on our business, financial condition and results of operations and could help our competitors develop products and services that are similar to or better than ours.
Our business will depend on customers increasing their use of our services and/or platform, and we may experience loss of customers or decline in their use of our services and/or platform.
Our ability to grow and generate revenue depends, in part, on our ability to maintain and grow our relationships with existing customers and convince them to increase their usage of our platform. If our customers do not increase their use of our platform, then our revenue may not grow and our results of operations may be harmed. It is difficult to accurately predict customers’ usage levels and the loss of customers or reductions in their usage levels may have a negative impact on our business, results of operations and financial condition. If a significant number of customers cease using, or reduce their usage of, our platform, then we may be required to spend significantly more on sales and marketing than we currently plan to spend in order to maintain or increase revenue from customers. These additional expenditures could adversely affect our business, results of operations and financial condition. Most of our customers do not have long-term contractual financial commitments to us and, therefore, most of our customers may reduce or cease their use of our platform at any time without penalty or termination charges.
| 18 |
2020, our customer base remained relatively level whereas in 2019 our operating results were adversely affected as a result of the loss of several customer contracts, principally due to consolidation in the health care industry. Some customer contracts were lost due to the acquisition of our customer by another organization. Additionally, other smaller customer contracts were lost because these smaller customers were unable to compete against the larger consolidated companies and they subsequently had to discontinue their businesses.
Interruptions or performance problems associated with our technology and infrastructure may adversely affect our business and operating results.
Our continued growth will depend in part on the ability of customers to access our platform at any time and within an acceptable amount of time. We may experience, disruptions, outages and other performance problems due to a variety of factors, including infrastructure changes, introductions of new applications and functionality, software errors and defects, capacity constraints due to an increasing number of users accessing our platform simultaneously, or security related incidents. In addition, from time to time we may experience limited periods of server downtime due to server failure or other technical difficulties (as well as maintenance requirements). It may become increasingly difficult to maintain and improve our performance, especially during peak usage times and as our platform becomes more complex and our user traffic increases. If our platform is unavailable or if our users are unable to access our platform within a reasonable amount of time or at all, our business would be adversely affected, and our brand could be harmed. In the event of any of the factors described above, or certain other failures of our infrastructure, customer or consumer data may be permanently lost. To the extent that we do not effectively address capacity constraints, upgrade our systems as needed, and continually develop our technology and network architecture to accommodate actual and anticipated changes in technology, customers and consumers may cease to use our platform and our business and operating results may be adversely affected.
The security of our platform, networks or computer systems may be breached, and any unauthorized access to our customer data will have an adverse effect on our business and reputation.
The use of our platform will involve the storage, transmission and processing of our clients’ private data, and this data may contain confidential and proprietary information of our clients or other personal or identifying information regarding our clients, their employees or other persons. Individuals or entities may attempt to penetrate our network or platform security, or that of our third-party hosting and storage providers, and could gain access to our clients’ private data, which could result in the destruction, disclosure or misappropriation of proprietary or confidential information of our clients’ or their customers, employees and business partners. If any of our clients’ private data is leaked, obtained by others or destroyed without authorization, it could harm our reputation, we could be exposed to civil and criminal liability, and we may lose our ability to access private data, which will adversely affect the quality and performance of our platform.
In addition, our platform may be subject to computer malware, viruses and computer hacking, fraudulent use attempts and phishing attacks, all of which have become more prevalent in our industry. Though it is difficult to determine what, if any, harm may directly result from any specific interruption or attack, they may include the theft or destruction of data owned by us or our customers, and/or damage to our platform. Any failure to maintain the performance, reliability, security and availability of our products or services and technical infrastructure to the satisfaction of our customers may harm our reputation and our ability to retain existing customers and attract new users.
| 19 |
While we will implement procedures and safeguards that are designed to prevent security breaches and cyber-attacks, they may not be able to protect against all attempts to breach our systems, and we may not become aware in a timely manner of any such security breach. Unauthorized access to or security breaches of our platform, network or computer systems, or those of our technology service providers, could result in the loss of business, reputational damage, regulatory investigations and orders, litigation, indemnity obligations, damages for contract breach, civil and criminal penalties for violation of applicable laws, regulations or contractual obligations, and significant costs, fees and other monetary payments for remediation. If customers believe that our platform does not provide adequate security for the storage of sensitive information or its transmission over the Internet, our business will be harmed. Customers’ concerns about security or privacy may deter them from using our platform for activities that involve personal or other sensitive information.
Privacy and data security laws and regulations could require us to make changes to our business, impose additional costs on us and reduce the demand for our software solutions.
Our business model contemplates that we will store, process and transmit both public data and our clients’ private data. Our customers may store and/or transmit a significant amount of personal or identifying information through our platform. Privacy and data security have become significant issues in the United States and in other jurisdictions where we may offer our software solutions. The regulatory framework relating to privacy and data security issues worldwide is evolving rapidly and is likely to remain uncertain for the foreseeable future. Federal, state and foreign government bodies and agencies have in the past adopted, or may in the future adopt, laws and regulations regarding the collection, use, processing, storage and disclosure of personal or identifying information obtained from customers and other individuals. In addition to government regulation, privacy advocates and industry groups may propose various self-regulatory standards that may legally or contractually apply to our business. Because the interpretation and application of many privacy and data security laws, regulations and applicable industry standards are uncertain, it is possible that these laws, regulations and standards may be interpreted and applied in a manner inconsistent with our existing privacy and data management practices. As we expand into new jurisdictions or verticals, we will need to understand and comply with various new requirements applicable in those jurisdictions or verticals.
To the extent applicable to our business or the businesses of our customers, these laws, regulations and industry standards could have negative effects on our business, including by increasing our costs and operating expenses, and delaying or impeding our deployment of new core functionality and products. Compliance with these laws, regulations and industry standards requires significant management time and attention, and failure to comply could result in negative publicity, subject us to fines or penalties or result in demands that we modify or cease existing business practices. In addition, the costs of compliance with, and other burdens imposed by, such laws, regulations and industry standards may adversely affect our customers’ ability or desire to collect, use, process and store personal information using our software solutions, which could reduce overall demand for them. Even the perception of privacy and data security concerns, whether or not valid, may inhibit market acceptance of our software solutions in certain verticals. Furthermore, privacy and data security concerns may cause our customers’ clients, vendors, employees and other industry participants to resist providing the personal information necessary to allow our customers to use our applications effectively. Any of these outcomes could adversely affect our business and operating results.
| 20 |
Any failure to offer high-quality customer support may adversely affect our relationships with our customers.
Our ability to retain existing customers and attract new customers will depend in part on our ability to maintain a consistently high level of customer service and technical support. Our customers depend on our service support team to assist them in utilizing our platform effectively and to help them to resolve issues quickly and to provide ongoing support. If we are unable to hire and train sufficient support resources or are otherwise unsuccessful in assisting our customers effectively, it could adversely affect our ability to retain existing customers and could prevent prospective customers from adopting our platform. We may be unable to respond quickly enough to accommodate short-term increases in demand for customer support. We also may be unable to modify the nature, scope and delivery of our customer support to compete with changes in the support services provided by our competitors. Increased demand for customer support, without corresponding revenue, could increase our costs and adversely affect our business, results of operations and financial condition. Our sales are expected to be highly dependent on our business reputation and on positive recommendations from customers. Any failure to maintain high-quality customer support, or a market perception that we do not maintain high-quality customer support, could adversely affect our reputation, business, results of operations and financial condition.
We could incur substantial costs in protecting or defending our intellectual property rights, and any failure to protect our intellectual property could adversely affect our business, results of operations and financial condition.
Our success depends, in part, on our ability to protect our brand and the proprietary methods and technologies that we develop under patent and other intellectual property laws of the United States and foreign jurisdictions so that we can prevent others from using our inventions and proprietary information. Clinigence Health Inc. owns U.S. Patent Application No. 15/882,688, which is a utility patent application currently pending before the United States Patent and Trademark Office. Any patents that have been applied for or that may be issued in the future may not provide significant protection for our intellectual property. If we fail to protect our intellectual property rights adequately, our competitors might gain access to our technology and our business, results of operations and financial condition may be adversely affected.
The particular forms of intellectual property protection that we seek, or our business decisions about when to file patent applications and trademark applications, may not be adequate to protect our business. We could be required to spend significant resources to monitor and protect our intellectual property rights. Litigation may be necessary in the future to enforce our intellectual property rights, determine the validity and scope of our proprietary rights or those of others, or defend against claims of infringement or invalidity. Such litigation could be costly, time-consuming and distracting to management, result in a diversion of significant resources, lead to the narrowing or invalidation of portions of our intellectual property and have an adverse effect on our business, results of operations and financial condition. Our efforts to enforce our intellectual property rights may be met with defenses, counterclaims and countersuits attacking the validity and enforceability of our intellectual property rights or alleging that we infringe the counterclaimant’s own intellectual property. Any of our patents, patent applications, copyrights, trademarks or other intellectual property rights could be challenged by others or invalidated through administrative process or litigation.
We expect to also rely, in part, on confidentiality agreements with our business partners, employees, consultants, advisors, customers and others in our efforts to protect our proprietary technology, processes and methods. These agreements may not effectively prevent disclosure of our confidential information, and it may be possible for unauthorized parties to copy our software or other proprietary technology or information, or to develop similar software independently without our having an adequate remedy for unauthorized use or disclosure of our confidential information. In addition, others may independently discover our trade secrets and proprietary information, and in these cases we would not be able to assert any trade secret rights against those parties. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and the failure to obtain or maintain trade secret protection could adversely affect our competitive business position.
| 21 |
In addition, the laws of some countries do not protect intellectual property and other proprietary rights to the same extent as the laws of the United States. To the extent we expand our international activities, our exposure to unauthorized copying, transfer and use of our proprietary technology or information may increase.
Our means of protecting our intellectual property and proprietary rights may not be adequate or our competitors could independently develop similar technology. If we fail to meaningfully protect our intellectual property and proprietary rights, our business, results of operations and financial condition could be adversely affected.
Assertions by third parties of infringement or other violations by us of their intellectual property rights could result in significant costs and harm our business and operating results.
Our success depends upon our ability to refrain from infringing upon the intellectual property rights of others. Some companies, including some of our competitors, own large numbers of patents, copyrights and trademarks, which they may use to assert claims against us. As we grow and enter new markets, we will face a growing number of competitors. As the number of competitors in our industry grows and the functionality of products in different industry segments overlaps, we expect that software and other solutions in our industry may be subject to such claims by third parties. Third parties may in the future assert claims of infringement, misappropriation or other violations of intellectual property rights against us. We cannot assure you that infringement claims will not be asserted against us in the future, or that, if asserted, any infringement claim will be successfully defended. A successful claim against us could require that we pay substantial damages or ongoing royalty payments, prevent us from offering our services, or require that we comply with other unfavorable terms. We may also be obligated to indemnify our customers or business partners or pay substantial settlement costs, including royalty payments, in connection with any such claim or litigation and to obtain licenses, modify applications or refund fees, which could be costly. Even if we were to prevail in such a dispute, any litigation regarding our intellectual property could be costly and time-consuming and divert the attention of our management and key personnel from our business operations.
The information that we expect to provide to our clients could be inaccurate or incomplete, which could harm our business reputation, financial condition, and results of operations.
We expect to aggregate, process, and analyze healthcare-related data and information for use by our clients. Because data in the healthcare industry is fragmented in origin, inconsistent in format, and often incomplete, the overall quality of data received or accessed in the healthcare industry is often poor, the degree or amount of data which is knowingly or unknowingly absent or omitted can be material, and we frequently discover data issues and errors during our data integrity checks. If the analytical data that we expect to provide to our clients are based on incorrect or incomplete data or if we make mistakes in the capture, input, or analysis of these data, our reputation may suffer and our ability to attract and retain clients may be materially harmed.
| 22 |
In addition, we expect to assist our clients with the management and submission of data to governmental entities, including CMS. These processes and submissions are governed by complex data processing and validation policies and regulations. If we fail to abide by such policies or submit incorrect or incomplete data, we may be exposed to liability to a client, court, or government agency that concludes that our storage, handling, submission, delivery, or display of health information or other data was wrongful or erroneous.
Our proprietary applications may not operate properly, which could damage our reputation, give rise to a variety of claims against us, or divert our resources from other purposes, any of which could harm our business and operating results.
Proprietary software and application development is time-consuming, expensive, and complex, and may involve unforeseen difficulties. We may encounter technical obstacles, and it is possible that we discover additional problems that prevent our proprietary applications from operating properly. If our applications and services do not function reliably or fail to achieve client expectations in terms of performance, clients could assert liability claims against us and attempt to cancel their contracts with us. Moreover, material performance problems, defects, or errors in our existing or new applications and services may arise in the future and may result from, among other things, the lack of interoperability of our applications with systems and data that we did not develop and the function of which is outside of our control or undetected in our testing. Defects or errors in our applications might discourage existing or potential clients from purchasing services from us. Correction of defects or errors could prove to be time consuming, costly, impossible, or impracticable. The existence of errors or defects in our applications and the correction of such errors could divert our resources from other matters relating to our business, damage our reputation, increase our costs, and have a material adverse effect on our business, financial condition, and results of operations.
As a result of variable sales and implementation cycles, we might not be able to recognize revenue to offset expenditures, which could result in fluctuations in our quarterly results of operations or otherwise adversely affect our future operating results.
The sales cycle for our services is expected to be typically four to six months from initial contact to contract execution, but can vary depending on the particular client, product under consideration, and time of year, among other factors. Some clients, for instance, undertake a more prolonged evaluation process, which has in the past resulted in extended sales cycles. Our sales efforts are expected to involve educating potential clients about the use, technical capabilities, and benefits of our services, and gaining an understanding of their needs and budgets. During the sales cycle, we expect to expend significant time and resources, and we do not recognize any revenue to offset such expenditures, which could result in fluctuations in our quarterly results of operations and adversely affect our future operating results. In addition, we may be unable to enter into definitive contracts at the end of a sales cycle on terms that are favorable to us or at all, in some cases for reasons outside our control, which may materially adversely affect our business and prospects.
After a client contract is signed, we expect to provide an implementation process for the client during which we load, test, and integrate data into our system and train client personnel. Our implementation cycle generally ranges from 20 to 90 days from contract execution to completion of implementation but can vary depending on the amount and quality of the client’s data and how quickly the client facilitates access to data. In addition, for certain clients, our third-party vendors must go through delegation processes in order to become authorized to provide certain services to those clients, which could delay our ability to provide such services to those clients. During the implementation cycle, we expect to expend time, effort, and financial resources implementing our services, but accounting principles do not allow us to recognize the resulting revenue until implementation is complete and the services are available for use by our clients. If implementation periods are extended, revenue recognition will be delayed, which could adversely affect our results of operations in certain periods.
| 23 |
In addition, because most of our revenue in each quarter is expected to be derived from agreements entered into with our clients during previous quarters, the negative impacts resulting from a decline in new or renewed agreements in any one quarter may not be fully reflected in our revenue for that quarter. Such declines, however, would negatively affect our revenue in future periods and the effect of significant downturns in sales of and market demand for our services, and potential changes in our renewal rates or renewal terms may not be fully reflected in our results of operations until future periods. Our sales and implementation cycles are expected to also make it difficult for us to rapidly increase our total revenue through additional sales in any period. As a result, the effect of changes in the industry impacting our business, or changes we experience in our new sales, may not be reflected in our short-term results of operations.
We could experience losses or liability not covered by insurance.
Our business will expose us to risks that are inherent in the provision of analytics and toolsets that assist clinical decision-making. If clients or individuals assert liability claims against us, any ensuing litigation, regardless of outcome, could result in a substantial cost to us, divert management’s attention from operations, and decrease market acceptance of our toolsets. We expect to attempt to limit our liability to clients by contract; however, the limitations of liability set forth in the contracts may not be enforceable or may not otherwise protect us from liability for damages. Additionally, we may be subject to claims that are not explicitly covered by contract. We also maintain general liability coverage; however, this coverage may not continue to be available on acceptable terms, may not be available in sufficient amounts to cover one or more large claims against us, and may include larger self-insured retentions or exclusions for certain products. In addition, the insurer might disclaim coverage as to any future claim. A successful claim not fully covered by our insurance could have a material adverse impact on our liquidity, financial condition, and results of operations.
If we are unable to hire, retain and motivate qualified personnel, our business will suffer.
Our future success depends, in part, on our ability to continue to attract and retain highly skilled personnel. We believe that there is, and will continue to be, intense competition for highly skilled management, engineering, data science, sales and other personnel with experience in our industry. We must provide competitive compensation packages and a high-quality work environment to hire, retain and motivate employees. If we are unable to retain and motivate our existing employees and attract qualified personnel to fill key positions, we may be unable to manage our business effectively, including the development, marketing and sale of our products, which could adversely affect our business, results of operations and financial condition. To the extent we hire personnel from competitors, we also may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information. If we are unable to retain our employees, our business, results of operations and financial condition could be adversely affected.
| 24 |
Our Board of Directors may change our strategies, policies, and procedures without stockholder approval, and we may become more highly leveraged, which may increase our risk of default under our debt obligations.
Our investment, financing, leverage, and dividend policies, and our policies with respect to all other activities, including growth, capitalization, and operations, are determined exclusively by our board of directors, and may be amended or revised at any time by our board of directors without notice to or a vote of our stockholders. This could result in us conducting operational matters, making investments, or pursuing different business or growth strategies than those contemplated in this private placement memorandum. Further, our charter and bylaws do not limit the amount or percentage of indebtedness, funded or otherwise, that we may incur. Higher leverage also increases the risk of default on our obligations. In addition, a change in our investment policies, including the manner in which we allocate our resources across our portfolio or the types of assets in which we seek to invest, may increase our exposure to interest rate risk and liquidity risk. Changes to our policies with regards to the foregoing could materially adversely affect our financial condition, results of operations, and cash flow.
The COVID-19 pandemic has impacted our operations and similar unforeseen and uncontrollable events may impact our operations in the future.
The COVID-19 pandemic has resulted in social distancing, travel bans and quarantine, and this has limited access to our facilities, customers, management, support staff and professional advisors. These factors, in turn, have had an impact on our operations, financial condition and demand for our goods and services as well as our overall ability to react timely to mitigate the impact of this event. Also, it has hampered our efforts to comply with our filing obligations with the Securities and Exchange Commission. While we have learned from the COVID-19 pandemic and its result on our operations and financial condition, because of the nature of these events, we cannot assure you that we will be well-prepared for similar unforeseen and uncontrollable events that may occur in the future.
Our business will be subject to the risks of earthquakes, fire, floods and other natural catastrophic events, health epidemics or pandemics, and to interruption by man-made problems such as power disruptions, computer viruses, data security breaches or terrorism.
We expect to have facilities located in the Southeast United States, including Florida, a region known for hurricane activity. A significant natural disaster, such as a hurricane or a flood, occurring at our headquarters, at one of our other facilities or where a business partner is located could adversely affect our business, results of operations and financial condition. Further, if a natural disaster, health epidemics or pandemic, or man-made problem were to affect our network service providers or Internet service providers, this could adversely affect the ability of our customers to use our products and platform. In addition, health epidemics or pandemics, natural disasters and acts of terrorism could cause disruptions in our business, or the businesses of our customers or service providers. We also expect to rely on our network and third-party infrastructure and enterprise applications and internal technology systems for our engineering, sales and marketing and operations activities. Although we maintain incident management and disaster response plans, in the event of a major disruption caused by a health epidemic or pandemic, natural disaster or man-made problem, we may be unable to continue our operations and may endure system interruptions, reputational harm, delays in our development activities, lengthy interruptions in service, breaches of data security and loss of critical data, any of which could adversely affect our business, results of operations and financial condition.
| 25 |
Our solutions face intense competition in the marketplace. If we are unable to compete effectively, our operating results could be adversely affected.
The market for our solutions is increasingly competitive, rapidly evolving and fragmented, and is subject to changing technology and shifting customer needs. Although we believe that our platform and the solutions that it offers are unique, many vendors develop and market products and services that compete to varying extents with our offerings, and we expect competition in our market to continue to intensify. Moreover, industry consolidation may increase competition.
Many of our existing expected competitors, as well as a number of potential new competitors, have longer operating histories, greater name recognition, more established customer bases and significantly greater financial, technical, marketing and other resources than we do. As a result, our competitors may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards or customer requirements. We could lose customers if our competitors introduce new competitive products and technologies, add new features, acquire competitive products, reduce prices, form strategic alliances with other companies or are acquired by third parties with greater available resources. We expect to also face competition from a variety of vendors of cloud-based and on-premise software applications that address only a portion of one of our solutions. We may also face increasing competition from open source software initiatives, in which competitors may provide software and intellectual property for free. In addition, if a prospective customer is currently using a competing solution, the customer may be unwilling to switch to our solutions without access to setup support services. If we are unable to provide those services on terms attractive to the customer, the prospective customer may be unwilling to utilize our solutions. If our competitors’ products, services or technologies become more accepted than our solutions, if they are successful in bringing their products or services to market earlier than ours, or if their products or services are more technologically capable than ours, then our revenue could be adversely affected. In addition, some of our competitors may offer their products and services at a lower price. If we are unable to achieve our target pricing levels, our operating results would be negatively affected. Pricing pressures and increased competition could result in reduced sales, reduced margins, losses or a failure to maintain or improve our competitive market position, any of which would adversely affect our business.
If we do not keep pace with technological changes, our solutions may become less competitive and our business may suffer.
Our market is expected to be characterized by rapid technological change, frequent product and service innovation and evolving industry standards. If we are unable to provide enhancements and new features for our existing solutions or new solutions that achieve market acceptance or that keep pace with these technological developments, our business could be adversely affected. The success of enhancements, new features and solutions depends on several factors, including the timely completion, introduction and market acceptance of the enhancements or new features or solutions. Failure in this regard may significantly impair our revenue growth. In addition, because our solutions are designed to operate on a variety of systems, we will need to continuously modify and enhance our solutions to keep pace with changes in internet-related hardware, software, communication, browser and database technologies. We may not be successful in either developing these modifications and enhancements or in bringing them to market in a timely fashion. Furthermore, uncertainties about the timing and nature of new network platforms or technologies, or modifications to existing platforms or technologies, could increase our research and development expenses. Any failure of our solutions to keep pace with technological changes or operate effectively with future network platforms and technologies could reduce the demand for our solutions, result in customer dissatisfaction and adversely affect our business.
| 26 |
We may record future intangible asset impairment charges related to one or more of our subsidiaries, which could materially adversely impact our results of operations.
We test our goodwill balances during the fourth quarter of each year for impairment, or more frequently if indicators are present or changes in circumstances suggest that impairment may exist. We assess goodwill for impairment at the reporting unit level and, in evaluating the potential for impairment of goodwill, we make assumptions regarding estimated revenue projections, growth rates, cash flows and discount rates. On a quarterly basis, we monitor the key drivers of fair value to detect events or other changes that would warrant an interim impairment test of our goodwill and other intangible assets. Relatively small declines in the future performance and cash flows of a reporting unit or asset group, changes in our reporting units or in the structure of our business as a result of future reorganizations, acquisitions or divestitures of assets or businesses, or small changes in other key assumptions, may result in the recognition of significant asset impairment charges, which could have a material adverse impact on our results of operations.
Economic conditions or changing consumer preferences could adversely impact the Company.
A downturn in economic conditions in one or more of its markets, such as the current global pandemic associated with COVID-19, could have a material adverse effect on the results of operations, financial condition, business and prospects. Although the Company attempts to stay informed of customer preferences, any sustained failure to identify and respond to trends could have a material adverse effect on its results of operations, financial condition, business and prospects.
The Company’s success depends upon its ability to adapt to a changing market and its continued development of additional services.
Although the Company believes that it will provide a competitive range of products and services, there can be no assurance of acceptance by the marketplace. The procurement of new contracts by the Company may be dependent upon the continuing results achieved with current clients, upon pricing and operational considerations, as well as the potential need for continuing improvement to existing services. Moreover, the markets for such services may not develop as expected nor can there be any assurance that the Company will be successful in its marketing of any such services.
Legal claims could be filed that would have a material adverse effect on our business, operating results and financial condition. We may in the future face risks of litigation and liability claims on technological liability and other matters, the extent of such exposure can be difficult or impossible to estimate and which can negatively impact our financial condition and results of operations.
From time to time, we may be involved in disputes or regulatory inquiries that arise in the ordinary course of business. We expect that the number and significance of these potential disputes may increase as our business expands and our company grows larger. While our agreements with customers limit our liability for damages arising from our solutions, we cannot assure you that these contractual provisions will protect us from liability for damages in the event we are sued. Although we may carry general liability insurance coverage, our insurance may not cover all potential claims to which we are exposed or may not be adequate to indemnify us for all liability that may be imposed. Any claims against us, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time, and result in the diversion of significant operational resources. Because litigation is inherently unpredictable, we cannot assure you that the results of any of these actions will not have a material adverse effect on our business, financial condition, results of operations and prospects.
| 27 |
Although there is no current pending litigation against the Company or its subsidiaries, in the future, clients or competitors may threaten lawsuits for what they believe to be infractions against themselves.
Our operations are subject to numerous US laws and regulations. Liability under these laws involves inherent uncertainties. Violations of these laws and regulations are subject to civil, and, in some cases, criminal sanctions. Although we are not aware of any compliance related issues, we may not have been, or may not be, at all times, in complete compliance with all requirements, and we may incur costs or liabilities in connection with such requirements. We may also incur unexpected interruptions to our operations, administrative injunctions requiring operation stoppages, fines and other penalties.
There can also be no assurance that any insurance coverage we take will be adequate or that we will prevail in any future cases. We can provide no assurance that we will be able to obtain liability insurance that would protect us from any such lawsuits. We are not currently subject to any claims from our employees or customers; however, we may be subject to such claims in the future. In the event that are not covered by insurance, our management could expend significant time addressing any such issues.
If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired.
We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and the rules and regulations of the applicable listing standards of the New York Stock Exchange. We expect that the requirements of these rules and regulations will continue to increase our legal, accounting, and financial compliance costs; make some activities more difficult, time-consuming, and costly; and strain our personnel, systems, and resources.
The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are also required to make a formal assessment and provide an annual management report on the effectiveness of our internal control over financial reporting.. In order to maintain the effectiveness of our disclosure controls and procedures and internal control over financial reporting, we have expended, and anticipate that we will continue to expend, resources, including accounting-related costs and management oversight.
Additionally, current controls and any new controls that we develop may become inadequate because of changes in conditions in our business. Further, additional weaknesses in our disclosure controls and internal control over financial reporting may be discovered in the future. Any failure to maintain or develop effective controls or any difficulties encountered in their implementation or improvement could harm our operating results or cause us to fail to meet our reporting obligations and may result in a restatement of our financial statements for prior periods. Any failure to maintain effective internal control over financial reporting also could adversely affect the results of periodic management evaluations regarding the effectiveness of our internal control over financial reporting.
| 28 |
ITEM 1B. UNRESOLVED STAFF COMMENTS
None.
ITEM 2. PROPERTIES
Our Clinigence operations office is located at 501 1st Avenue, Suite 901 St. Petersburg, FL 33701. AHA’s operations are located at 2455 East Sunrise Blvd. Suite 1204 Fort Lauderdale FL, 33304 and AHP’s operations are located at 7422 Garvey Ave. Ste 101 Rosemead, CA 91755, which we believe is sufficient to accommodate anticipated future growth. We do not own any real property and operate pursuant to leases on the properties described above. We believe our existing leased facilities are in good condition and suitable for the conduct of our business.
ITEM 3. LEGAL PROCEEDINGS
From time-to-time, the Company is involved in various civil actions as part of its normal course of business. The Company is not a party to any litigation that is material to ongoing operations as defined in Item 103 of Regulation S-K as of the period ended December 31, 2020.
ITEM 4. MINE SAFETY DISCLOSURES
Not Applicable
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES
MARKET INFORMATION
In connection with the Acquisition, the Company amended its certificate of incorporation to (i) effect a reverse stock split of the Company Shares at a ratio of 1 for 500 and (ii) change its name to Clinigence Holdings, Inc. to better align with the business of Clinigence. Both our CUSIP number and our trading symbol changed as a result of the name change. Effective October 31, 2019, the Financial Information Regulatory Association, Inc. (“FINRA”) confirmed and announced the Company’s name change, reverse stock split and our new trading symbol of “CLNH,” although the letter “D” was appended to the Company’s current trading symbol IGMB for approximately 20 trading days following the Closing to indicate the completion of the reverse stock split. The new CUSIP number for the Company Shares following the reverse stock split is 18727D105. The Company Shares began trading on the OTC Pink Marketplace with the new name and symbol on a reverse stock split-adjusted basis on November 1, 2019.
HOLDERS
As of March 31, 2021, there are 39,251,013 shares of our common stock outstanding, held of 827 shareholders of record. Because many of our shares of common stock capital stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders. There are 70,000 shares held in reserve. We have 5,758,519, common stock warrants outstanding and 2,890,430 common stock options outstanding.
As of March 31, 2021, approximately 3,090,006 shares of our common stock are eligible to be sold under Rule 144.
| 29 |
Options
In 2019, the Company adopted the 2019 Omnibus Equity Incentive Plan (the "2019 Plan"). Awards granted under the 2019 Plan have a ten-year term and may be incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units or performance shares. The awards are granted at an exercise price equal to the fair market value on the date of grant and generally vest over a four-year period.
All outstanding options fully vested upon the Closing of the AHP and AHA Acquisitions.
Stock option activity during the years ended December 31, 2020 and 2019 follows:
| Options Options Outstanding | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (Years) | ||||||||||
| Options outstanding at December 31, 2018 | -- | $-- | -- | |||||||||
| Options granted | 48,854 | 5.11 | ||||||||||
| Options outstanding at December 31, 2019 | 48,854 | 5.11 | 8.05 | |||||||||
| Options granted | 1,130,734 | 1.49 | ||||||||||
| Options expired | (400 | ) | 0.01 | |||||||||
| Options cancelled | (4,374 | ) | 5.56 | |||||||||
| Options outstanding at December 31, 2020 | 1,174,814 | $ | 1.61 | 8.11 | ||||||||
Options outstanding at December 31, 2020 consist of:
| Date Issued | Number Outstanding | Number Exercisable | Exercise Price | Expiration Date | ||||||||||
| August 5, 2019 | 40,480 | 40,480 | $ | 5.56 | August 5, 2029 | |||||||||
| October 29, 2019 | 3,600 | 3,600 | $ | 0.0725 | June 6, 2027 | |||||||||
| January 27, 2020 | 307,884 | 307,884 | $ | 1.50 | January 27, 2030 | |||||||||
| January 27, 2020 | 225,000 | 225,000 | $ | 1.50 | January 27, 2027 | |||||||||
| February 29, 2020 | 95,794 | 95,794 | $ | 1.25 | February 28, 2030 | |||||||||
| May 11, 2020 | 380,000 | 380,000 | $ | 1.50 | May 11, 2027 | |||||||||
| June 30, 2020 | 122,056 | 122,056 | $ | 1.45 | June 30, 2030 | |||||||||
| Total | 1,174,814 | 1,174,814 | ||||||||||||
Warrants
In 2018, the Company issued fully vested warrants to investors as part of a private placement offering. Each unit offered in the private placement consisted of one share of common stock, and a warrant convertible into 0.4 shares of common stock at an exercise of $1.50 per whole share. The warrants are exercisable for a period of five years from the date of issuance. The warrants were cancelled on March 1, 2019 and reissued upon the Qualmetrix acquisition and are each convertible into one share of common stock at an exercise price of $6.67 per share until December 31, 2024.
| 30 |
In November 2019, the Company issued fully vested warrants to investors as part of private placement subscription agreements pursuant to which the Company issued convertible promissory notes. Each noteholder received warrants to purchase common stock of 50% of the principal at an exercise price of $5.56 per share with an expiration date of October 31, 2025.
Warrant activity during the years ended December 31, 2020 and 2019 follows:
Warrants Outstanding | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (Years) | ||||||||||
| Warrants outstanding at December 31, 2018 | 138,997 | $ | 0.81 | 5.55 | ||||||||
| Warrants granted | 1,065,251 | 6.04 | ||||||||||
| Warrants cancelled | (138,997 | ) | 0.81 | |||||||||
| Warrants outstanding at December 31, 2019 | 1,065,251 | $ | 6.04 | 5.17 | ||||||||
| Warrants cancelled | (507,378 | ) | — | |||||||||
| Warrants outstanding at December 31, 2020 | 557,873 | $ | 6.77 | 3.79 | ||||||||
Warrants outstanding at December 31, 2020 consist of:
| Date Issued | Number Outstanding | Number Exercisable | Exercise Price | Expiration Date | ||||||||||
| March 21, 2019 | 96,433 | 96,433 | $ | 6.67 | December 31, 2024 | |||||||||
| April 30, 2019 | 3,598 | 3,598 | $ | 6.67 | December 31, 2024 | |||||||||
| May 13, 2019 | 14,393 | 14,393 | $ | 6.67 | December 31, 2024 | |||||||||
| May 28, 2019 | 199,703 | 199,703 | $ | 6.67 | December 31, 2024 | |||||||||
| June 5, 2019 | 7,197 | 7,197 | $ | 6.67 | December 31, 2024 | |||||||||
| June 25, 2019 | 208,361 | 208,361 | $ | 6.67 | December 31, 2024 | |||||||||
| September 6, 2019 | 25,188 | 25,188 | $ | 6.67 | December 31, 2024 | |||||||||
| October 29, 2019 | 1,500 | 1,500 | $ | 25.00 | February 5, 2023 | |||||||||
| October 29, 2019 | 1,500 | 1,500 | $ | 25.00 | April 27, 2023 | |||||||||
| Total | 557,873 | 557,873 | ||||||||||||
DIVIDENDS
We have never declared or paid any dividends on our common stock. Any determination to pay dividends in the future will be at the discretion of our Board of Directors and will be dependent upon our results of operations, financial condition, capital requirements, contractual restrictions and other factors deemed relevant by the Board of Directors. The Board of Directors is not expected to declare dividends or make any other distributions in the foreseeable future, but instead intends to retain earnings, if any, for use in business operations.
| 31 |
EQUITY COMPENSATION PLAN INFORMATION
Awards granted under the 2019 Plan have a ten-year term and may be incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units or performance shares. The awards are granted at an exercise price equal to the fair market value on the date of grant and generally vest over a four-year period.
RECENT SALES OF UNREGISTERED SECURITIES
During 2020 we engaged in sales securities in transactions that were not registered under the Securities Act of 1933, as amended (the “Securities Act”) as more fully described below.
Designation of Preferred Stock
On August 2, 2018, the Company filed a Certificate of Designation with the Delaware Division of Corporations whereby the Company designated a Series A Preferred Stock and issued 1,000 shares to the Company’s CEO. The holders of Series A Preferred Stock will have voting rights, when combined with their existing holdings of the Company’s common stock, that entitle them to have an aggregate of 51% of the votes eligible to be cast by all stockholders with respect to all matters brought before a vote of the stockholders of the Company. In connection with the Clinigence reverse merger on October 29, 2019, the Company filed a Certificate of Withdrawal of the Certificates of Designation, Preferences and Rights of the Series A Preferred Stock with the Delaware Secretary of State and returned all previously designated shares to their status as authorized preferred stock available for issuance.
Reverse Stock Split
On October 25, 2019, prior to the effectiveness of the Reverse Merger Agreement, we effected a 1-for-500 reverse stock split of our common stock. On the effective date of the reverse stock split, each 500 shares of outstanding common stock were reduced to one share of common stock. All share and per share information presented have been adjusted on a retrospective basis to reflect this 1-for-500 reverse stock split.
Common Stock Issued
We issued 225,820 restricted common shares to employees for salaries on June 30, 2020, valued at $361,312. On September 28, 2020, 23,276 of these shares issued to an employee, valued at $33,750 were cancelled in connection with a separation agreement.
We issued 228,346 common shares to an employee in connection with a separation agreement on July 12, 2020, valued at $290,000.
To assist in funding the Company’s operations on August 12, 2020, we sold 190,476 restricted shares of common stock valued at $0.63 per share to 5 directors and an investor for proceeds of $120,000.
We issued 12,000 common shares to an employee in connection with a separation agreement on September 11, 2020, valued at $15,000.
| 32 |
Convertible Notes Payable
In March 2019, we made a cash payment totaling $200,000 to settle a previously outstanding convertible note payable. In conjunction with the payment, approximately 400,000 underlying warrants to purchase units of CLI expired unexercised.
During the years ended December 31, 2020 and 2019 we recognized total interest expense of $335,450 and $92,158, respectively.
Under a subscription agreement dated November 19, 2019, we issued convertible promissory notes to various individuals totaling $2,345,375 at December 31, 2019. The notes are convertible at any time through the maturity date of October 31, 2020. In connection with the issuance of the convertible promissory notes, the Company issued 263,727 warrants to purchase shares of the Company’s common stock. The Company allocated the proceeds between the fair value of the notes and warrants. The Company allocated $370,714 to the warrants which has been recorded as a debt discount to be amortized over the life of the notes. Notes payable is presented net of debt discount of $0 and $328,652 at December 31, 2020 and 2019, respectively.
We issued convertible debentures in the amount of $75,000 to three individuals in 2016 and 2017. We restated the convertible debentures on November 15, 2019 to comply with the terms of the November 19, 2019 promissory notes previously mentioned and added $22,500 of accrued interest to the principal balances. Notes payable is presented net of debt discount of $0 and $2,163 at December 31, 2020 and 2019, respectively.
The principal balances of the November 19, 2019 convertible notes and the 2016 and 2017 convertible debentures totaling $2,442,875 were included in the Assumed Liabilities of the AHA Asset Purchase Agreement, as discussed in Note 1. Loss on extinguishment of debt of $167,797 was recorded for the debt discount balance on May 29, 2020. During the year ended December 31, 2019, we issued 143,642 shares of common stock for the full conversion of previously outstanding related party convertible notes totaling $399,996. We recognized a loss on extinguishment of the debt of $130,140 based on the difference between the fair value of the stock issued and the net carrying amount of the debt totaling $399,996 on the date of conversion.
Convertible notes payable consisted of the following at December 31, 2020 and 2019:
| 2020 | 2019 | |||||||
| Notes payable convertible into Clinigence common shares at $5.56 per share; bearing interest at a rate of 10%; net of debt discount of $0 and $328,652, respectively; maturing in October 2020 | $ | — | $ | 2,016,723 | ||||
| Notes payable convertible into Clinigence common shares at $1.25 per share; bearing interest at a rate of 10%; net of debt discount of $1,100 and $2,163, respectively; maturing in October 2020 | — | 95,337 | ||||||
| Total convertible notes payable | — | 2,112,060 | ||||||
| Current portion | — | (2,112,060 | ) | |||||
| Total convertible notes payable, net | $ | — | $ | — | ||||
| 33 |
No underwriters were involved in the transactions described above. All of the securities issued in the foregoing transactions were issued by the Company in reliance upon the exemption from registration available under Section 4(2) of the Securities Act, including Regulation D and Regulation S promulgated thereunder, in that the transactions involved the issuance and sale of the Company’s securities to financially sophisticated individuals or entities that were aware of the Company’s activities and business and financial condition and took the securities for investment purposes and understood the ramifications of their actions, or were non-U.S. persons. The Company did not engage in any form of general solicitation or general advertising in connection with the transactions. The individuals represented that they were each and “accredited investor” as defined in Regulation D or non-U.S. person as defined in Regulation S at the time of issuance of the securities, and that it was acquiring such securities for its own account and not for distribution. All certificates representing the securities issued have a legend imprinted on them stating that the shares have not been registered under the Securities Act and cannot be transferred until properly registered under the Securities Act or an exemption applies.
ITEM 6. SELECTED FINANCIAL DATA
Not Required
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
SIGNIFICANT ACCOUNTING POLICIES
Our management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of financial statements may require us to make estimates and assumptions that may affect the reported amounts of assets and liabilities and the related disclosures at the date of the financial statements. We do not currently have any estimates or assumptions where the nature of the estimates or assumptions is material due to the levels of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change or the impact of the estimates and assumptions on financial condition or operating performance is material, except as described below.
Principles of Consolidation
Our consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Clinigence Health, Inc., and HealthDatix Inc. All intercompany accounts and transactions have been eliminated.
| 34 |
Use of Estimates in the Preparation of Financial Statements
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
Fair Value Measurements
We adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.
The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk. The Company’s investment in AHA was valued at level 3 input.
ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:
Level 1 – quoted prices in active markets for identical assets or liabilities
Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable
Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
Convertible Instruments
We evaluate and account for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.
Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.
We account for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.
| 35 |
We account for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.
Revenue Recognition
Revenue is generated primarily by software licenses, training, and consulting. Software licenses are provided as SaaS-based subscriptions that grants access to proprietary online databases and data management solutions. Training and consulting are project based and billable to customers on a monthly-basis or task-basis.
Revenue from training and consulting are generally recognized upon delivery of training or completion of the consulting project. The duration of training and consulting projects are typically a few weeks or months and last no longer than 12 months.
SaaS-based subscriptions are generally marketed under multi-year agreements with annual, semi-annual, quarterly, or month-to-month renewals and revenue is recognized ratably over the renewal period with the unearned amounts received recorded as deferred revenue.
On January 1, 2019, we adopted the new revenue recognition standard Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606)”, using the modified retrospective method. The modified retrospective adoption used by the Company did not result in a material cumulative effect adjustment to the opening balance of accumulated deficit. Revenue from substantially all the Company’s contracts with customers continues to be recognized over time as performance obligations are satisfied.
We provide our customers with software licensing, training, and consulting through SaaS-based subscriptions. This subscription revenue represents revenue earned under contracts in which we bill and collect the charges for licensing and related services. We determine the measurement of revenue and the timing of revenue recognition utilizing the following core principles:
| 1. | Identifying the contract with a customer; |
| 2. | Identifying the performance obligations in the contract; |
| 3. | Determining the transaction price; |
| 4. | Allocating the transaction price to the performance obligations in the contract; and |
| 5. | Recognizing revenue when (or as) the Company satisfies its performance obligations. |
Revenues from subscriptions are deferred when cash payments are received in advance of the satisfaction of the Company’s performance obligations and recognized over the period in which the performance obligations are satisfied. We complete our contractual performance obligations through providing our customers access to specified data through subscriptions for a service period, and training on consulting associated with the subscriptions. We primarily invoice our customers on a monthly basis and does not provide any refunds, rights of return, or warranties to its customers.
| 36 |
Cost of Sales
Our costs of sales primarily consist of cloud computing and storage costs, datasets, and contracted and internal labor costs.
Advertising Costs
We expense advertising costs as incurred. Advertising costs of $41,418 and $115,647 were charged to operations for the years ended December 31, 2020 and 2019, respectively.
Cash and Cash Equivalents
Cash and cash equivalents are comprised of cash and highly liquid investments with original maturities of 90 days or less at the date of purchase. We do not have any cash equivalents as of December 31, 2020 and 2019. We are exposed to credit risk in the event of default by the financial institutions or the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured.
Accounts Receivable
We analyze the collectability of accounts receivable from continuing operations each accounting period and adjusts its allowance for doubtful accounts accordingly. A considerable amount of judgment is required in assessing the realization of accounts receivables, including the creditworthiness of each customer, current and historical collection history and the related aging of past due balances. We evaluate specific accounts when it becomes aware of information indicating that a customer may not be able to meet its financial obligations due to deterioration of its financial condition, lower credit ratings, bankruptcy or other factors affecting the ability to render payment.
Inventory
Inventory consisting of finished products is stated at the lower of cost or net realizable value.
Property and equipment and depreciation
Property and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows:
| Office equipment and fixtures | 5 - 7 years | |||
| Computer hardware | 5 years | |||
| Computer software | 3 years | |||
| Development equipment | 5 years |
| 37 |
Amortization
Intangible assets are amortized using the straight-line method over the estimated lives of the respective assets as follows:
| Developed technology | 13 years | |||
| Customer relationships | 10 years |
Goodwill
Goodwill represents the excess of assets acquired over liabilities assumed of QMX and the fair market value of the common shares issued by the Company for the acquisition of QMX. In accordance with ASC Topic No. 350 “Intangibles – Goodwill and Other”), the goodwill is not being amortized, but instead will be subject to an annual assessment of impairment by applying a fair-value based test, and will be reviewed more frequently if current events and circumstances indicate a possible impairment. An impairment loss is charged to expense in the period identified. If indicators of impairment are present and future cash flows are not expected to be sufficient to recover the asset’s carrying amount, an impairment loss is charged to expense in the period identified. An impairment expense of $3,471,508 was recorded during the year ended December 31, 2020 in connection with the sale of intellectual property.
Long-Lived Assets
We assess the valuation of components of our property and equipment and other long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. We base our evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, we determine whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, we recognize a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.
Deferred Revenue
Deposits from customers are not recognized as revenues, but as liabilities, until the following conditions are met: revenues are realized when cash or claims to cash (receivable) are received in exchange for goods or services or when assets received in such exchange are readily convertible to cash or claim to cash or when such goods/services are transferred. When such income item is earned, the related revenue item is recognized, and the deferred revenue is reduced. To the extent revenues are generated from our support and maintenance services, we recognize such revenues when services are completed and billed. We received deposits from our various customers that have been recorded as deferred revenue and presented as current liabilities the amount of $76,687 and $165,560 as of December 31, 2020 and 2019, respectively.
| 38 |
Stock-Based Compensation
We accounts for our stock-based awards granted under our employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, which requires the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value on the date of grant and recognition of compensation expense over the related service period for awards expected to vest. We use the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected stock price volatility of the Company’s common stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption related to forfeitures of such grants. Changes in these subjective input assumptions can materially affect the fair value estimate of the Company’s stock options and warrants.
Income Taxes
We account for income taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.
We apply the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in our financial statements. In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position.
Going Concern
The notes accompanying our December 31, 2020 and 2019 audited financial statements, and as noted on the Reports of Independent Registered Public Accounting Firm , contain an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern . The financial statements have been prepared “assuming that the Company will continue as a going concern.” Our ability to continue as a going concern is dependent on raising additional capital to fund our operations and ultimately on generating future profitable operations. There can be no assurance that we will be able to raise sufficient additional capital or eventually have positive cash flow from operations to address all of our cash flow needs. If we are not able to find alternative sources of cash or generate positive cash flow from operations, our business and shareholders may be materially and adversely affected.
Recent Accounting Pronouncements
We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Introduction
Clinigence is a company focused on the medical technology markets. Our primary focus is the expansion of our medical technology business through our wholly-owned subsidiary Clinigence Health, Inc.
Year Ended December 31, 2020 as Compared to Year Ended December 31, 2019
Assets. At December 31, 2020, we had $ 157,056, in current assets and $169,857 in total assets, compared to $1,243,352 in current assets and $6,692,504 in total assets as of December 31, 2019. There was a decrease in current assets from the decrease in cash, and there was a decrease in total assets primarily as a result of the AHA Asset Purchase Sale and impairment of goodwill.
Liabilities. At December 31, 2020, we had total liabilities of $1,303,652 compared to $4,834,071 at December 31, 2019. The decrease in liabilities was primarily due to a decrease in accounts payable and accrued expenses, a decrease in convertible notes payable and a decrease in amount due to related parties as a result of the AHA Asset Purchase Sale, and a decrease in lease liability and notes payable.
| 39 |
Stockholders’ Equity (Deficiency). Our stockholders’ deficiency was $1,133,795 for the year ended December 31, 2020, whereas our stockholders’ equity was $1,858,433 for the years ended December 31, 2019.. This decrease was due to the write down of the Series E Preferred Shares related to the AHA Asset Purchase Sale and impairment of goodwill.
Revenue. We had revenue of $1,585,952 for the year ended December 31, 2020, compared to $1,366,419 for the year ended December 31, 2019. We had a loss from operations of $(5,187,702) and $(6,897,848) for the years ended December 31, 2020 and December 31, 2019, respectively. The increase in revenue was due to increased customer usage for the year ended December 31, 2020.
Costs and Expenses
Cost of Sales. We had cost of sales of $909,780 for the year ended December 31, 2020, compared to $830,443 for the year ended December 31, 2019. Our cost of sales for the year ended December 31, 2020 consisted of direct labor costs of $413,361, service hosting costs of $449,990, and third-party software costs of $46,429, whereas our cost of sales for the year ended December 31, 2019 consisted of direct labor costs of $288,311, service hosting costs of $363,475, and third-party software costs of $178,657.
Operating Expenses. General and Administrative expense was $3,251,353 and $3,667,178 for the years ended December 31, 2020 and December 31, 2019, respectively. Overall, our General and Administrative expenses decreased by $ 415,825 due primarily to a decrease in payroll headcount. We expect our overall corporate overhead to increase with the merger and acquisitions transactions related to Accountable Healthcare America, Inc. and AHP Management Inc.
The COVID-19 pandemic has resulted in social distancing, travel bans and quarantine, and this has limited access to our facilities, customers, management, support staff and professional advisors. These factors, in turn, have had an impact on our operations, financial condition and demand for our goods and services as well as our overall ability to react timely to mitigate the impact of this event. Also, it has hampered our efforts to comply with our filing obligations with the Securities and Exchange Commission. While we have learned from the COVID-19 pandemic and its result on our operations and financial condition, because of the nature of these events, we cannot assure you that we will be well-prepared for similar unforeseen and uncontrollable events that may occur in the future.
Sales and Marketing expense was $166,759 and $577,739 for the years ended December 31, 2020 and December 31, 2019, respectively. The decrease in Sales and Marketing expenses was primarily a result of decreased payroll due to decreased headcount and decrease in trade shows/travel costs.
Research and Development expense was $557,257 and $768,103 for the years ended December 31, 2020 and December 31, 2019 respectively, and consisted of internal payroll and external consultants continuing to develop and improve our platform.
Impairment of Goodwill. We recorded an impairment charge of the Company’s goodwill of $3,471,508 in the year ended December 31, 2020 arising from goodwill impairment related to certain intellectual property sold to AHA in the IP purchase agreement in May 2021. Accordingly, we do not expect to receive future economic benefits from such goodwill. We recorded an impairment charge of the Company’s goodwill of $2,257,058 for the year ended December 31, 2019 arising from goodwill impairment incurred with the HealthDatix Acquisition. The net assets acquired included significant intangible assets related to our HealthDatix subsidiary. We discontinued operations of our HealthDatix subsidiary in February 2020 and accordingly, we do not expect to receive future economic benefits from such goodwill.
| 40 |
Gain on Sale of Assets. We recorded a gain on the sale of assets of $1,993,424 in the year ended December 31, 2020 related to the AHA IP purchase agreement. Pursuant to AHA IP purchase agreement we received AHA Series E Preferred Stock as part of the purchase price. The Series E Preferred Stock investment in AHA was initially recorded at $6,402,278 based on 1,252,892 shares outstanding at a fair value of $5.11 per share based on an appraised valuation of the Series E Preferred Stock. As of December 31, 2020, we determined that the fair value of the AHA Series E Preferred Stock fell below its’ carrying value based on an independent valuation report and wrote off the investment in AHA. The Preferred Stock was surrendered pursuant to the AHA Merger Agreement.
Other Operating Expenses. For the year ended December 31, 2020 we reported a gain on lease termination of $25,174, a loss on sale of fixed assets of $54,819, a loss on the sale of subsidiary of $158,744 and a gain on lease termination of $25,174.
Other Income (Expense). For the year ended December 31, 2020 we reported, a non-recurring loss on extinguishment of debt related party convertible debt conversions of $167,797, which represents the write off of debt discount of the debt assumed by AHA in the IP purchase agreement. For the year ended December 31, 2019 we reported a non-recurring loss on extinguishment of debt for related party convertible debt conversions of $130,140 based on the difference between the estimated fair value of the stock issued ($0.83 per share) to convert the debt and the net carrying amount of the debt totaling $399,997 on the date of conversion. We had interest expense of $335,450 and $92,158 on outstanding notes and convertible notes payable, for the years ended December 31, 2020 and 2019, respectively. We had interest income of $1,030 and $3,626 for the years ended December 31, 2020 and 2019, respectively. We had income from discontinued operations of $39,752 for the year ended December 31, 2020.
LIQUIDITY AND CAPITAL RESOURCES
General
As reflected in the accompanying consolidated financial statements, we had cash of $26,931 and $1,065,434 as of December 31, 2020 and 2019, respectively. As of December 31, 2020, we had a working capital deficiency and we have operated at a net loss since inception. In order to execute our business plans, including the expansion of operations, our primary capital requirements in 2021 are likely to rise. It is not possible to quantify those costs at this point in time, in that they depend on Clinigence Health’s business opportunities and the state of the overall economy. We anticipate raising capital in the private markets to cover any such costs, though there can be no guaranty we will be able to do so on terms we deem to be acceptable. We do not have any plans at this point in time to obtain a line of credit or other loan facility from a commercial bank.
Cash Flow Activity
Cash used in operating activities was $1,475,075 for the year ended December 31, 2020, compared to $4,040,578 for the year ended December 31, 2019. Net cash used in operating activities primarily consisted of our operating revenues not being sufficient to cover our on-going obligations, partially off-set by a non-recurring loss on debt conversion of $167,797. Additional contributing factors to the change were from gain on the sale of assets of $1,993,424, impairment expense of $3,471,508 amortization of $94,761, non-cash interest expense of $474,344, stock-based compensation expense of $2,571,689, gain on lease termination of $25,174, loss on the sale of assets of $54,819, cancellation of common stock of $33,750, a decrease in accounts receivable of $71,900, a decrease in accounts payable and accrued expenses of $648,475, and a decrease in deferred revenue of $88,873.
| 41 |
Cash used in investing activities was $60,900 and $748,196 for the years ended for the year ended December 31, 2020 and December 31, 2019, respectively. Net cash provided by continuing investing activities primarily consisted of a decrease in restricted cash of $100,000 from the use of a letter of credit for the termination of our Atlanta operations office facility lease and the sale of property and equipment of $500. Net cash in discontinued investing activities was $161,400 from the sale of the Healthdatix subsidiary
Cash provided by financing activities was $497,472 and $5,734,941 for the years ended December 31, 2020 and December 31, 2019, respectively. We issued shares of common stock for net cash proceeds of $120,000, issued notes and convertible notes for proceeds of $461,125, received a related party loan of $30,000 and made principal payments on previously outstanding notes and convertible notes payable totaling $113,653.
Plan of Operation and Funding
We expect that working capital requirements will continue to be funded through a combination of our existing funds and further issuances of securities. Our working capital requirements are expected to increase in line with the growth of our business. Existing working capital, further advances and debt instruments, and anticipated cash flow are anticipated to be adequate to fund our operations over the next twelve months. We have no lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. We intend to finance these expenses with further issuances of securities, and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock that may have a greater dilutive impact to our current shareholders. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.
| 42 |
OFF BALANCE SHEET ARRANGEMENTS
We have no off balance-sheet arrangements.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not Required.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The Financial Statements required by this Item 8 are included in this Report beginning on page F-1, as follows:
| Report of Independent Registered Public Accounting Firm | F-1 | |
| Consolidated Balance Sheets as of December 31, 2020 and 2019 | F-3 | |
| Consolidated Statements of Income for the years ended December 31, 2020 and 2019 | F-4 | |
| Consolidated Statement of Changes in Stockholder’s Equity for the years ended December 31, 2020 and 2019 | F-5 | |
| Consolidated Statement of Cash Flows for the years ended December 31, 2020 and 2019 | F-6 | |
| Notes to Financial Statements | F-7 |
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
ITEM 9A. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our senior management, including our chief executive officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this Annual Report on Form 10-K (the “Evaluation Date”). Based on this evaluation, our chief executive officer concluded as of the Evaluation Date that our disclosure controls and procedures were effective such that the information relating to us required to be disclosed in our Securities and Exchange Commission (“SEC”) reports (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and (ii) is accumulated and communicated to our management, including our chief executive officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the year ended December 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 43 |
Management’s Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives. With the participation of our chief executive officer and chief financial officer, our management conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2020 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control – Integrated Framework.
Based upon such evaluation, our management concluded that we did maintain effective internal control over financial reporting as of December 31, 2020 based on the COSO framework criteria, as more fully described below.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.
ITEM 9B. OTHER INFORMATION
None.
| 44 |
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
DIRECTORS AND EXECUTIVE OFFICERS
Our board of directors manages our business and affairs. Under our Articles of Incorporation and Amended and Restated Bylaws, the Board of directors must consist of one or more members and those members hold office until the expiration of the term for which elected and until such director’s successor is elected and qualified or until such director’s earlier death, resignation or removal. Currently, our Board consists of ten directors, of which seven directors were appointed to serve on October 29, 2019 and three were appointed on February 26, 2021.
Warren Hosseinion, M.D., Chief Executive Officer and Chairman of the Board and Director
On February 26, 2021, Dr. Hosseinion was appointed Chief Executive Officer of Clinigence Holdings, Inc. Dr. Hosseinion has served as Chairman of the Board for Clinigence Holdings, Inc. since April 2019. Dr. Hosseinion is a Co-Founder of Apollo Medical Holdings, Inc. (Nasdaq: AMEH) and served as a member of the Board of Directors of Apollo Medical Holdings, Inc. since July 2008, the Chief Executive Officer of Apollo Medical Holdings, Inc. from July 2008 to December 2017, and the Co-Chief Executive Officer of Apollo Medical Holdings, Inc. from December 2017 to March 2019. In 2001, Dr. Hosseinion co-founded ApolloMed Hospitalists. Dr. Hosseinion received his B.S. in Biology from the University of San Francisco, his M.S. in Physiology and Biophysics from the Georgetown University Graduate School of Arts and Sciences, his Medical Degree from the Georgetown University School of Medicine, and completed his residency in internal medicine from the Los Angeles County-University of Southern California Medical Center. Dr. Hosseinion’s qualifications to serve on our Board of Directors include his position as our Chief Executive Officer of the Company. In addition, Dr. Hosseinion as a physician along with his background at Apollo Medical Holdings, Inc. brings to our Board of Directors and our Company a depth of understanding of physician culture and the healthcare market, as well as a strong knowledge of the public markets.
Fred Sternberg, President and Director (Newly appointed Director as of the Closing of the AHP and AHA Acquisitions. )
Mr. Sternberg has served as the CEO of Accountable Healthcare America, Inc. since 2014. Mr. Sternberg has been instrumental in negotiating for and acquiring ACMG, the first ACO to be acquired by AHA. In 1996, Mr. Sternberg as a founder, was instrumental in forming Metropolitan Health Networks, Inc. (MDF: AMEX). In February 2000, He became Chairman of the Board of Directors, President and CEO, where he served through March 2003. Metropolitan was a Medical Services Organization that provides and coordinates medical care for approximately 87,500 Medicare Advantage, Medicaid, and other beneficiaries, primarily in Florida utilizing a primary care-centric business model. Metropolitan’s integrated care delivery systems include approximately 35 state-of-the-art primary care medical centers and a robust network of affiliated physicians serving mainly Humana members. Metropolitan Health Networks was sold to Humana for $850m. MetCare Health Plans which was also sold to Humana for $14m. Metcare Health Plans provided Medicare Advantage plan, called AdvantageCare, to about 7,000 beneficiaries in 13 Florida counties. Previously, as President of Sternco, Inc., Mr. Sternberg was providing consulting services to various healthcare companies in the managed care and related industries. In 1968, Mr. Sternberg acquired the J. Bird Moyer Co., Inc. and took it public. Later the name was changed to Moyco Technologies, Inc., a publicly traded dental products manufacturing company. Mr. Sternberg has also provided consulting services to Assisted Care living facilities and skilled nursing homes.
| 45 |
Michael Bowen, Chief Financial Officer
Mr. Bowen has served as the CFO of Accountable Healthcare America, Inc. since 2014. Michael Bowen, has over 50 years of broad experience in the world of finance including public transactions such as Initial Public Offerings, mergers and acquisitions, private equity transactions and extensive experience of international securities markets. For the past 10 years, Mr. Bowen has been Chief Financial Officer for a predecessor company of AHA and for AHA. He began his career at Goldman, Sachs & Co.in 1965 where he became a Vice President of the Corporate Finance Department and latterly helped establish the Tokyo office for Goldman Sachs. In 1976, he joined Salomon Brothers with the task of helping establish their first Asian office located in Honk Kong. He then moved to London to rebuild the International Capital Markets business for Chase Manhattan Ltd, the merchant banking arm of Chase Manhattan Bank where he was responsible for all of the international securities business of the bank/merchant bank. Mr. Bowen ended his international career as a Main Board Director for Kleinwort Benson, a British merchant bank where he was responsible for corporate finance business within the USA. Mr. Bowen returned to the US and, after a period of semi-retirement, in 2004 became CFO of TruBamboo, Inc. an innovative company selling bamboo houseware products to large US retailers. In 2008 he joined Diversified Health & Fitness as CFO and in 2014 became CFO of AHA. Mr. Bowen has an MBA from the Darden School of the University of Virginia and a BA also from UVA
Lawrence Schimmel, M.D., Chief Medical Information Officer
Dr. Schimmel is the Chief Medical Officer of Clinigence Holdings, Inc. since April 2019. Dr. Schimmel served as Chief Executive Officer of Clinigence Holdings, Inc. from July 2020 to February 2021. In 2013 he co-founded and served as Chief Medical Officer of QualMetrix, Inc., a healthcare analytics company headquartered in South Florida, until QualMetrix, Inc. merger with Clinigence LLC. Dr. Schimmel is also the founding Chairman of Professional Bank headquartered in South Florida from 2018 to present. Previously, Dr. Schimmel was the managing partner of Allied Health Advisors, LLC a boutique healthcare consulting company in Miami. Dr. Schimmel is a serial medical-related business entrepreneur having been Co-founder and CEO of Allied Health Group, a national medical management company, and Florida Specialty Network. Allied Health Group and Florida Specialty Network managed approximately $500 million in provider payments on behalf of managed care organizations for approximately 3 million lives during his time as CEO. Allied Health Group was a licensed TPA in Florida and Texas and acted as a third-party intermediary in other areas of the country. Previously, Dr. Schimmel was the Founding Chairman and served on the Board of Directors of Megabank and subsequently served on the Board of Directors of Executive National Bank in South Florida. Dr. Schimmel practiced General and Vascular Surgery in the Miami community for 18 years. In addition to his lengthy medical career as a general and vascular surgeon, he held a management role with the South Florida Surgical Group, and has consulted for physicians, hospitals, healthcare delivery systems, and Fortune 500 companies.
He received his B.A. from Rutgers College, received his Doctor of Medicine degree from the New Jersey College of Medicine and conducted his post graduate training at the University of Miami.
| 46 |
Elisa Luqman, Executive Vice President of Finance, General Counsel and Director
Ms. Luqman served as the Chief Financial Officer and General Counsel of Clinigence Holdings, Inc since October 29, 2019 where Ms. Luqman was responsible for maintaining the corporation’s accounting records and statements all CLNH’s SEC filings and compliance requirements. Ms. Luqman also serves as a Director and Secretary of the Board for Clinigence Holdings, Inc. Ms. Luqman was the co-founder of bigVault Storage Technologies a cloud- based file hosting company acquired by Digi-Data Corporation in February 2006. From March 1, 2006 through February 28, 2009, Ms. Luqman was employed as Chief Operating Officer of the Vault Services Division of Digi-Data Corporation, and subsequently during her tenure with Digi-Data Corporation she became General Counsel for the entire corporation. In that capacity she was responsible for acquisitions, mergers, patents, customer, supplier, and employee contracts, and worked very closely with Digi-Data’s outside counsel firms. On March 1, 2009, Ms. Luqman rejoined iGambit Inc. (“IGMB”) as Chief Financial Officer and General Counsel. Ms. Luqman has overseen and been responsible for IGMB’s SEC filings, FINRA filings and public company compliance requirements from its initial Form10 filing with the SEC in 2010 through its’ Reverse Merger with Clinigence Holdings, Inc. on October 29, 2019. Ms. Luqman received a BA degree, a JD in Law, and an MBA Degree in Finance from Hofstra University. Ms. Luqman is a member of the bar in New York and New Jersey.
Andrew Barnett, Executive Vice President of Corporate Development
Mr. Barnett has served as Executive Vice President of Corporate Development for Accountable Healthcare America, Inc. since its inception in 2014. Throughout his career, Mr. Barnett has been engaged in various aspects of the health care industries. Mr. Barnett served as Vice President of Corporate Development of Dental Partners, Inc., a dental practice management company. At Dental Partners, he was responsible for establishing a $15 million bank line of credit, closing on $30 million of acquisitions, and selling the company. At Trident, a PPM, Mr. Barnett assisted in raising over $20 million through a private placement and assisted in $60 million of acquisitions. Prior to Trident, Mr. Barnett served as Executive Vice President and Director of Metropolitan Health Networks, Inc. (MDF: AMEX) where he was involved in raising capital, acquisitions, and the Company’s initial public offering. Mr. Barnett received a B.S. degree from Pennsylvania State University.
Non-Management Directors
Terence Martin Breslin, Director
From 2016 to 2019 Mr. Breslin was the Chief Executive Officer of QualMetrix, Inc. and was responsible for charting QualMetrix, Inc.'s strategic direction to drive customer value for payer and provider organizations. In 2013 Mr. Breslin joined QualMetrix, Inc. as an investor and co-founder, later assuming the roles of chairman and Chief Executive Officer. He has extensive experience with technology companies that serve healthcare as well as other industries. Prior to QualMetrix, Inc., Mr. Breslin founded VSS Monitoring. VSS, which focused on the network packet broker market, quickly established itself as an industry leader and, in 2011, was recognized as the Silicon Valley's ninth-fastest-growing privately held company. Mr. Breslin later sold VSS to Danaher Corp. where he remained for two years serving as president of the VSS unit and as chief technology officer for Danaher's $1 billion in revenue communications division.
Mr. Breslin has played both executive and advisory roles at a number of technology start-ups, including a Switzerland-based healthcare technology firm. His experience there led to an interest in the application of advanced analytics in healthcare.
Mr. Breslin holds a Master of Business Administration from Golden Gate University of San Francisco. He received a Bachelor's degree in Engineering from the University of Ulster in Northern Ireland as well as a Bachelor's degree in Computer Science from National University of Ireland, Maynooth.
| 47 |
Robert Chan, M.D., Director (Newly appointed as of the Closing of the AHP and AHA Acquisitions).
Dr. Chan has served as Chief Executive Officer and Chairman of the Board of AHP IPA since 2015. Dr. Chan is affiliated with several HMOs and IPAs. As a hospitalist physician, Dr. Chan is on the staff of multiple local hospitals. Dr. Chan received his B.S. in Biology from the University of California, Irvine, his Medical Degree from the University of California, Irvine College of Medicine, and completed his residency in internal medicine from the University of California, Los Angeles. Dr. Chan’s qualifications to serve on our Board of Directors include his position as Chief Executive Officer of AHP IPA. In addition, Dr. Chan as a physician along with his background at various healthcare organizations, brings to our Board of Directors and our Company a depth of understanding of physician culture and the healthcare markets.
Mitchell Creem, Director
Mr. Creem has spent over 30 years as a “C-level” executive of healthcare organizations, and he brings strong business evaluation and operational experience to the Company. Since July 2017 to Present Mr. Creem has served as President of The Bridgewater Healthcare Group, which provides hospital and health network management services and performance consulting. From October 2015 to July 2017 Mr. Creem served as the CEO of Verity Health System, a six-hospital system in California. Prior to this, he served as the CFO and Board Member of ApolloMed from October 2012 to October 2015. Prior to ApolloMed, he served as the CEO of the Keck Hospital of USC and USC Norris Cancer Center. Prior to his tenure at USC, he served as the CFO and Associate Vice Chancellor of UCLA Health Sciences, including UCLA Medical Center, the Geffen School of Medicine at UCLA, and UCLA Faculty Practice. Prior to UCLA, he served as CFO of Beth Israel Deaconess Medical Center, a Harvard University teaching hospital, and CFO of Tufts University Medical Center. Prior to this, he worked for several years in a senior management position at the healthcare practice group of PricewaterhouseCoopers, where he was responsible for numerous consulting engagements, financial statement audits and financial feasibility studies. He has been a guest lecturer at USC, UCLA and Harvard. Mr. Creem holds a B.S. in Accounting and Business Administration from Boston University and a Master’s degree in Health Administration from Duke University.
Jacob Margolin, Director
Mr. Margolin is a director of Clinigence Holdings, Inc. Mr. Margolin served as Chief Executive Officer of Clinigence Holdings, Inc. from April 2019 to July 2020. Mr. Margolin is a successful serial entrepreneur with over 25 years’ experience in HIT, and is the Co-Founder of Clinigence, LLC. In the mid-1990’s, Mr. Margolin co-founded a pioneering Medical Imaging technology company and led its marketing, global business development and North American operations through a $50 million acquisition by Carestream Health (2004). In 2005, he joined Accelerad – a Georgia Tech Advanced Technology Development Center (ATDC) incubator company acquired in 2014 by Nuance Communications (NASDAQ: NUAN). In 2008, he started a consulting firm helping Israeli medical technologies enter the US market. In 2010, Mr. Margolin founded Clinigence, LLC with the vision that big data and business intelligence technologies would become crucial to the healthcare industry. Mr. Margolin holds an MS degree in medical physics (magna cum laude) and BS degrees in Mathematics and Physics (magna cum laude) from Tel-Aviv University in Israel. He is a board member of the American-Israeli Chamber of Commerce and a member of the Technology Association of Georgia (TAG) and HIMSS.
| 48 |
David Meiri, Director
Mr. Meiri was a member of the Board of Managers of Clinigence, LLC. Since 2014 Mr. Meiri has served as a Director of Software Engineering in the Xtremio Division of Dell EMC, has been leading a project for Native Replication of contents-based data storage, David has received multiple awards for innovation at Dell EMC, including the 2018 and 2019 prolific inventor awards, and holds close to a hundred patents. He has led several such projects for third parties resulting in the successful commercialization of products. Mr. Meiri has expertise in high-performance multi-threaded systems, storage arrays and data replication. Since 1997 he has developed, innovated, and led teams building products in diverse technologies such as synchronous and asynchronous remote replication, business continuity, high availability, clones & snapshots, active/active replication, and performance optimization. Mr. Meiri has researched virtualization technologies and integration of hypervisors with storage products. This led him to work on federation, cluster algorithms and cloud infrastructure. Other areas Mr. Meiri is interested in are caching, data reduction, encryption, data deduplication and compression. He holds 78 US issued patents with an additional 30 pending. Mr. Meiri holds a Ph.D. in Mathematics (Ergodic Theory), from the Hebrew University in Jerusalem, Israel.
Randall Stern, Director (Newly appointed as of the Closing of the AHP and AHA Acquisitions).
Mr. Stern has served as the Managing Member of RoundTable Financial Group, LLC, an alternative investment merchant bank since 2011. Additionally, since 2016 Mr. Stern was the Founder and Managing Member of Boone Opportunity Lenders, LLC (“Boone”), an Independent Sponsor and former Investment Manager of several private credit funds that originated and managed senior and junior cash-flow loans to, and equity investments in lower middle-market growth companies with EBITDA between $2-$10 million, for acquisitions, recapitalizations and growth. From 1995 to 2006 Mr. Stern seved as the Managing Director in the Corporate Finance Department of Burnham Securities Inc., a New York-based investment banking firm. From 2019 to the present Mr. Stern has served as Chairman of the Board of Kleen-Tech Services, LLC., a custodial service company based in in Denver, Colorado. With more than 1,300 employees, Kleen-Tech is a national provider of cleaning services to commercial and government customers occupying more than 30 million square feet of facilities located throughout the United States. . In 2019, the Company was bought by an investment group led by Mr. Stern and is seeking acquisitions in addition to organic growth. Mr. Stern received his B.A. from Middlebury College (1975, cum laude), where his major was Psychology and minor was Religion. He received an M.B.A. from New York University (1978) where his major was Finance.
John Waters, Director, Audit Committee Chairman
Mr. Waters is a former Senior Partner at Arthur Andersen (1967-2001) with exceptional leadership skills in mergers and acquisitions (particularly reverse mergers) and 1933 Act fillings with the SEC. In the last fifteen years with the firm Mr. Waters built three very successful businesses within Andersen in the areas of merger and acquisition, manufacturing and entertainment. In 2001, Mr. Waters started his own merger and acquisition advisory consulting business and has consummated the acquisition of three manufacturing companies with combined annual sales of $50 million. In 2003, he participated in a group that acquired A-1 Components Corp., a wholly owned subsidiary of United Technologies Corp. Mr. Waters led due diligence efforts and created a tax structure beneficial to both the buyer and seller. In September 2004 participated with a group of investors that acquired Metpar Corp., a $19 million manufacturer of metal sanitary and plastic plumbing fixtures. In October 2007, he participated with a group of investors that acquired World Dryer Corporation, a $20 million manufacturer of hand dryer products. He prepared pro-forma financial statements for the lenders and assisted in obtaining financing for these transactions. In July of 2004 he was appointed Chief Administrative Officer of Authentidate Holding Corp. and led a massive restructuring of the business and hired an entirely new executive management team. In January of 2006 he was appointed Chief Financial Officer of Avantair Inc., which was taken public through a merger with a Special Purpose Acquisition Company (SPAC) and raised $60 million in capital for this company. From 2016 until the closing of the Acquisition, Mr. Waters served as an Advisor to the Board of Directors of iGambit, Inc. Previously he was a member of the Board of Directors of iGambit and served as a member of the Audit Committee. Mr. Waters is a Certified Public Accountant, Member of AICPA and New York State Society of CPA's and has a BBA degree from Iona College.
| 49 |
The names, ages, positions and dates appointed of our current directors and executive officers are set forth below.
| (1) Name | Age | Position | ||||
| Executive Officers and Directors | ||||||
| Dr. Warren Hosseinion | 48 | Chief Executive Officer and Chairman of the Board | ||||
| Fred Sternberg | 75 | President, Director | ||||
| Michael Bowen | 71 | Chief Financial Officer | ||||
| Dr. Lawrence Schimmel | 71 | Chief Medical Information Officer | ||||
| Elisa Luqman | 56 | General Counsel, EVP of Finance and Director | ||||
| Andrew Barnett | 50 | Executive Vice President of Corporate Development | ||||
| Non-Management Directors | ||||||
| Martin Breslin | 48 | Director | ||||
| Dr. Robert Chan | 52 | Director | ||||
| Mitchell Creem | 60 | Director | ||||
| Jacob Margolin | 52 | Director | ||||
| David Meiri | 52 | Director | ||||
| Randall Stern | 67 | Director | ||||
| John Waters | 74 | Director | ||||
(1) Unless otherwise noted, the address of record for the directors and officers is 501 1st Ave. N, suite 901, St. Petersburg, FL 33701.
No director or executive officer is party to any arrangement or understanding with another person under which he or she was selected as a director or officer (as applicable).
COMMITTEES OF THE BOARD
The Board has established an Audit Committee, a Compensation Committee and Governance and Nominating Committee.
Audit Committee
The Audit Committee consisted of Messrs. John Waters, Mitchell Creem and Terence Breslin, with Mr. Waters serving as Chairman. The Company’s Board of Directors has determined that Mr. Waters is an “audit committee financial expert” (as that term is defined under SEC rules implementing Section 407 of the Sarbanes-Oxley Act) and, each of the three audit committee members are “independent” directors that satisfy the heightened audit committee independence requirements under the NYSE Listing Rules and Rule 10A-3 of the Exchange Act.. The Audit Committee is responsible for monitoring and reviewing our financial statements and internal controls over financial reporting. In addition, they recommend the selection of the independent auditors and consult with management and our independent auditors prior to the presentation of financial statements to stockholders and the filing of our forms 10-Q and 10-K. The Audit Committee has adopted a charter and it is posted on our web site at www.clinigencehealth,com.
| 50 |
Compensation Committee
The Compensation Committee consisted of Messrs. David Meiri, John Waters, Mitchell Creem, and Terence Breslin.. The Compensation Committee is responsible for reviewing and recommending to the Board the compensation and over-all benefits of our executive officers. The Compensation Committee may, but is not required to, consult with outside compensation consultants. The Compensation Committee has adopted a charter and the charter is posted on our web site at www.clinigencehealth.com.
Governance and Nominating Committee
The Governance and Nominating Committee activities are currently handled by the full board of directors. The Governance and Nominating Committee is responsible assisting the Board in fulfilling its fiduciary responsibilities with respect to the oversight of the Company’s affairs in the areas of corporate governance and Board membership matters.
LEGAL PROCEEDINGS INVOLVING OFFICERS AND DIRECTORS
None of our directors or executive officers have been involved in any of the legal proceedings described in Item 401(f) of Regulation S-K.
COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT.
Based solely upon a review of Forms 3 and 4 and amendments thereto furnished to the Company under Rule 16a-3(e) under the Exchange Act during its most recent fiscal year and Forms 5 and amendments thereto furnished to the Company with respect to its most recent fiscal year, and any written representation to the Company from the reporting person that no Form 5 is required, no person who, at any time during the fiscal year, was a director, officer, beneficial owner of more than ten percent of the Company’s Common Stock, or any other person known to the Company to be subject to section 16 of the Exchange Act with respect to the Company, failed to file on a timely basis, as disclosed in the above Forms, reports required by section 16(a) of the Exchange Act during the most recent fiscal year or prior fiscal years.
CODE OF ETHICS
The Company has adopted a Code of Business Conduct and Ethics that applies to its principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of the Code of Business Conduct and Ethics is available on the Company’s website at www.clingencehealth.com.
| 51 |
ITEM 11. EXECUTIVE COMPENSATION
Summary Compensation Table
The following table sets forth the compensation received by our executive officers, for their service, during the years ended December 31, 2019 and December 31, 2020.
| Current Officers Name & Principal Position | Year | Salary ($) | Bonus ($) | Stock ($) | Option Awards ($) | Non-equity Incentive Plan Compensation ($) | Nonqualified Deferred Compensation Earnings ($) | All Other Compensation ($) | Total ($) | |||||||||||||||||||||||||||
| Jacob Margolin Former CEO, & Director | 2020 | 85,325 | 335,000 | 0 | 0 | 0 | 0 | 420,325 | ||||||||||||||||||||||||||||
| 2019 | 2019 | 124,925 | 0 | 0 | 0 | 0 | 0 | 0 | 124,925 | |||||||||||||||||||||||||||
| Dr. Lawrence Schimmel CMIO & Director | 2020 | 113,400 | 65,000 | 45,000 | 0 | 0 | 0 | 223,400 | ||||||||||||||||||||||||||||
| 2019 | 2019 | 121,525 | 0 | 0 | 0 | 0 | 0 | 0 | 121,525 | |||||||||||||||||||||||||||
| Elisa Luqman EVP Finance GC Director | 2020 | 133,225 | 0 | 0 | 75,000 | 0 | 0 | 0 | 208,255 | |||||||||||||||||||||||||||
| 2019 | 2019 | 27,413 | 0 | 0 | 0 | 0 | 0 | 0 | 27,413 | |||||||||||||||||||||||||||
| Charles Kandzierski COO Clinigence Health, Inc. (Subsidiary) | 2020 | 109,863 | 0 | 37,500 | 24,731 | 0 | 0 | 0 | 172,094 | |||||||||||||||||||||||||||
| 2019 | 2019 | 172,463 | 0 | 0 | 0 | 0 | 0 | 0 | 172,463 | |||||||||||||||||||||||||||
Equity Compensation Plan Information
In 2019, we adopted the 2019 Omnibus Equity Incentive Plan (the "2019 Plan"). Awards granted under the 2019 Plan have a ten-year term and may be incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units or performance shares. The awards are granted at an exercise price equal to the fair market value on the date of grant and generally vest over a four-year period.
The following table sets forth the Outstanding Equity Awards received by our executive officers, for their service, during the year ended December 31, 2020.
Name |
Option awards | Stock awards | |||||||
| Number of securities underlying unexercised options (#) exercisable | Number of securities underlying unexercised options (#) unexercisable | Equity incentive plan awards: Number of securities underlying unexercised unearned options (#) | Option exercise price ($) | Option expiration date | Number of shares or units of stock that have not vested (#) | Market value of shares of units of stock that have not vested ($) | Equity
incentive plan awards: Number of unearned shares, units or other rights that have not vested (#) |
Equity incentive plan awards: Market or payout value of unearned shares, units or other rights that have not vested ($) | |
| Jacob Margolin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lawrence Schimmel | 6,288 | 0 | 0 | $1.50 | 1/27/2030 | 0 | 0 | 0 | 0 |
| Elisa Luqman | 67,106 | 0 | 0 | $1.50 | 1/27/2030 | 0 | 0 | 0 | 0 |
| Elisa Luqman | 50,000 | 0 | 0 | $1.50 | 5/11/2027 | 0 | 0 | 0 | 0 |
| Charles Kandzierski | 17,056 | 0 | 0 | $1.45 | 6/30/2030 | 0 | 0 | 0 | 0 |
| 52 |
Employment Arrangements with Named Executive Officers
Clinigence is party to three (3) year employment agreements with Elisa Luqman, and Dr. Lawrence Schimmel each dated October 29, 2019 and April 1, 2019. Pursuant to the employment agreements with Ms. Luqman and Dr. Schimmel, each is entitled to receive a base annual salary of $150,000 and 180,000, respectively, during the term. Dr. Hosseinion entered into a five (5) year employment agreement with the Company which became effective on February 26, 2021, and pursuant to which Dr. Hosseinion is entitled to receive a base salary of $250,000 during the term. AHP is party to a (5) year employment agreements with Fred Sternberg. Michael Bowen and Andrew Barnett each dated May 1, 2020. Pursuant to the employment agreements with Mr. Sternberg, Mr. Bowen, and Mr. Barnett, each is entitled to receive a base annual salary of $250,000, $150,000, and $250,000, respectively, during the term.
Pursuant to the employment agreements with the named officers, upon termination, each such individual is entitled to receive payment of all salary and benefits accrued up to the termination date of his or her employment in all employment termination events. Thereafter, Ms. Luqman would be entitled to receive twelve (12) months of base salary as a severance payment, Dr. Schimmel would be entitled to receive twenty-four (24) months of base salary as a severance payment, Dr. Hosseinion would be entitled to receive twenty four (24) months of base salary as a severance payment, Mr. Sternberg would be entitled to receive twenty four (24) months of base salary as a severance payment, Mr. Bowen would be entitled to receive twelve (12) months of base salary as a severance payment, and Mr. Barnett would each be entitled to the balance of the remaining months under his employment agreement of base salary as a severance payment, upon termination of his or her employment by the Company without cause or by such individual for good reason.
The Company’s board of directors may, in its discretion, award bonuses to its executive officers on a case-by-case basis.
Each of the Company’s named executive officers is eligible to participate in the Company’s employee benefit plans and programs, including medical, dental and vision benefits, vacation and PTO, and the Company’s 2019 Omnibus Incentive Plan, to the same extent as its other full-time employees, subject to the terms and eligibility requirements of those plans.
The Agreements for all of the executive officers contain automatic one-year extensions at the end of their respective terms unless notice of non-extension is delivered by either party pursuant to the terms of the agreement and are identical except as described below.
Termination For Cause, Resignation Without Good Reason or due to Death or Disability.
If, during the term of his or her Employment Agreement, an officer is terminated for cause, resigns without good reason, or is unable to perform due to death or disability, we are required to pay or provide such officer (or such officer’s authorized representative or estate) any earned but unpaid base salary and/or unpaid bonus for services rendered through the date of termination, unpaid expense reimbursements, and accrued but unused paid time off within thirty (30) days. With respect to vested compensation or benefits, the officers may have under any employee benefit or compensation plan, program or arrangement of the Company, we are required to pay the executive under the terms of the applicable plan, program or arrangement.
Termination Without Cause, Resignation With Good Reason or Change in Control
If, during the term of the his or her employment agreement, an officer is terminated without cause (as defined in the applicable employment agreement) or resigns with good reason (as defined in the applicable employment agreement), we are required to pay the officer (1) an amount equal to two times the sum of the officer’s most recent base salary, except in the Ms. Luqman, who will be paid an amount equal to one times the sum of her most recent base salary, and target annual bonus (but determined prior to any action involving base salary that would constitute “Good Reason” as defined in the applicable employment agreement), and (2) an amount in cash equal to the Company’s premium amounts paid for coverage of the officer at the time of the officer’s termination of coverage under the Company’s group medical, dental and vision programs for a period of twelve (12) months, to be paid directly to the officer at the same times such payments would be paid on behalf of a current employee for such coverage.
We do not currently have any other employment agreements with our executive officers.
| 53 |
Compensation of the Board of Directors
The following table sets forth the compensation received by our directors, for their service as directors, during the year ended December 31, 2020.
| Name | Fees earned or paid in cash ($) | Stock awards ($) | Option awards ($) | Non-equity incentive plan compensation ($) | Nonqualified deferred compensation earnings ($) | All other compensation ($) | Total ($) | |||||||||||||||||||||
| Warren Hosseinion (1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||
| Elisa Luqman (1) | 0 | 0 | 33,333 | ((2) | 0 | 0 | 0 | 33,333 | ||||||||||||||||||||
| Jacob Margolin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||
| Terence Martin Breslin | 0 | 0 | 50,000 | ((3) | 0 | 0 | 0 | 50,000 | ||||||||||||||||||||
| Mitchell Creem | 0 | 0 | 50,000 | (3) | 0 | 0 | 0 | 50,000 | ||||||||||||||||||||
| David Meiri | 0 | 0 | 50,000 | (3) | 0 | 0 | 0 | 50,000 | ||||||||||||||||||||
| John Waters | 0 | 0 | 63,333 | ((4) | 0 | 0 | 0 | 63,333 | ||||||||||||||||||||
(1) These individuals serve as executive officers of the Company, and do not receive any compensation for the services they provide as directors of the Company.
(2) 50,000 Stock Options at an exercise price of $1.50
(3) 75,000 Stock Options at an exercise price of $1.50
(4) 95,000 Stock Options at an exercise price of $1.50
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
The following table sets forth information known to us, as of March 31, 2021, relating to the beneficial ownership of shares of common stock by: (i) each person who is known by us to be the beneficial owner of more than 5% of the Company’s outstanding common stock; (ii) each director; (iii) each executive officer; and (iv) all executive officers and directors as a group. Under securities laws, a person is considered to be the beneficial owner of securities owned by him (or certain persons whose ownership is attributed to him) or securities that can be acquired by him within 60 days, including upon the exercise of options, warrants or convertible securities. The Company determines a beneficial owner’s percentage ownership by assuming that options, warrants and convertible securities that are held by the beneficial owner and which are exercisable within 60 days, have been exercised or converted. The Company believes that all persons named in the table have sole voting and investment power with respect to all shares of common stock shown as being owned by them. Unless otherwise indicated, the address of each beneficial owner in the table set forth below is care of Clinigence Holdings, Inc. 501 1st Avenue N, Suite 901, St. Petersburg, FL 33701. The percentages in the following table are based upon 39,251,013 shares outstanding as of March 31, 2021.
| 54 |
| Name of Beneficial Owner | Amount and Nature of Beneficial Ownership | Percent of Class | ||||||
| Dominis-Embree AHA Investor, LLC | 6,473,483 | 16.49 | % | |||||
| Robert Chan, Director | 4,389,691 | 11.18 | % | |||||
| Singh Boun | 2,022,984 | 5.15 | % | |||||
| Oscar Chien | 2,211,984 | 5.63 | % | |||||
| Nick H. Lee | 2,022,984 | 5.15 | % | |||||
Warren Hosseinion, CEO and Chairman of the Board | 1,973,153 | (1) | 5.03 | % | ||||
| Fred Sternberg, President and Director | 1,821,672 | 4.64 | % | |||||
| Andrew Barnet, Officer | 1,709,896 | 4.36 | % | |||||
Terence Martin Breslin, Director | 854,616 | (2) | 2.18 | % | ||||
| Jacob Margolin, C.E.O. and Director | 649,998 | (3) | 1.66 | % | ||||
| Elisa Luqman, C.F.O., General Counsel and Director | 529,976 | (4) | 1.35 | % | ||||
| Michael Bowen, CFO | 447,105 | 1.14 | % | |||||
David Meiri, Director | 396,747 | (4) | 1.01 | % | ||||
Lawrence Schimmel, CMO and Director | 299,731 | (5) | .76 | % | ||||
John Waters, Director | 276,320 | (6) | .70 | % | ||||
Mitchell Creem, Director | 161,866 | (4) | .41 | % | ||||
Charles Kandzierski, COO, Clinigence Health, Inc. | 94,435 | (7) | .24 | % | ||||
Executive Officers and Directors as Group: | 13,606,206 | (8) | 34.66 | % | ||||
| 1. | Includes options to purchase 200,000 shares of the common stock at $1.50 per share, options to purchase 600,000 shares of the common stock at $1.61 per share and a warrant to purchase 21,590 common shares at $5.56 per share |
| 2. | Includes options to purchase 10,120 shares of the common stock at $5.56 per share, options to purchase 75,000 shares of common stock at $1.50 per share and options to purchase 45,000 shares at $1.61. |
| 3. | Includes options to purchase 30,000 shares of common stock at $1.50 per share and options to purchase 45,000 shares at $1.61. |
| 4. | Includes 1,370 shares of common stock held by Muhammad Luqman, Ms. Luqman’s husband, options to purchase 67,106 shares of the commons stock at $1.50 per share and options to purchase 600,000 shares of the common stock at $1.61 per share. |
| 5. | Includes options to purchase 6,288 shares of the common stock at $1.50 per share, options to purchase 30,000 shares of the common stock at $1.50 per share, convertible debenture to purchase 19,597 common shares at $1.55 and warrant to purchase 9,799 common shares at $1.55 per share. |
| 6. | Includes options to purchase 17,986 shares of the common stock at $5.56 per share, 52,800 shares of common stock at $1.50 per share, 26,000 shares of common stock at $1.25 per share, convertible debenture to purchase 66,516 common shares at $1.55 and warrant to purchase 32,258 common shares at $1.55 per share. |
| 7. | Includes options to purchase 17,056 shares of the common stock at $1.45. |
| 8. | Includes items 1, 2, 3, 4, 5, and 7 above. |
| 55 |
ITEM 13. CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE
RELATED PARTY TRANSACTIONS
Amounts Due to Related Parties
We have amounts due to related parties with balances of $30,000 and $128,477 at December 31, 2020 and 2019, respectively. A shareholder and former officer, Mihir Shah, made a $30,000 non-interest bearing, loan to the Company on December 31, 2020, which was repaid with common stock on January 28, 2021. The Company’s former subsidiary, Arcmail owed amounts on a credit card that is guaranteed by the husband of the Company’s Chief Financial Officer, Muhammad Luqman, who was held personally responsible by the credit card company for the unpaid balance. The balance of $128,477 was included in the Assumed Liabilities of the AHA Asset Purchase Agreement.
During the first quarter of 2019, the Chairman Warren Hosseinion made a $300,000 equity investment and was issued 21,590 warrants pursuant to the Equity Private Placement Memorandum.
During the first quarter of 2019, former Director Mark Fawcett made a $50,000 equity investment and was issued 3,598 warrants pursuant to the Equity Private Placement Memorandum.
BOARD INDEPENDENCE
The Company has elected to use the independence standards of the NYSE AMEX Equities Exchange in its determination of whether the members of its Board are independent.
Accordingly, our Board of Directors has evaluated the independence of its members based upon the rules of the NYSE AMEX Equities Exchange and the SEC and the transactions referenced under “Certain Relationships and Related Party Transactions” discussed above. Applying these standards, our Board of Directors determined that none of the directors who currently serve, other than Messrs. Hosseinion and Sternberg and Madame Luqman, have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that Messrs. Breslin, Chan, Creem, Margolin, Meiri, Stern and Waters “independent” as that term is defined under NYSE Rule 407(a)(1). Messrs. Hosseinion, Sternberg, and Madame Luqman are not considered independent because they are officers of the Company. Our Board of Directors also determined that each non-employee director who serves as a member of the Audit, Compensation, and Nominating Committees satisfies the independence standards for such committee established by the SEC and NYSE AMEX Equities Exchange, as applicable. The Board has established an Audit Committee, a Compensation Committee and a Governance and Nominating Committee.
FAMILY RELATIONSHIPS
Mr. Barnett is Mr. Sternberg’s son. There are no other family relationships amongst any of the Company’s executive officers and directors.
| 56 |
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
The following table shows what Marcum LLP fees were for the audit and other services for the year ended December 31, 2020 and Prager Metis CPA LLC. fees were for the year ended December 31, 2019.
| Year Ended | Year Ended | |||||||
| 12/31/ 2020 | 12/31/2019 | |||||||
| Audit Fees | $ | 55,000 | $ | 42,500 | ||||
| Audit-Related Fees | — | — | ||||||
| All Tax Fees | — | — | ||||||
| Other Fees | — | — | ||||||
| Total | $ | 55,000 | $ | 42,500 | ||||
Audit Fees — This category includes the audit of the Company’s annual financial statements, review of financial statements included in the Company’s Form 10-Q Quarterly Reports and services that are normally provided by the independent auditors in connection with engagements for those years.
Audit-Related Fees — This category includes assurance and related services by the independent auditor that are reasonably related to the performance of the audit or review of the Company’s financial statements and that are not reported under the caption “Audit Fees.”
Tax Fees — This category includes services rendered by the independent auditor for tax compliance, tax advice, and tax planning.
All Other Fees — This category includes products and services provided by the independent auditor other than the services reported under the captions “Audit Fees,” “Audit-Related Fees,” and “Tax Fees.”
Overview — The Company’s Audit Committee, reviews, and in its sole discretion pre-approves, our independent auditors’ annual engagement letter including proposed fees and all audit and non-audit services provided by the independent auditors. Accordingly, all services described under “Audit Fees,” “Audit-Related Fees,” “Tax Fees,” and “All Other Fees” were pre-approved by our Company’s Audit Committee. The Audit Committee may not engage the independent auditors to perform the non-audit services proscribed by law or regulation. The Company’s Audit Committee may delegate pre-approval authority to a member of the Board of Directors, and authority delegated in such manner must be reported at the next scheduled meeting of the Board of Directors.
| 57 |
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
PART IV
(a) Financial Statements
| Report of Independent Registered Public Accounting Firm | F-1 | |
| Consolidated Balance Sheets as of December 31, 2020 and 2019 | F-3 | |
| Consolidated Statements of Income for the years ended December 31, 2020 and 2019 | F-5 | |
| Consolidated Statement of Changes in Stockholder’s Equity for the years ended December 31, 2020 and 2019 | F-6 | |
| Consolidated Statement of Cash Flows for the years ended December 31, 2020 and 2019 | F-7 | |
| Notes to Financial Statements | F-9 |
(b) Exhibits
| (1) | Incorporated by reference to Form 10 filed on December 31, 2009. |
| (2) | Incorporated by reference to Form Def 14(c) filed on October 7, 2019. |
| (3) | Incorporated by reference to Form Def 14(c) filed on September 27, 2018. |
| (4) | Incorporated by reference to current Form 8-K filed on August 6, 2018. |
| (5) | Incorporated by reference to Amendment No. 1 to Form 10 filed on June 11, 2010. |
| (6) | Incorporated by reference to current Form 8-K filed on November 22, 2019. |
| (7) | Incorporated by reference to current Form 8-K filed on November 1, 2019. |
| (8) | Incorporated by reference to current Form 8-K filed on March 2, 2021. |
| (9) | Incorporated by reference to current Form 8-K filed on June 3, 2020. |
| (10) | We hereby agree to furnish the SEC with any omitted schedule or exhibit upon request. |
| 58 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of St Petersburg, FL, on March 31, 2021.
| Clinigence Holdings, Inc. | ||
| March 31, 2021 | By: | /s/ Warren Hosseinion |
| Warren Hosseinion, Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed by the following persons in the capacities indicated:
| Signature | Title | Date |
/s/ Warren Hosseinion Warren Hosseinion |
Chief Executive Officer and Chairman of the Board of Directors |
March 31, 2021 |
/s/ Michael Bowen Michal Bowen |
Chief Financial Officer | March 31, 2021 |
/s/ Elisa Luqman Elisa Luqman |
EVP of Finance and Director | March 31, 2021 |
Fred Sternberg
|
President and Director | March 31, 2021 |
/s/ Terence Martin Breslin Terence Martin Breslin |
Director | March 31, 2021 |
/s/ John Waters John Waters |
Chairman, Audit Committee, Director | March 31, 2021 |
| Robert Chan | Director | March 31, 2021 |
/s/ Mitchell R. Creem Mitchell R. Creem |
Director | March 31, 2021 |
|
Jacob Margolin |
Director | March 31, 2021 |
/s/ David Meiri David Meiri |
Director | March 31, 2021 |
| Randall Stern | Director | March 31, 2021 |
| 59 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Shareholders and Board of Directors of
Clinigence Holdings, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheet of Clinigence Holdings, Inc. (the “Company”) as of December 31, 2020, the related consolidated statements of operations, stockholders’ equity and cash flows for the year ended December 31, 2020, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020, and the results of its operations and its cash flows for the year ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.
Explanatory Paragraph – Going Concern
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 4, the Company has a significant working capital deficiency, has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 4. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.
Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
Valuation of Certain Level 3 Investments
Description of the Matter
The Company estimates the fair value of certain investments by utilizing valuation models with unobservable inputs. Unlike Level 1 and 2 inputs, Level 3 inputs are unobservable, supported by little or no market activity, and are significant to the fair value of certain investments. At December 31, 2020, the Company determined that the fair value of the Level 3 investment with a recorded value of $6,402,278, fell below the carrying value, based on an independent valuation report, and therefore recognized an unrealized loss from re-measurements for the entire amount.
Subjective and challenging judgement is required by management to determine the assumptions and valuation methodology to record financial assets at their fair value using Level 3 inputs. Auditing management’s models to determine the fair value of certain investments was complex and required judgement, particularly when evaluating underlying inputs such as the investee equity structure and asset values. These assumptions are affected by expectations about future economic and industry factors as well as estimates of the investee’s future growth potential.
How We Addressed the Matter in Our Audit
Procedures performed to address this critical audit matter included, but were not limited to, obtaining an understanding of the valuation methodology and determine assumptions used in valuation models to record financial assets and their fair value. For example, we tested management’s review controls over the significant assumptions described above as well as over data used in the valuation models.
With assistance from our valuation specialists, we evaluated the reasonableness of the valuation methodology and significant assumptions, tested inputs for reasonableness, and corroborated with audit evidence from external sources, comparison to historical transaction values and other external anticipated activities. We also evaluated audit evidence from events or transactions occurring after the measurement date for comparison to management’s estimate.
Evaluation of the Company’s goodwill impairment assessment
As discussed in Note 2 to the consolidated financial statements, due to the sale of certain intellectual property, the Company determined that the goodwill with a recorded value of $3,471,508 was impaired, as the asset associated with goodwill was transferred to the counter party per terms of an intellectual property asset purchase agreement. The Company also determined that the value of goodwill was not only less than its carrying amount, but no longer had any remaining useful life. As a result, the Company recorded a goodwill impairment charge of $3,471,508. The goodwill impairment charge represented the impairment of all of the goodwill recorded.
We identified the evaluation of the goodwill impairment assessment as a critical audit matter because of the high degree of subjectivity in evaluating the assumptions used in to estimate the fair value of the Company’s reporting units. The fair value estimation methodologies utilized, are based on limited observable market information. Such fair values are sensitive to changes to which include the following key assumptions:
| · | Forecasted reporting unit cash flows |
| · | Estimated long term growth rates |
The primary procedures we performed to address this critical audit matter included, testing the key assumptions listed above and obtaining the executed intellectual property asset purchase agreement. We assessed these assumptions including the viability of future cash flows determined the fair value of goodwill to be $0.
/s/ Marcum llp
Marcum llp
We have served as the Company’s auditor since 2020.
New York, NY
March 31, 2021
| F-1 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of
Clinigence Holdings, Inc.
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheet of Clinigence Holdings, Inc. (the Company) as of December 31, 2019, and the related consolidated statement of operations, stockholders’ equity, and cash flows for the year ended December 31, 2019, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019, and the results of its operations and its cash flows for the year ended December 31, 2018, in conformity with accounting principles generally accepted in the United States of America.
Going Concern
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As described in Note 4 to the consolidated financial statements, the Company has an accumulated deficit , and a working capital deficit at December 31, 2019. These factors, among others, raise substantial doubt regarding the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 4 to the accompanying financial statements. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
| /s/ Prager Metis CPA’s LLC |
| We have served as the Company’s auditor since 2019 |
| Hackensack, New Jersey |
| May 14, 2020 |
| F-2 |
| CLINIGENCE HOLDINGS, INC. | ||||||||
| CONSOLIDATED BALANCE SHEETS | ||||||||
| DECEMBER 31, | ||||||||
| 2020 | 2019 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | $ | 26,931 | $ | 1,065,434 | ||||
| Accounts receivable | 18,283 | 100,183 | ||||||
| Inventory | — | 26,988 | ||||||
| Prepaid expenses and other current assets | 111,842 | 50,747 | ||||||
| Total current assets | 157,056 | 1,243,352 | ||||||
| Long-term assets | ||||||||
| Property and equipment, net | 12,391 | 83,353 | ||||||
| Right of use asset, net | — | 247,196 | ||||||
| Intangible assets, net | — | 1,535,974 | ||||||
| Goodwill | — | 3,471,508 | ||||||
| Deposits and other assets | 410 | 11,121 | ||||||
| Restricted cash | — | 100,000 | ||||||
| Total assets | $ | 169,857 | $ | 6,692,504 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued expenses | $ | 695,424 | $ | 1,752,659 | ||||
| Customer deposits | 38,651 | — | ||||||
| Accrued interest on notes payable | — | 34,358 | ||||||
| Due to related parties | 30,000 | 128,477 | ||||||
| Lease liability - current | — | 50,406 | ||||||
| Deferred revenue | 76,687 | 165,560 | ||||||
| Current portion of convertible notes payable | — | 2,112,060 | ||||||
| Current portion of notes payable | 312,890 | 366,933 | ||||||
| Total current liabilities | 1,153,652 | 4,610,453 | ||||||
| Long-term liabilities | ||||||||
| Lease liability - long term | — | 223,618 | ||||||
| Notes payable | 150,000 | — | ||||||
| Total liabilities | 1,303,652 | 4,834,071 | ||||||
| Stockholders' equity (deficiency) | ||||||||
| Preferred stock, $.001 par value; authorized - 100,000,000 shares; issued and outstanding - 0 shares in 2020 and 2019, respectively | — | — | ||||||
| Common stock, $.001 par value; authorized - 800,000,000 shares; 5,282,545 and 4,649,179 shares issued and outstanding as of December 31, 2020 and 2019, respectively | 5,282 | 4,649 | ||||||
| Additional paid-in capital | 17,079,885 | 14,422,579 | ||||||
| Accumulated deficit | (18,218,962 | ) | (12,568,795 | ) | ||||
| Total stockholders' equity (deficiency) | (1,133,795 | ) | 1,858,433 | |||||
| Total liabilities and stockholders' equity (deficiency) | $ | 169,857 | $ | 6,692,504 | ||||
| See accompanying notes to the consolidated financial statements. | ||||||||
| F-3 |
| CLINIGENCE HOLDINGS, INC. | ||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||
| YEARS ENDED DECEMBER 31, | ||||||||
| 2020 | 2019 | |||||||
| Sales | $ | 1,585,952 | $ | 1,366,419 | ||||
| Cost of sales | 909,780 | 830,443 | ||||||
| Gross profit | 676,172 | 535,976 | ||||||
| Operating expenses | ||||||||
| Research and development | 557,257 | 768,103 | ||||||
| Sales and marketing | 166,759 | 577,739 | ||||||
| General and administrative expenses | 3,251,353 | 3,667,178 | ||||||
| Goodwill impairment loss | 3,471,508 | 2,257,058 | ||||||
| Gain on sale of assets | (1,993,424 | ) | — | |||||
| Gain on lease termination | (25,174 | ) | — | |||||
| Loss on sale of fixed assets | 54,819 | — | ||||||
| Loss on sale of subsidiary | 158,744 | — | ||||||
| Amortization | 222,032 | 163,746 | ||||||
| Total operating expenses | 5,863,874 | 7,433,824 | ||||||
| Loss from operations | (5,187,702 | ) | (6,897,848 | ) | ||||
| Other income (expenses) | ||||||||
| Loss on extinguishment of debt | (167,797 | ) | (130,140 | ) | ||||
| Interest income | 1,030 | 3,626 | ||||||
| Interest expense | (335,450 | ) | (92,158 | ) | ||||
| Total other income (expenses) | (502,217 | ) | (218,672 | ) | ||||
| Loss from continuing operations | (5,689,919 | ) | (7,116,520 | ) | ||||
| Income from discontinued operations (including gain on disposal of $142,027 for the year ended December 31, 2020) | 39,752 | — | ||||||
| Net loss | $ | (5,650,167 | ) | $ | (7,116,520 | ) | ||
| Basic and fully diluted income (loss) per common share: | ||||||||
| Continuing operations | $ | (1.15 | ) | $ | (1.96 | ) | ||
| Discontinued operations | .01 | — | ||||||
| Net income (loss) per common share | $ | (1.14 | ) | $ | (1.96 | ) | ||
| Weighted average common shares outstanding - basic and fully diluted | 4,942,268 | 3,630,075 | ||||||
| See accompanying notes to the consolidated financial statements. | ||||||||
| F-4 |
| CLINIGENCE HOLDINGS, INC. | ||||||||||||||||||||
| CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY) | ||||||||||||||||||||
| YEARS ENDED DECEMBER 31, 2020 AND 2019 | ||||||||||||||||||||
| Common stock | ||||||||||||||||||||
| Shares | Amount | Additional Paid-in Capital | Accumulated Deficit | Totals | ||||||||||||||||
| Balances, December 31, 2018 | 1,775,064 | $ | 1,775 | $ | 3,953,147 | $ | (5,452,275 | ) | $ | (1,497,353 | ) | |||||||||
| Common stock issued for cash | 739,891 | 740 | 4,111,760 | — | 4,112,500 | |||||||||||||||
| Stock-based compensation | 212,522 | 212 | 449,842 | — | 450,054 | |||||||||||||||
| Common stock issued in Qualmetrix acquisition | 1,124,594 | 1,125 | 4,167,094 | — | 4,168,219 | |||||||||||||||
| Effect of reverse merger | 797,108 | 797 | 836,166 | — | 836,963 | |||||||||||||||
| Warrants issued in connection with issuance of convertible debt | — | — | 374,178 | — | 374,178 | |||||||||||||||
| Notes payable converted to common stock | 143,642 | 144 | 530,248 | — | 530,392 | |||||||||||||||
| Common shares cancelled | (143,642 | ) | (144 | ) | 144 | — | — | |||||||||||||
| Net loss | (7,116,520 | ) | (7,116,520 | ) | ||||||||||||||||
| Balances, December 31, 2019 | 4,649,179 | 4,649 | 14,422,579 | (12,568,795 | ) | 1,858,433 | ||||||||||||||
| Common stock issued for cash | 190,476 | 190 | 119,810 | — | 120,000 | |||||||||||||||
| Stock-based compensation | 466,166 | 466 | 2,571,223 | — | 2,571,689 | |||||||||||||||
| Common stock cancelled | (23,276 | ) | (23 | ) | (33,727 | ) | — | (33,750 | ) | |||||||||||
| Net loss | (5,650,167 | ) | (5,650,167 | ) | ||||||||||||||||
| 5,282,545 | $ | 5,282 | $ | 17,079,885 | $ | (18,218,962 | ) | $ | (1,133,795 | ) | ||||||||||
| See accompanying notes to the consolidated financial statements. | ||||||||||||||||||||
| F-5 |
| CLINIGENCE HOLDINGS, INC. | ||||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
| YEARS ENDED DECEMBER 31, | ||||||||
| 2020 | 2019 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | (5,650,167 | ) | $ | (7,116,520 | ) | ||
| (Income) loss from discontinued operations | 118,992 | — | ||||||
| Net loss from continuing operations | (5,531,175 | ) | (7,116,520 | ) | ||||
| Adjustments to reconcile net loss to net cash used in operating activities | ||||||||
| Depreciation | 14,514 | 15,723 | ||||||
| Amortization | 94,761 | 156,092 | ||||||
| Non cash interest expense | 474,344 | 140,487 | ||||||
| Stock-based compensation expense | 2,571,689 | 450,054 | ||||||
| Goodwill impairment loss | 3,471,508 | 2,257,058 | ||||||
| Gain on sale of assets | (1,993,424 | ) | — | |||||
| Gain on lease termination | (25,174 | ) | — | |||||
| Loss on sale of assets | 54,819 | — | ||||||
| Cancellation of common stock | (33,750 | ) | — | |||||
| Loss on extinguishment of debt | 167,797 | 130,396 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 71,900 | 111,567 | ||||||
| Prepaid expenses and other current assets | (65,467 | ) | (45,280 | ) | ||||
| Deposits and other assets | 10,411 | 10,264 | ||||||
| Accounts payable and accrued expenses | (648,475 | ) | (304,441 | ) | ||||
| Customer deposits | 38,651 | — | ||||||
| Accrued interest on notes payable | (21,730 | ) | — | |||||
| Lease liability | (37,401 | ) | (11,238 | ) | ||||
| Deferred revenue | (88,873 | ) | 165,260 | |||||
| NET CASH USED IN OPERATING ACTIVITIES | (1,475,075 | ) | (4,040,578 | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchases of property and equipment | — | (84,002 | ) | |||||
| Advances to acquisition target | — | (577,046 | ) | |||||
| (Increase) decrease in restricted cash | 100,000 | (100,000 | ) | |||||
| Sale of property and equipment | 500 | — | ||||||
| Cash acquired from acquisitions | — | 12,852 | ||||||
| Net cash provided by (used) in continuing investing activities | 100,500 | (748,196 | ) | |||||
| Net cash used in discontinued investing activities | (161,400 | ) | — | |||||
| NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES | (60,900 | ) | (748,196 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from issuance of notes and convertible notes payable | 461,125 | 2,359,700 | ||||||
| Proceeds from sale of common stock | 120,000 | 4,112,500 | ||||||
| Proceeds from related party loans | 30,000 | — | ||||||
| Payments on notes and convertible notes payable | (113,653 | ) | (737,259 | ) | ||||
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 497,472 | 5,734,941 | ||||||
| NET INCREASE (DECREASE) IN CASH | (1,038,503 | ) | 946,167 | |||||
| CASH - BEGINNING OF YEAR | 1,065,434 | 119,267 | ||||||
| CASH - END OF YEAR | $ | 26,931 | $ | 1,065,434 | ||||
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||||||||
| Cash paid during the year for: | ||||||||
| Interest | $ | 18,077 | $ | 75,882 | ||||
| Non-cash investing and financing activities: | ||||||||
| Sale of software in consideration of Series E preferred stock and liabilities assumed | $ | 3,470,385 | $ | — | ||||
| Right of use asset added for operating lease | — | 285,262 | ||||||
| Notes payable converted to common stock | — | 399,996 | ||||||
| Notes payable converted to convertible notes payable | — | 32,500 | ||||||
| Accrued interest converted to convertible notes payable | — | 22,500 | ||||||
| Accrued salaries converted to convertible notes payable | — | 30,375 | ||||||
| Common stock issued for acquisitions | — | 5,005,182 | ||||||
| Intangible assets acquired | — | 7,281,555 | ||||||
| Warrants issued for convertible debt | — | 374,178 | ||||||
| See accompanying notes to the consolidated financial statements. | ||||||||
| F-6 |
CLINIGENCE HOLDINGS, INC.
Notes to Consolidated Financial Statements
Years Ended December 31, 2020 and 2019
Note 1 - Organization and Basis of Presentation
The consolidated financial statements presented are those of Clinigence Holdings, Inc., formerly known as iGambit Inc., (the “Company”) and its wholly-owned subsidiaries, Clinigence Health, Inc. (“Clinigence”) and HealthDatix, Inc. (“HealthDatix”). The Company’s name was changed to Clinigence Holdings, Inc. on October 29, 2019 in connection with a reverse merger. In October 2018, Clinigence was incorporated as a wholly-owned subsidiary of Clinigence LLC. The Company is a population health analytics company that provides turnkey SaaS solutions that enable connected intelligence across the care continuum by transforming massive amounts of data into actionable insights. The Company’s solutions help healthcare organizations throughout the United States improve the quality and cost-effectiveness of care, enhance population health management and optimize provider networks. The Company enables risk-bearing healthcare organizations achieve their objectives on the path to value-based care. The Company’s platform automatically extracts and delivers targeted data insights from its cloud-based analytics engine directly to the workflows and technologies of its customers. This enhances end-user workflows with actionable analytics, seamlessly delivers data from disparate sources to the point of engagement, automates the delivery of data to ensure on-time access, and reduces dependency on non-essential applications from the end-user’s workflow. All of this allows the healthcare organization to enable population health management, manage cost and utilization, improve quality, identify gaps in care, risk stratify and target patients, increase collaboration among providers and to optimize network provider performance.
Sale of Intellectual Property
On May 27, 2020, Clinigence Holdings Inc. entered into an Intellectual Property Asset Purchase Agreement (the “IP APA Agreement”) by and among Clinigence Health, Inc., a Delaware corporation (“Clinigence Health” or “Seller”), Clinigence Holdings, Inc., a Delaware corporation (“CLNH” or “Shareholder”), AHA Analytics, Inc., a Delaware corporation (“Purchaser”) and Accountable Healthcare America Inc., a Delaware corporation (“AHA”). The transactions contemplated by the IP APA Agreement were consummated on May 29, 2020 (the “Closing”).
The IP APA Agreement provided for the sale of certain intellectual property and rights, including but not limited to copyrights, patents, pending patents, and continuation in part, (the “Transferred Assets”) to Purchaser from the Seller, hereafter referred to as the “Asset Sale.”
Subject to the provisions of the IP APA Agreement, the Asset Sale provided for an aggregate purchase price (“Purchase Price”) to Seller and Shareholder equal to the sum of the Series E Preferred Stock, (the “Preferred Stock”), the Assumed Liabilities, and an adjustment to the Stated Value.
The Preferred Stock was to have an initial stated value of $15,000,000 in the aggregate, subject to adjustment as mentioned below. The Stated Value, however, shall be reduced by the Assumed Liabilities as set forth herein which includes the Hold Back amount as set forth in Article 9 of the IP APA Agreement, and shall automatically convert upon either of the following events:
| (1) | Immediately before (A) the Purchaser’s consummation of a merger with or an acquisition by a Publicly Traded Company listed on NASDAQ all of the Preferred Shares shall be automatically converted into shares of Common Stock of Purchaser or (B) upon Purchaser’s consummation of the Merger into Common Shares of the Publicly Traded Company (“Pubco Shares”) equal to the Stated Value (as may be adjusted in accordance with the terms of the Certificate of Designation), which Pubco Shares shall be valued at the Fair Market Value of those shares; |
| (2) | After two hundred and forty (240) days from the date of Closing, if the merger with or an acquisition by a Publicly Traded Company has not occurred, the Preferred Stock shall automatically convert into 3,750,000 of Common Shares of Stock of the Purchaser, based upon a $4 per share valuation on the date of Conversion. |
| F-7 |
The investment in AHA was initially recorded at $6,402,278 based on 1,252,892 shares outstanding at a fair value of $5.11 per share based on an appraised valuation of the Preferred Stock.
The Assumed Liabilities consist of the following:
| Convertible notes payable | $ | 2,442,875 | ||
| Related party loan payable | 128,477 | |||
| Note payable - Jerrold Young | 15,000 | |||
| Note payable - Lighter Capital | 487,579 | |||
| Accounts payable | 323,563 | |||
| Accrued interest on notes payable | 72,891 | |||
| $ | 3,470,385 |
The initial Stated Value of $15,000,000 (less the Assumed Liabilities) in the aggregate upon the Purchaser’s consummation of a merger with or an acquisition by a Publicly Traded Company listed on NASDAQ (the “Merger”) shall be based upon a minimum valuation of Purchaser equal to twelve (12) times the Audited EBITDA of Purchaser upon the closing of the Merger (the “Valuation”). Should the Purchaser’s Valuation in a Merger be adjusted downward due to market conditions, as reflected in and governed by the terms of, the definitive agreements relating to such Merger between Purchaser and the Publicly Traded Company, the Stated Value shall be adjusted downward proportionally.
As of December 31, 2020, the Company determined that the fair value of the AHA Series E Preferred Stock fell below its carrying value based on an independent valuation report and wrote off its investment in AHA.
Gain on sale of assets reported in the statements of operations consists of the following:
| Fair value of AHA Series E Preferred Stock received | $-- | |||
| Assumed liabilities | 3,470,385 | |||
| Less assets sold: | ||||
| Intangible assets | (1,476,961 | ) | ||
| Gain on sale of assets | $ | 1,993,424 | ||
An impairment expense of $3,471,508 was recorded for the balance of goodwill included in the assets sold to AHA. During the third and fourth quarters of the year ending December 31, 2020, the Company recorded an additional gain on the sale of intellectual property as a result of obtaining a legal discharge of its obligations from the lenders and noteholders and payment made by AHA in regards to the debt.
| F-8 |
Business Acquisitions
A) Reverse Merger
On August 8, 2019, iGambit, Inc. entered into an Agreement and Plan of Merger (the “Reverse Merger Agreement”) by and among Clinigence Health, Inc., a Delaware corporation (“Clinigence”), iGambit, Inc., a Delaware corporation (“iGambit” or the “Company”), HealthDatix, Inc., a Delaware corporation and wholly owned subsidiary of iGambit (“Merger Sub”), and John Salerno, an individual and holder of shares of iGambit capital stock constituting a majority of the votes eligible to be cast by all of the stockholders of iGambit (the “Signing Stockholder”). The transactions contemplated by the Reverse Merger Agreement were consummated on October 29, 2019 (the “Closing”).
The Reverse Merger Agreement provided for the merger of Merger Sub with and into Clinigence, hereafter referred to as the “Acquisition.” As a result of the Acquisition, Merger Sub ceased to exist, and Clinigence became the surviving corporation and a direct wholly owned subsidiary of iGambit, and the former stockholders of Clinigence (the “Clinigence Stockholders”) have a direct equity ownership and controlling interest in iGambit. Merger Sub was renamed Clinigence Health Inc. iGambit was renamed Clinigence Holdings, Inc. Merger Sub was originally incorporated in Delaware on October 17, 2013 and had no operating activity prior to the reported transaction.
At the Closing, all of the outstanding shares of Clinigence common stock (the “Clinigence Shares”) were converted solely into the right to receive a number of shares of iGambit common stock (the “Company Shares”) such that the holders of outstanding equity of Clinigence immediately prior to the Closing own 85%, on a fully-diluted basis, of the outstanding equity of iGambit immediately following the Closing, and holders of outstanding equity of iGambit immediately prior to the Closing own 15%, on a fully-diluted basis, of the outstanding equity of iGambit. For each share of Clinigence Shares, each former Clinigence Stockholder received 0.22489093 shares of Company Shares after giving effect to the reverse stock split.
The Business Combination was treated as a “reverse acquisition” for accounting purposes, whereby Clinigence is considered the acquirer for accounting purposes, and the historical financial statements before the Business Combination have been replaced with the historical financial statements of Clinigence and its subsidiaries before the Business Combination.
In connection with the Acquisition, the Company amended its certificate of incorporation to (i) effect a reverse stock split of the Company Shares at a ratio of 1 for 500 (the “Reverse Split Certificate of Amendment”), and (ii) change its name to Clinigence Holdings, Inc. (the “Name Change Certificate of Amendment”).
The following table represents the fair value of the consideration paid allocated to the assets and liabilities acquired in applying the acquisition method for the completion of the reverse merger:
| Consideration: | ||||
| Issuance of 797,108 shares of common stock | $ | 836,963 | ||
| Net liabilities assumed | 1,467,897 | |||
| Total consideration | $ | 2,304,860 | ||
| Assets Acquired: | ||||
| Current assets | $ | 46,209 | ||
| Property, equipment, and other non-current assets | 1,593 | |||
| Goodwill | 2,257,058 | |||
| Total assets acquired | $ | 2,304,860 | ||
| F-9 |
B) QualMetrix Acquisition
On March 1, 2019, prior to the reverse merger referred to above, the Company entered into a Contribution Agreement by and among Clinigence Holdings, Inc. (“Holdings”), Qualmetrix, Inc. (“QMX”), and the Members of Clinigence, LLC (“Agreement”) whereby Clinigence Holdings, Inc. acquired all of the assets and operations and assumed all of the liabilities of Qualmetrix, Inc. The Company acquired QMX to further its SAAS-based offerings to its customers and expand into new markets. The goodwill is derived largely from the expected growth of the Company, as well as synergies and economies of scale expected from combining the operations of QMX with the Company. Pursuant to the Agreement, all of the outstanding Series A and Series B Preferred Stock and Common Stock of Qualmetrix, Inc. totaling 34,726,659 shares were exchanged for 5,021,950 common shares of Clinigence Holdings, Inc. All outstanding shares of Qualmetrix, Inc. immediately preceding the exchange were treated as one class. On the date of the transaction, the shares of common stock issued to Qualmetrix, Inc. had an estimated fair value of $0.83 per share based on an independent valuation.
The following table represents the fair value of the consideration paid allocated to the assets and liabilities acquired in applying the acquisition method for the completion of the Qualmetrix, Inc. business combination:
| Consideration: | ||||
| Issuance of 5,021,950 shares of common stock | $ | 4,168,219 | ||
| Net liabilities assumed | 989,805 | |||
| Total consideration | $ | 5,158,024 | ||
| Assets Acquired: | ||||
| Current assets | $ | 24,698 | ||
| Property, equipment, and other non-current assets | 7,818 | |||
| Identifiable intangible assets | 1,654,000 | |||
| Goodwill | 3,471,508 | |||
| Total assets acquired | $ | 5,158,024 | ||
| F-10 |
Note 2 – Discontinued Operations
Sale of Business
On April 21, 2020 (effective March 1, 2020) the Company completed the sale of HealthDatix, Inc., a Florida corporation (“HDX FL”) to Jerry Robinson, Mary-Jo Robinson and Kathleen Shepherd (“HDX Management”) in accordance with a Stock Purchase Agreement (the “Purchase Agreement”) by and between the Company and HDX Management. Pursuant to the Purchase Agreement, the total consideration paid for the outstanding capital stock of HDX FL was the execution of Settlement and Release Agreements by HDX Management, releasing the Company from all obligations pursuant to certain HDX Management Employment Agreements dated April 1, 2017, and remittance of 1,000 shares of HDX common stock previously issued to HDX Management. As per the Purchase Agreement, the Company’s operations of HDX FL ended February 29, 2020 and HDX Management’s operation of the business is effective as of March 1, 2020.
The components of loss from discontinued operations presented in the consolidated statements of operations for the year ended December 31, 2020 are presented as follows:
| Sales | $ | 5,958 | ||
| Cost of sales | (6,795 | ) | ||
| General and administrative expenses | (101,100 | ) | ||
| Depreciation and amortization | (75 | ) | ||
| Interest expense | (263 | ) | ||
| Loss from operations | (102,275 | ) | ||
| Loss on disposal of HealthDatix | (16,717 | ) | ||
| Loss from discontinued operations | $ | (118,992 | ) |
Note 3 – Summary of Significant Accounting Policies
Principles of Consolidation
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Clinigence Health, Inc., HealthDatix Inc. All intercompany accounts and transactions have been eliminated.
Use of Estimates in the Preparation of Financial Statements
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
Fair Value Measurements
The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.
| F-11 |
The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk. The Company’s investment in AHA was valued at level 3 input.
ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:
Level 1 – quoted prices in active markets for identical assets or liabilities
Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable
Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
Convertible Instruments
The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.
Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.
The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.
The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.
| F-12 |
Revenue Recognition
Revenue is generated primarily by software licenses, training, and consulting. Software licenses are provided as SaaS-based subscriptions that grants access to proprietary online databases and data management solutions. Training and consulting are project based and billable to customers on a monthly-basis or task-basis.
Revenue from training and consulting are generally recognized upon delivery of training or completion of the consulting project. The duration of training and consulting projects are typically a few weeks or months and last no longer than 12 months.
SaaS-based subscriptions are generally marketed under multi-year agreements with annual, semi-annual, quarterly, or month-to-month renewals and revenue is recognized ratably over the renewal period with the unearned amounts received recorded as deferred revenue.
On January 1, 2019, the Company adopted the new revenue recognition standard Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606)”, using the modified retrospective method. The modified retrospective adoption used by the Company did not result in a material cumulative effect adjustment to the opening balance of accumulated deficit. Revenue from substantially all the Company’s contracts with customers continues to be recognized over time as performance obligations are satisfied.
The Company provides its customers with software licensing, training, and consulting through SaaS-based subscriptions. This subscription revenue represents revenue earned under contracts in which the Company bills and collects the charges for licensing and related services. The Company determines the measurement of revenue and the timing of revenue recognition utilizing the following core principles:
| 1. | Identifying the contract with a customer; |
| 2. | Identifying the performance obligations in the contract; |
| 3. | Determining the transaction price; |
| 4. | Allocating the transaction price to the performance obligations in the contract; and |
| 5. | Recognizing revenue when (or as) the Company satisfies its performance obligations. |
Revenues from subscriptions are deferred and recorded as deferred revenue when cash payments are received in advance of the satisfaction of the Company’s performance obligations and recognized over the period in which the performance obligations are satisfied. The Company completes its contractual performance obligations through providing its customers access to specified data through subscriptions for a service period, and training on consulting associated with the subscriptions. The Company primarily invoices its customers on a monthly basis and does not provide any refunds, rights of return, or warranties to its customers.
Advertising Costs
The Company expenses advertising costs as incurred. Advertising costs of $41,418 and $115,647 were charged to operations for the years ended December 31, 2020 and 2019, respectively.
Cash and Cash Equivalents
Cash and cash equivalents are comprised of cash and highly liquid investments with original maturities of 90 days or less at the date of purchase. The Company does not have any cash equivalents as of December 31, 2020 and 2019. The Company is exposed to credit risk in the event of default by the financial institutions or the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured.
| F-13 |
Accounts Receivable
The Company analyzes the collectability of accounts receivable from continuing operations each accounting period and adjusts its allowance for doubtful accounts accordingly. A considerable amount of judgment is required in assessing the realization of accounts receivables, including the creditworthiness of each customer, current and historical collection history and the related aging of past due balances. The Company evaluates specific accounts when it becomes aware of information indicating that a customer may not be able to meet its financial obligations due to deterioration of its financial condition, lower credit ratings, bankruptcy or other factors affecting the ability to render payment.
Inventory
Inventory consisting of finished products is stated at the lower of cost or net realizable value.
Property and equipment and depreciation
Property and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows:
| Office equipment and fixtures | 5 - 7 years | |||
| Computer hardware | 5 years | |||
| Computer software | 3 years | |||
| Development equipment | 5 years |
Amortization
Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:
| Developed technology | 13 years | |||
| Customer relationships | 10 years |
Goodwill
Goodwill represents the excess of assets acquired over liabilities assumed of QMX and the fair market value of the common shares issued by the Company for the acquisition of QMX. In accordance with ASC Topic No. 350 “Intangibles – Goodwill and Other”), the goodwill is not being amortized, but instead will be subject to an annual assessment of impairment by applying a fair-value based test, and will be reviewed more frequently if current events and circumstances indicate a possible impairment. An impairment loss is charged to expense in the period identified. If indicators of impairment are present and future cash flows are not expected to be sufficient to recover the asset’s carrying amount, an impairment loss is charged to expense in the period identified. An impairment expense of $3,471,508 was recorded during the year ended December 31, 2020 in connection with the sale of intellectual property, as discussed in Note 1.
| F-14 |
Long-Lived Assets
The Company assesses the valuation of components of its property and equipment and other long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.
Deferred Revenue
Deposits from customers are not recognized as revenues, but as liabilities, until the following conditions are met: revenues are realized when cash or claims to cash (receivable) are received in exchange for goods or services or when assets received in such exchange are readily convertible to cash or claim to cash or when such goods/services are transferred. When such income item is earned, the related revenue item is recognized, and the deferred revenue is reduced. To the extent revenues are generated from the Company’s support and maintenance services, the Company recognizes such revenues when services are completed and billed. The Company has received deposits from its various customers that have been recorded as deferred revenue and presented as current liabilities in the amount of $76,687 and $165,560 as of December 31, 2020 and 2019, respectively.
Stock-Based Compensation
The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, which requires the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value on the date of grant and recognition of compensation expense over the related service period for awards expected to vest. The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected stock price volatility of the Company’s common stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption related to forfeitures of such grants. Changes in these subjective input assumptions can materially affect the fair value estimate of the Company’s stock options and warrants.
Income Taxes
The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.
The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements. In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position.
| F-15 |
Recent Accounting Pronouncements
We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.
Note 4 – Going Concern
The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has an accumulated deficit of $18,218,962, and a working capital deficit of $996,596 at December 31, 2020. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for the next twelve months from the date that the financial statements are issued. Management’s plans and assessment of the probability that such plans will mitigate and alleviate any substantial doubt about the Company’s ability to continue as a going concern, is dependent upon the ability to attain funding to secure additional resources to generate sufficient revenues and increased margin, which without these represent the principal conditions that raise substantial doubt about our ability to continue as a going concern.
As a result of the spread of the COVID-19 coronavirus, economic uncertainties have arisen which are likely to negatively impact operations. Other financial impact could occur though such potential impact is unknown at this time. A pandemic typically results in social distancing, travel bans and quarantine, and this may limit access to our facilities, customers, management, support staff and professional advisors. These factors, in turn, may not only impact our operations, financial condition and demand for our goods and services but our overall ability to react timely to mitigate the impact of this event. Also, it may hamper our efforts to comply with our filing obligations with the Securities and Exchange Commission.
The Company expects that working capital requirements will continue to be funded through a combination of its existing funds and further issuances of securities. Working capital requirements are expected to increase in line with the growth of the business. Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund operations over the next twelve months. The Company has no lines of credit or other bank financing arrangements. The Company has financed operations to date through the proceeds of a private placement of equity and debt instruments. In connection with the Company’s business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. The Company intends to finance these expenses with further issuances of securities, and debt issuances. Thereafter, the Company expects it will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to current stockholders. Further, such securities might have rights, preferences or privileges senior to common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, the Company may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict business operations.
The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
| F-16 |
Note 5 – Property and Equipment
Property and equipment are carried at cost and consist of the following at December 31, 2020 and 2019:
| 2020 | 2019 | |||||||
| Office equipment and fixtures | $ | 5,300 | $ | 109,468 | ||||
| Computer hardware | 41,065 | 44,866 | ||||||
| Computer software | 16,121 | 16,121 | ||||||
| Less: Accumulated depreciation | 50,095 | 87,102 | ||||||
| $ | 12,391 | $ | 83,353 | |||||
Depreciation expense of $14,514 and $15,723 was charged to operations for the years ended December 31, 2020 and 2019, respectively.
Note 6 – Intangible Assets
The following tables provide detail associated with the Company’s acquired identifiable intangible assets:
| As of December 31, 2019 | ||||||||||||||||
Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | Weighted Average Useful Life (in years) | |||||||||||||
| Amortized intangible assets: | ||||||||||||||||
| Customer relationships | $ | 624,000 | $ | (52,000 | ) | $ | 572,000 | 10 | ||||||||
| Developed technology | 1,030,000 | (66,026 | ) | 963,974 | 13 | |||||||||||
| Total | $ | 1,654,000 | $ | (118,026 | ) | $ | 1,535,974 | |||||||||
Aggregate Amortization Expense:
| For the year ended December 31, 2020 | $ | 59,013 |
In connection with the sale of intellectual property as discussed in Note 1, the Company sold its intangible assets of $1,476,961, net of accumulated amortization of $177,039 to AHA pursuant to the Asset Purchase Agreement on May 29, 2020, resulting in a balance of $0 at December 31, 2020.
| F-17 |
Note 7 – Operating Lease
The Company determines if a contract is, or contains, a lease at contract inception. Operating leases are included in operating lease right-of-use ("ROU") assets, current portion of operating lease liabilities and operating lease liabilities, net of current portion in the Company's consolidated balance sheets. Finance leases are included in property and equipment, current portion of finance lease obligations and finance lease obligations, net of current portion in the Company's unaudited consolidated balance sheets.
ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. In addition, ROU assets include initial direct costs incurred by the lessee as well as any lease payments made at or before the commencement date and exclude lease incentives. The Company used the implicit rate in the lease in determining the present value of lease payments. Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of one year or less are generally not included in ROU assets and liabilities.
Operating lease ROU assets and operating lease liabilities are recorded on the consolidated balance sheet as follows:
| December 31, | ||||
| 2019 | ||||
| Operating Lease: | ||||
| Operating lease right-of-use assets, net | $ | 247,196 | ||
| Current portion of operating lease liabilities | 50,406 | |||
| Operating lease liabilities, net of current portion | 223,618 | |||
Effective October 15, 2020, the Company terminated the operating lease for its Atlanta, Georgia office that was set to expire in 2024. The lease termination agreement required the Company to forfeit its Letter of Credit and all of its furniture and fixtures to the landlord. The early termination resulted in a gain on lease termination of $25,174, calculated as follows:
| Current portion of operating lease liabilities at September 30, 2020 | $ | 54,564 | ||
| Operating lease liabilities, net of current portion at September 30, 2020 | 182,059 | |||
| Less: Operating lease right-of-use assets, net at September 30, 2020 | 211,449 | |||
| Gain on lease termination | $ | 25,174 |
The balance of the Letter of Credit of $100,000 was charged to rent expense and the book value of the assets abandoned of $53,198 was charged to loss on sale of assets.
Consolidated rental expense for all operating leases was $143,307 and $126,944 for the years ended December 31, 2020 and 2019, respectively.
The following table summarizes the cash paid and related right-of-use operating lease recognized for the year ended December 31, 2020.
| Year Ended | ||||
| December 31, 2020 | ||||
| Cash paid for amounts included in the measurement of lease liabilities: | ||||
| Operating cash flows from operating leases | $ | 50,446 | ||
| Right-of-use lease assets obtained in the exchange for lease liabilities: | ||||
| Operating leases | 37,401 | |||
| F-18 |
Note 8 - Earnings (Loss) Per Common Share
The Company calculates net income (loss) per common share in accordance with ASC 260 “Earnings Per Share” (“ASC 260”). Basic and diluted net earnings (loss) per common share was determined by dividing net earnings (loss) applicable to common stockholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, common stock warrants, and convertible debt have not been included in the computation of diluted net loss per share for the years ended December 31, 2020 and 2019 as the result would be anti-dilutive.
| Years Ended | ||||||||
| December 31, | ||||||||
| 2020 | 2019 | |||||||
| Stock options | 1,174,814 | 48,854 | ||||||
| Stock warrants | 557,873 | 1,065,251 | ||||||
| Total shares excluded from calculation | 1,732,687 | 1,114,105 | ||||||
Note 9 – Stock Based Compensation
Options
In 2019, the Company adopted the 2019 Omnibus Equity Incentive Plan (the "2019 Plan"). Awards granted under the 2019 Plan have a ten-year term and may be incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units or performance shares. The awards are granted at an exercise price equal to the fair market value on the date of grant and generally vest over a four-year period.
Stock option activity during the years ended December 31, 2020 and 2019 follows:
| Options Outstanding | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (Years) | ||||||||||
| Options outstanding at December 31, 2018 | – | $ | – | – | ||||||||
| Options granted | 48,854 | 5.11 | ||||||||||
| Options outstanding at December 31, 2019 | 48,854 | 5.11 | 8.05 | |||||||||
| Options granted | 1,130,734 | 1.49 | ||||||||||
| Options expired | (400 | ) | 0.01 | |||||||||
| Options cancelled | (4,374 | ) | 5.56 | |||||||||
| Options outstanding at December 31, 2020 | 1,174,814 | $ | 1.61 | 8.11 | ||||||||
| F-19 |
Options outstanding at December 31, 2020 consist of:
| Date Issued | Number Outstanding | Number Exercisable | Exercise Price | Expiration Date | ||||||||||
| August 5, 2019 | 40,480 | 40,480 | $ | 5.56 | August 5, 2029 | |||||||||
| October 29, 2019 | 3,600 | 3,600 | $ | 0.0725 | June 6, 2027 | |||||||||
| January 27, 2020 | 307,884 | 307,884 | $ | 1.50 | January 27, 2030 | |||||||||
| January 27, 2020 | 225,000 | 225,000 | $ | 1.50 | January 27, 2027 | |||||||||
| February 29, 2020 | 95,794 | 95,794 | $ | 1.25 | February 28, 2030 | |||||||||
| May 11, 2020 | 380,000 | 380,000 | $ | 1.50 | May 11, 2027 | |||||||||
| June 30, 2020 | 122,056 | 122,056 | $ | 1.45 | June 30, 2030 | |||||||||
| Total | 1,174,814 | 1,174,814 | ||||||||||||
Warrants
In 2018, the Company issued fully vested warrants to investors as part of a private placement offering. Each unit offered in the private placement consisted of one share of common stock, and a warrant convertible into 0.4 shares of common stock at an exercise of $1.50 per whole share. The warrants are exercisable for a period of five years from the date of issuance. The warrants were cancelled on March 1, 2019 and reissued upon the Qualmetrix acquisition and are each convertible into one share of common stock at an exercise price of $6.67 per share until December 31, 2024.
In November 2019, the Company issued fully vested warrants to investors as part of private placement subscription agreements pursuant to which the Company issued convertible promissory notes. Each noteholder received warrants to purchase common stock of 50% of the principal at an exercise price of $5.56 per share with an expiration date of October 31, 2025.
Warrant activity during the years ended December 31, 2020 and 2019 follows:
Warrants Outstanding | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (Years) | ||||||||||
| Warrants outstanding at December 31, 2018 | 138,997 | $ | 0.81 | 5.55 | ||||||||
| Warrants granted | 1,065,251 | 6.04 | ||||||||||
| Warrants cancelled | (138,997 | ) | 0.81 | |||||||||
| Warrants outstanding at December 31, 2019 | 1,065,251 | $ | 6.04 | 5.17 | ||||||||
| Warrants cancelled | (507,378 | ) | — | |||||||||
| Warrants outstanding at December 31, 2020 | 557,873 | $ | 6.77 | 3.79 | ||||||||
| F-20 |
Warrants outstanding at December 31, 2020 consist of:
| Date Issued | Number Outstanding | Number Exercisable | Exercise Price | Expiration Date | ||||||||||
| March 21, 2019 | 96,433 | 96,433 | $ | 6.67 | December 31, 2024 | |||||||||
| April 30, 2019 | 3,598 | 3,598 | $ | 6.67 | December 31, 2024 | |||||||||
| May 13, 2019 | 14,393 | 14,393 | $ | 6.67 | December 31, 2024 | |||||||||
| May 28, 2019 | 199,703 | 199,703 | $ | 6.67 | December 31, 2024 | |||||||||
| June 5, 2019 | 7,197 | 7,197 | $ | 6.67 | December 31, 2024 | |||||||||
| June 25, 2019 | 208,361 | 208,361 | $ | 6.67 | December 31, 2024 | |||||||||
| September 6, 2019 | 25,188 | 25,188 | $ | 6.67 | December 31, 2024 | |||||||||
| October 29, 2019 | 1,500 | 1,500 | $ | 25.00 | February 5, 2023 | |||||||||
| October 29, 2019 | 1,500 | 1,500 | $ | 25.00 | April 27, 2023 | |||||||||
| Total | 557,873 | 557,873 | ||||||||||||
Note 10 – Convertible Notes Payable
Convertible notes payable consisted of the following at December 31, 2020 and 2019:
| 2020 | 2019 | |||||||
| Notes payable convertible into Clinigence common shares at $5.56 per share; bearing interest at a rate of 10%; net of debt discount of $0 and $328,652, respectively; maturing in October 2020 | $ | — | $ | 2,016,723 | ||||
| Notes payable convertible into Clinigence common shares at $1.25 per share; bearing interest at a rate of 10%; net of debt discount of $1,100 and $2,163, respectively; maturing in October 2020 | — | 95,337 | ||||||
| Total convertible notes payable | — | 2,112,060 | ||||||
| Current portion | — | (2,112,060 | ) | |||||
| Total convertible notes payable, net | $ | — | $ | — | ||||
In March 2019, the Company made a cash payment totaling $200,000 to settle a previously outstanding convertible note payable. In conjunction with the payment, approximately 400,000 underlying warrants to purchase units of CLI expired unexercised.
During the years ended December 31, 2020 and 2019 the Company recognized total interest expense of $335,450 and $92,158, respectively.
Under a subscription agreement dated November 19, 2019, the Company issued convertible promissory notes to various individuals totaling $2,345,375 at December 31, 2019. The notes are convertible at any time through the maturity date of October 31, 2020. In connection with the issuance of the convertible promissory notes, the Company issued 263,727 warrants to purchase shares of the Company’s common stock. The Company allocated the proceeds between the fair value of the notes and warrants. The Company allocated $370,714 to the warrants which has been recorded as a debt discount to be amortized over the life of the notes. Notes payable is presented net of debt discount of $0 and $328,652 at December 31, 2020 and 2019, respectively.
| F-21 |
The Company issued convertible debentures in the amount of $75,000 to three individuals in 2016 and 2017. The Company restated the convertible debentures on November 15, 2019 to comply with the terms of the November 19, 2019 promissory notes previously mentioned and added $22,500 of accrued interest to the principal balances. Notes payable is presented net of debt discount of $0 and $2,163 at December 31, 2020 and 2019, respectively.
The principal balances of the November 19, 2019 convertible notes and the 2016 and 2017 convertible debentures totaling $2,442,875 were included in the Assumed Liabilities of the AHA Asset Purchase Agreement, as discussed in Note 1. Loss on extinguishment of debt of $167,797 was recorded for the debt discount balance on May 29, 2020.
Note 11 – Notes Payable
Notes payable consisted of the following at December 31, 2020 and 2019:
| 2020 | 2019 | |||||||
| Notes payable with maturities between six months and twelve months from the date of issuance with annual percentage interest rates between 24% and 31% | $ | 1,765 | $ | 63,226 | ||||
| SBA Paycheck Protection Program note payable issued in April 2020 with a maturity date of October 2022 and interest rate of 1% | 311,125 | — | ||||||
| SBA Economic Injury Disaster Loan note payable issued in May 2020 with a maturity date of May 2051 and interest rate of 3.75% | 150,000 | — | ||||||
| Demand note payable issued to former officers of Qualmetrix, Inc. with an annual percentage interest rate of 8% | — | 16,200 | ||||||
| Note payable issued in June 2017 with a maturity date of June 2022 and effective interest rate of 10.66% | — | 287,507 | ||||||
| Total notes payable | 462,890 | 366,933 | ||||||
| Current portion | (312,890 | ) | (366,933 | ) | ||||
| Total notes payable, net | $ | 150,000 | $ | — | ||||
Beginning in April 2018, the Company entered into a series of short-term notes with interest rates ranging from 24% to 31% per annum. Throughout the year ended December 31, 2020 the Company made average monthly principal and interest payments approximating $8,200 per month. The outstanding balance on the short-term notes at December 31, 2020 and 2019 was $1,765 and $63,226, respectively.
| F-22 |
In October 2017, Qualmetrix entered into demand notes with its former Chief Executive Officer totaling $100,000. In January through April 2018, the Company issued additional notes to its former Chief Executive Officer totaling $92,000 maturing one year from the date of issuance. In April 2019, one of the notes was settled via a cash payment of interest and principal totaling $195,789. The outstanding balance of the note issued in January 2018 was $0 and $16,200 at December 31, 2020 and 2019, respectively and includes accrued interest of $1,200.
In June 2017, the Company entered into a Revenue Loan Investment for net working capital proceeds of $500,000. The Company is required to make monthly principal and interest payment on the Revenue Loan based on its net cash receipts from operations in the following 3 tiers:
| • | Tier 1 – Payments at a rate of 6.0% of the net cash receipts from the immediate month prior until cumulative loan payments are based on $2,500,000 of net cash receipts. |
| • | Tier 2 – After achieving loan payments based on $2,500,000 of net cash receipts in a loan year, additional payments are based on 3.0% of amounts in excess of the Tier 1 Cap. |
| • | Tier 3 – Payments at a rate of 0.5% of net cash receipts in excess of $3,200,000 in a loan year. |
From the inception of the Revenue Loan in June 2017 through May 29, 2020 the Company has paid its monthly principal and interest payments based on the Tier 1 net cash receipts. Default interest on the Revenue Loan of $252,263 was recorded during the year ended December 31, 2020.
Principal on the Revenue Loan of $487,579, net of a $50,000 principal payment and the demand note payable of $15,000 and accrued interest of $1,600 were included in the Assumed Liabilities of the AHA Asset Purchase Agreement, as discussed in Note 1.
On May 22, 2020, the Company received loan proceeds of $150,000 pursuant to the U.S. Small Business Administration (“SBA”) COVID-19 Economic Injury Disaster Loan (EIDL) program. Under the terms of the loan, Borrower must pay principal and interest payments of $731.00 every month beginning Twelve (12) months from the date of the Note. The SBA will apply each installment payment first to pay interest accrued to the day the SBA receives the payment and will then apply any remaining balance to reduce principal. All remaining principal and accrued interest is due and payable Thirty (30) years from the date of the Note. Borrower may prepay this Note in part or in full at any time, without notice or penalty.
The Company’s long-term debt is comprised of promissory notes pursuant to the Paycheck Protection Program and Economic Injury Disaster Loan (see below), under Coronavirus Aid, Relief and Economic Security Act (“CARES ACT”) enacted on March 27, 2020 and revised under the provisions of the PayCheck Protection Flexibility Act of 2020 on June 5, 2020 and administered by the United States Small Business Administration (“SBA”).
On April 21, 2020, the Company received a loan in the amount of $333,125 under the Payroll Protection Program (“PPP Loan”). The loan accrues interest at a rate of 1% and has an original maturity date of two years which can be extended to five years by mutual agreement of the Company and SBA. The PPP loan contains customary events of default relating to, among other things, payment defaults and breaches of representations and warranties.
Under the terms of the loan, a portion or all of the loan is forgivable to the extent the loan proceeds are used to fund qualifying payroll, rent and utilities during a designated twenty-four week period. Payments are deferred until the SBA determines the amount to be forgiven. The Company has utilized the proceeds of the PPP loan in a manner which has enabled qualification as a forgivable loan. However, no assurance can be provided that all or any portion of the PPP loan will be forgiven. The balance on this PPP loan was $333,125 as of December 31, 2020 and has been classified as a long-term liability in notes payable, less current portion on the accompanying consolidated balance sheets.
| F-23 |
Note 12 – Stock Transactions
Designation of Preferred Stock
On August 2, 2018, the Company filed a Certificate of Designation with the Delaware Division of Corporations whereby the Company designated a Series A Preferred Stock and issued 1,000 shares to the Company’s CEO. The holders of Series A Preferred Stock will have voting rights, when combined with their existing holdings of the Company’s common stock, that entitle them to have an aggregate of 51% of the votes eligible to be cast by all stockholders with respect to all matters brought before a vote of the stockholders of the Company. In connection with the Clinigence reverse merger on October 29, 2019, the Company filed a Certificate of Withdrawal of the Certificates of Designation, Preferences and Rights of the Series A Preferred Stock with the Delaware Secretary of State and returned all previously designated shares to their status as authorized preferred stock available for issuance.
Reverse Stock Split
On October 25, 2019, prior to the Clinigence reverse merger agreement, the Company effected a 1-for-500 reverse stock split of its common stock. On the effective date of the reverse stock split, each 500 shares of outstanding common stock were reduced to one share of common stock. All share and per share information presented have been adjusted on a retrospective basis to reflect this 1-for-500 reverse stock split.
Common Stock Issued
The Company issued 225,820 restricted common shares to employees for salaries on June 30, 2020, valued at $361,312. On September 28, 2020, 23,276 of these shares issued to an employee, valued at $33,750 were cancelled in connection with a separation agreement.
The Company issued 228,346 common shares to an employee in connection with a separation agreement on July 12, 2020, valued at $290,000.
On August 12, 2020, the Company sold 190,476 restricted shares of common stock valued at $0.63 per share to 5 directors and an investor for proceeds of $120,000.
The Company issued 12,000 common shares to an employee in connection with a separation agreement on September 11, 2020, valued at $15,000.
In connection with the acquisition of Qualmetrix the Company issued 1,124,594 common shares valued at $3.71 per share to the shareholders of Qualmetrix on March 1, 2019.
| F-24 |
The Company sold 479,468 shares of common stock to various investors valued at $5.56 per share in the first quarter of 2019 for proceeds of $2,665,000.
The Company issued 212,522 restricted common shares for services in connection with the Qualmetrix acquisition on March 1, 2019, valued at $308,157.
On August 8, 2018, the Board unanimously approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of Common Stock which the Company is authorized to issue from Four hundred million (400,000,000) to Eight Hundred Million (800,000,000) shares of Common Stock, $0.001 par value per share.
Note 13 - Income Taxes
Prior to March 1, 2019, the Company operated as a Limited Liability Company (“LLC”). Taxable income and losses of an LLC are passed through to its members and there is no entity level tax.
The reconciliation between income tax expense computed by applying the federal statutory corporate tax rate and actual income tax expense (benefit) is as follows:
| Years Ended | ||||||||
| December 31, | ||||||||
| 2020 | 2019 | |||||||
| Statutory U.S. federal income tax rate | 21.0 | % | 21.0 | % | ||||
| State income taxes, net of federal income tax benefit | (0.3 | )% | 0.0 | % | ||||
| Tax effect of expenses that are not deductible for income tax purposes | (13.8 | )% | (8.3 | )% | ||||
| Change in Valuation Allowance | (14.0 | )% | (12.7 | )% | ||||
| Effective tax rate | (7.1 | )% | 0.0 | % | ||||
At December 31, the significant components of the deferred tax assets (liabilities) are summarized below:
| 2020 | 2019 | |||||||
| Deferred Tax Assets: | ||||||||
| Net Operating Losses | $ | 1,374,283 | $ | 1,043,303 | ||||
| Stock-based compensation | 467,233 | — | ||||||
| Total deferred tax assets | 1,841,516 | 1,043,303 | ||||||
| Deferred Tax Liabilities | — | — | ||||||
| Valuation Allowance | (1,841,516 | ) | (1,043,303 | ) | ||||
| Net deferred tax assets | $ | — | $ | — | ||||
| F-25 |
On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a federal corporate tax rate decrease from 35% to 21% for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of foreign earnings.
Due to the changes in ownership of the Company in connection with the reverse merger referred to in Note 1, pre-merger federal and state net operating loss carryforwards of $4.5 million and $5.5 million (computed in accordance with IRS section 382) have been reduced. These NOLs begin to expire in 2029. In addition, losses incurred from the date of the merger to December 31, 2020 are available to reduce future taxable income. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the assessment, management has established a full valuation allowance against all of the deferred tax assets for every period because it is more likely than not that all of the deferred tax assets will not be realized.
In accordance with ASC 740, a valuation allowance must be established if it is more likely than not that the deferred tax assets will not be realized. This assessment is based upon consideration of available positive and negative evidence, which includes, among other things, the Company’s most recent results of operations and expected future profitability. Based on the Company’s cumulative losses in recent years, a full valuation allowance against the Company’s deferred tax assets as of December 31, 2020 and 2019 has been established as Management believes that the Company will more likely than not realize the benefit of those deferred tax assets. Therefore, no tax provision has been recorded for the years ended December 31, 2020 and 2019.
The Company complies with the provisions of ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. Management has determined that the Company has no significant uncertain tax positions requiring recognition under ASC 740-10.
The Company is subject to income tax in the U.S., and certain state jurisdictions. The Company has not been audited by the U.S. Internal Revenue Service, or any states in connection with income taxes. The Company’s tax years generally remain open to examination for all federal and state income tax matters until its net operating loss carryforwards are utilized and the applicable statutes of limitation have expired. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations.
The Company recognizes interest and penalties related to unrecognized tax benefits, if incurred, as a component of income tax expense.
| F-26 |
On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOL’s incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The Company is currently evaluating the impact of the CARES Act, but at present does not expect that the NOL carryback provision of the CARES Act would result in a material cash benefit to us.
Note 14 – Concentrations and Credit Risk
Sales and Accounts Receivable
The Company had sales to two customers which accounted for approximately 14% and 10%, respectively of total sales for the year ended December 31, 2020. The two customers accounted for less than 10%, respectively of accounts receivable at December 31, 2020.
The Company had sales to two customers which accounted for approximately 19% and 12%, respectively of total sales for the year ended December 31, 2019. The two customers accounted for less than 10%, respectively of accounts receivable at December 31, 2019.
Cash
Cash is maintained at a major financial institution. Accounts held at U.S. financial institutions are insured by the FDIC up to $250,000. Cash balances could exceed insured amounts at any given time, however, the Company has not experienced any such losses. The Company did not have any interest-bearing accounts at December 31, 2020 and 2019, respectively.
Note 15 - Related Party Transactions
Due to Related Parties
Due to related parties with a balance of $30,000 and $128,477 at December 31, 2020 and 2019, respectively, does not bear interest and is payable on demand. A shareholder and former officer made a $30,000 non-interest bearing loan to the Company on December 31, 2020, which was repaid with common stock on January 28, 2021. The Company’s former subsidiary, Arcmail owed amounts on a credit card that is guaranteed by the husband of the Company’s Chief Financial Officer, who was held personally responsible by the credit card company for the unpaid balance. The balance of $128,477 was included in the Assumed Liabilities of the AHA Asset Purchase Agreement.
During the first quarter of 2019, the Chairman Warren Hosseinion made a $300,000 equity investment and was issued 21,590 warrants pursuant to the Equity Private Placement Memorandum.
During the first quarter of 2019, Director Mark Fawcett made a $50,000 equity investment and was issued 3,598 warrants pursuant to the Equity Private Placement Memorandum.
| F-27 |
Note 16 – Commitments and Contingencies
Employment Arrangements With Executive Officers
Effective October 29, 2019, in connection with the merger with Clinigence Health, the Company entered into employment agreements with Jacob Margolin, Lawrence Schimmel, and Elisa Luqman each under a three-year term at a base salary of $180,000, $180,000 and $150,000, respectively plus customary employee benefits. The Company’s CEO, Jacob Margolin resigned from his employment effective July 11, 2020 and entered into a separation agreement with the Company. Under the terms of the separation agreement, Mr. Margolin received a one-time cash severance payment of $20,000 on the separation date and will receive a cash payment of $72,000 payable in 12 equal monthly payments of $6,000 beginning on August 15, 2020, and 228,346 shares of the Company’s common stock, valued at $290,000.
Effective April 1, 2017, in connection with the acquisition of HealthDatix Inc., the Company entered into employment agreements with Jerry Robinson, MaryJo Robinson, and Kathleen Shepherd each under a three-year term at a base salary of $75,000 per year, bonuses based upon objectives set by the Company, and participation in all benefit programs generally made available to HealthDatix employees. The employment agreements restrict the executive officers from engaging in certain competitive activities for the greater of 60 months from the date of the agreements or two years following the termination of their respective employment. The employment agreements were terminated in connection with the sale of HealthDatix effective March 1, 2020.
Note 17 – Subsequent Events
The Company evaluated its December 31, 2020 consolidated financial statements for subsequent events through the date the consolidated financial statements were issued.
Business Acquisitions
Merger With AHP Management Inc.
On February 25, 2021, Clinigence Holdings, Inc., a Delaware corporation (“Parent” or the “Company”), AHP, Inc., a California corporation (“AHP”), AHP Acquisition Corp., a Delaware corporation, a wholly owned subsidiary of Parent (“Merger Sub”), and Robert Chan (the “Shareholders’ Representative”) entered into an agreement and plan of merger (the “AHP Merger Agreement”). The transactions contemplated by the AHP Merger Agreement were consummated on February 26, 2021 (the “AHP Closing”).
The AHP Merger Agreement provided for the merger of Merger Sub with and into AHP, hereafter referred to as the “AHP Acquisition.” As a result of the Acquisition, Merger Sub ceased to exist, and AHP became the surviving corporation and a direct wholly owned subsidiary of Clinigence, and the former stockholders of AHP (the “AHP Stockholders”) have a direct equity ownership in Clinigence. Merger Sub was renamed AHP Management Inc. Merger Sub was originally incorporated in Delaware on January 26, 2021 and had no operating activity prior to the reported transaction.
AHP is a privately held company with controlling interest in its’ affiliate Associated Hispanic Physicians of Southern California IPA, a California Medical corporation, (“AHPIPA”). A key term of the AHP Merger Agreement is that at Closing, AHP Management Inc entered into a Management Services Agreement with AHPIPA (the “Management Services Agreements”) making AHPIPA a Variable Interest Entity (VIE) of Clinigence.
| F-28 |
Merger With Accountable Healthcare America, Inc.
On February 25, 2021, Clinigence Holdings, Inc., a Delaware corporation (“Parent” or the “Company”), Accountable Healthcare America, Inc., a Delaware corporation (“AHA”), and AHA Acquisition Corp., a Delaware corporation, a wholly owned subsidiary of Parent (“Merger Sub”) entered into an agreement and plan of merger (the “AHA Merger Agreement”). The transactions contemplated by the AHA Merger Agreement were consummated on February 26, 2021 (the “AHA Closing”).
The AHA Merger Agreement provided for the merger of Merger Sub with and into AHA, hereafter referred to as the “AHA Acquisition.” As a result of the Acquisition, Merger Sub ceased to exist, and AHA became the surviving corporation and a direct wholly owned subsidiary of Clinigence, and the former stockholders of AHA (the “AHA Stockholders”) have a direct equity ownership in Clinigence. Merger Sub was renamed Accountable Healthcare America, Inc. Merger Sub was originally incorporated in Delaware on January 2, 2020 and had no operating activity prior to the reported transaction.
Pursuant to the AHP Merger Agreement, at the Closing, the former AHP Stockholders were entitled to receive 19,000,000 Company Shares, inclusive of outstanding AHP options and warrants assumed by the Company, which constitutes 45% of the outstanding Company Shares on a fully diluted basis inclusive of outstanding options and warrants. For each share of AHP Shares, each former AHP Stockholder was entitled to receive 19,000,000 shares of Company Shares. Pursuant to the AHA Merger Agreement, at the Closing, the former AHA Stockholders were entitled to receive 14,800,000 Company Shares, inclusive of certain outstanding AHA options and warrants assumed by the Company, which constitutes 35% of the outstanding Company Shares on a fully diluted basis inclusive of outstanding options and warrants.
On January 28, 2021, the Company issued 1,225,000 options to officers and directors for services in connection with the AHP and AHA acquisitions.
On January 28, 2021, the Company issued 228,721 common shares to officers and employees for deferred salaries and bonuses and reimbursed expenses, including 153,606 common shares issued to directors and officers.
Financing Transaction
On February 25, 2021, the Company received loan proceeds of $260,088 pursuant to the U.S. Small Business Administration (“SBA”) COVID-19 Paycheck Protection Program (PPP). Under the terms of this program, loan proceeds may be forgiven if used for payroll costs, rent, utilities, and other operating expenses within 24 weeks of receipt.
| F-29 |
Delaware
The First State
I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:
"AHP MANAGMENT INC", A CALIFORNIA CORPORATION,
WITH AND INTO "AHP ACQUISITION CORP." UNDER THE NAME OF “AHP ACQUISITION CORP.”, A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE ON THE TWENTY-FIFTH DAY OF FEBRUARY, A.D. 2021, AT 1:19 O`CLOCK P.M.
| 1 |
CERTIFICATE OF MERGER OF
AHP MANAGEMENT INC.
WITH AND INTO
AHP ACQUSITION CORP.
Pursuant to Title 8, Section 251(c) of the Delaware General Corporation Law ("DGCL"), the undersigned corporation organized and existing under and by virtue of the DGCL executed the following Certificate of Merger:
FIRST: The name and state of incorporation of each of the constituent corporations of the
| Name | State of Incorporation | ||
| AHP Acquisition Corp. | Delaware | ||
| AHP Management Inc. | California |
SECOND: The Agreement and Plan of Merger, dated as of February 22, 2021, has been approved, adopted, certified, executed and acknowledged by each of the constituent corporations.
THIRD: The name of the surviving corporation is AHP Management, Inc., a Delaware corporation.
FOURTH: The Certificate oflncorporation of the surviving corporation as in effect immediately prior to the merger shall be amended and restated in its entirety as set forth in Exhibit A attached hereto and, as so amended and restated, shall be its Certificate of Incorporation.
FIFTH: The merger shall be effective on filing of this Certificate of Merger with the Secretary of State of the State of the State of Delaware.
SIXTH: The Agreement and Plan of Merger is on file at 501 1sr Ave. N, St. Petersburg. FL 33701, the place of business of the surviving corporation.
SEVENTH: A copy of the Agreement and Plan of Merger will be furnished by the surv1vmg corporation on request, without cost, to any stockholder of the constituent corporations.
[Signature Page Follows]
| 2 |
IN WITNESS WHEREOF, said surviving corporation has caused this certificate to be signed by an authorized officer, the 24th day of February,2021.
| AHP ACQUISITION CORP. | ||
| By: /s/ Elisa Luqman | ||
| Name: Elisa Luqman | ||
| Title: President |
| 3 |
EXHIBIT A
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
| 4 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
AHP ACQUISITION CORP.
AHP Acquisition Corp., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that:
1. The present name of the corporation (hereinafter called the "Corporation") is "AHP Acquisition Corp." which is the name under which the Corporation was originally incorporated; and the date of filing the original certificate of incorporation of the Corporation ("Original Certificate") with the Secretary of State of the State of Delaware is January 26, 2021.
2. This amended and restated certificate of incorporation has been duly adopted in accordaoce with the provisions of Sections 228,242, and 245 of the General Corporation Law of the State of Delaware.
3. The text of the Original Certificate of the Corporation is hereby amended and restated in its entirety to read as follows:
ARTICLE I
The name of this Corporation is AHP Management, Inc.
ARTICLE II
The address of the registered office of this Corporation in the State of Delaware is 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808. The Corporation's registered agent at that address is Corporation Service Company.
ARTICLE III
The purpose of this Corporation is to engage in any lawful act or activity for which a corporation may be organized under the General Corporation Law of Delaware.
ARTICLE IV
This Corporation is to have perpetual existence.
ARTICLEV
This Corporation is authorized to issue 1,000 shares of Common Stock with a par value of $0.0001 per share. Authority is hereby expressly granted to the Board of Directors of this Corporation from time to time to issue any authorized but unissued shares of common stock for such consideration and on such terms as it may determine.
| 5 |
ARTICLE VI
In furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to adopt, amend or repeal from time to time any or all of the Bylaws of this Corporation.
ARTICLE VII
The number of directors which shall constitute the whole Board of Directors of this Corporation shall be as specified in the Bylaws of this Corporation, subject to the provisions of Article VI and this Article VII.
ARTICLE VIII
A director of this Corporation shall not be personally liable to this Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director's duty of loyalty to this Corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the General Corporation Law of the State of Delaware, or (iv) for any transaction from which the director derived an improper personal benefit. Neither the amendment nor repeal of this Article VIII, nor the adoption of any provision of the Certificate of Incorporation or Bylaws or of any statute inconsistent with this Article VIII, shall eliminate or reduce the effect of this Article VIII in respect of any acts or omissions occurring, or any causes of action, suits or claims that, but for this Article VIII, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent provision.
ARTICLE IX
This Corporation reserves the right at any time and from time to time to amend, alter, change or repeal any provision contained herein, and other provisions authorized by the laws of the State of Delaware at the time in force may be added or inserted, in the manner now or hereafter prescribed by law, and all rights, preferences, and privileges of whatsoever nature conferred upon stockholders, directors, or any other person whomsoever by or pursuant to the Certificate of Incorporation in its present form or as hereafter amended are granted, subject to the rights reserved in this Article IX.
ARTICLE X
Meetings of stockholders may be held outside the State of Delaware, if the Bylaws so provide. The books of this Corporation may be kept (subject to any provision of law) outside of the State of Delaware. Elections of directors need not be by ballot unless the Bylaws of this Corporation shall so provide.
| 6 |
Delaware
The First State
I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:
"AHA ACQUISITION CORP.", A DELAWARE CORPORATION,
WITH AND INTO "ACCOUNTABLE HEALTHCARE AMERICA INC." UNDER THE NAME OF “ACCOUNTABLE HEALTHCARE AMERICA INC.”, A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE ON THE TWENTY-FIFTH DAY OF FEBRUARY, A.D. 2021, AT 1:35 O`CLOCK P.M.
| 1 |
CERTIFICATE OF MERGER OF
AHA ACQUISITION CORP.
WITH AND INTO
ACCOUNTABLE HEALTHCARE AMERICA INC.
Pursuant to Title 8, Section 25l(c) of the Delaware General Corporation Law ("DGCL"), the undersigned corporation organized and existing under and by virtue of the DGCL executed the following Certificate of Merger:
FIRST: The name and state of incorporation of each of the constituent corporations of the
| Name | State of Incorporation | ||
| AHP Acquisition Corp. | Delaware | ||
| AHP Healthcare America Inc. | Delaware |
SECOND: The Agreement and Plan of Merger, dated as of February 24, 2021, has been approved, adopted, certified, executed and acknowledged by each of the constituent corporations.
THIRD: The name of the surviving corporation is Accountable Healthcare America Inc_, a Delaware corporation and the name of the corporation being merged into the surviving corporation is AHA Acquisition Corp., a Delaware corporation.
FOURTH: The Certificate of Incorporation of the surviving corporation shall be its Certificate of Incorporation.
FIFTH: The merger shall be effective on filing of this Certificate of Merger with the Secretary of State of the State of the State of Delaware
SIXTH: The Agreement and Plan. of Merger is on file at 501 1sT Ave. N, St. Petersburg. FL 33701, the place of business of the surviving corporation.
SEVENTH: A copy of the Agreement and Plan of .Merger will be furnished by the surviving corporation on request, without cost, to any stockholder of the constituent corporations.
[Signature Page Follows]
| 2 |
IN WITNESS WHEREOF, said surviving corporation has caused this certificate to be signed by an authorized officer, the 24th day of February, 2021.
| ACCOUNTABLE HEALTHCARE AMERICA INC. | ||
| By: /s/ Michael Bowen | ||
| Name: Michael Bowen | ||
| Title: Chief Financial Officer |
| 3 |
Delaware
The First State
I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:
"AHA ANALYTICS, INC.", A DELAWARE CORPORATION,
WITH AND INTO "CLINIGENCE HEALTH INC." UNDER THE NAME OF “CLINIGENCE HEALTH INC.”, A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE ON THE TWENTY-FIFTH DAY OF FEBRUARY, A.D. 2021, AT 1:15 O`CLOCK P.M.
| 1 |
CERTIFICATE OF MERGER OF
AHA ANALYTICS, INC.
WITH AND INTO
CLINIGENCE HEALTH INC.
Pursuant to Title 8, Section 25l(c) of the Delaware General Corporation Law ("DGCL"), the undersigned corporation organized and existing under and by virtue of the DGCL executed the following Certificate of Merger:
FIRST: The name and state of incorporation of each of the constituent corporations of the
| Name | State of Incorporation | ||
| AHA Analytics, Inc.. | Delaware | ||
| Clinigence Health Inc. | Delaware |
SECOND: The Agreement and Plan of Merger, dated as of February 24, 2021, has been approved, adopted, certified, executed and acknowledged by each of the constituent corporations.
THIRD: The name of the sw-viving corporation is CHnigence Health Inc., a Delaware corporation and the name of the corporation being merged into the surviving corporation is AHA Analytics, Inc., a Delaware corporation.
FOURTH: The Certificate of Incorporation of the surviving corporation shall be its Certificate of Incorporation.
FIFTH: The merger shall be effective on filing of this Certificate of Merger with the Secretary of State of the State of the State of Delaware.
SIXTH: The Agreement and Plan. of Merger is on file at 501 1ST Ave. N, St. Petersburg. FL 33701, the place of business of the surviving corporation.
SEVENTH: A copy of the Agreement and Plan of .Merger will be furnished by the surviving corporation on request, without cost, to any stockholder of the constituent corporations.
[Signature Page Follows]
| 2 |
IN WITNESS WHEREOF, said surviving corporation has caused this certificate to be signed by an authorized officer, the 24th day of February 2021.
| CLINIGENCE HEALTH INC. | ||
| By: /s/ Elisa Luqman | ||
| Name: Elisa Luqman | ||
| Title: Chief Financial Officer |
| 3 |
Exhibit 31.1
CHIEF
EXECUTIVE OFFICER CERTIFICATION
PURSUANT TO SECTION 302
I, Warren Hosseinion, certify that:
1. I have reviewed this Annual Report on Form 10-K of Clinigence Holdings, Inc. (the “Registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;
4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
| a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c) | evaluated the effectiveness of the Registrant’s disclosure controls and procedures presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d) | disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and |
5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting to the Registrant’s auditors and the audit committee of Registrant’s board of directors (or persons performing the equivalent functions):
| a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and |
| b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting. |
| March 31, 2021 | /s/ Warren Hosseinion | |
| Warren Hosseinion | ||
| Chief Executive Officer | ||
| (Principal Executive Officer) |
Exhibit 31.2
CHIEF
FINANCIAL OFFICER CERTIFICATION
PURSUANT TO SECTION 302
I, Michael Bowen, certify that:
1. I have reviewed this Annual Report on Form 10-K of Clinigence Holdings, Inc. (the “Registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;
4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
| a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c) | evaluated the effectiveness of the Registrant’s disclosure controls and procedures presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d) | disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and |
5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of Registrant’s board of directors (or persons performing the equivalent functions):
| a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and |
| b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting. |
| March 31, 2021 | /s/ Michael Bowen | |
| Michael Bowen | ||
| Chief Financial Officer | ||
| (Principal Financial Officer) |
Exhibit 32.1
CERTIFICATION
PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the accompanying Annual Report of Clinigence Holdings, Inc. (the “Company”) on Form 10-K for the twelve months ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Warren Hosseinion, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fully presents, in all material respects, the financial condition and results of operations of the Company.
| March 31, 2021 | By: /s/ Warren Hosseinion | |
| Warren Hosseinion | ||
| Principal Executive Officer |
Exhibit 32.2
CERTIFICATION
PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the accompanying Annual Report of Clinigence Holdings, Inc. (the “Company”) on Form 10-K for the twelve months ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael Bowen, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fully presents, in all material respects, the financial condition and results of operations of the Company.
| March 31, 2021 | By: /s/ Michael Bowen | |
| Michael Bowen | ||
| Principal Financial Officer |